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• Section 3 – A prospective longitudinal study of pituitary function in survivors 
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Section I: Hypothalamo-Pituitary Axis 
The pituitary gland is embryologically derived from 2 sources, giving 2 distinct 
lobes. The anterior lobe is derived from Rathkes pouch and is functionally and 
endocrinologically distinct from the posterior lobe, which is embryologically 
continuous with the hypothalamus.  
The posterior lobe of the pituitary contains nerve fibres from the hypothalamus and 
secretes hormones in response to neuronal excitation, whereas the anterior lobe 
contains a number of different cell types which each secrete the various anterior 
pituitary hormones. These cells are under neuro-hormonal control from the 
hypothalamus via the long portal veins. Main cell types, hormones produced and 
control mechanisms for the anterior pituitary are shown in table 1. 
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Cell Type  Hormone  %Pituitary 
population  
Hypothalamic 
hormone 
Thyrotroph  TSH  3-5%  TRH (+) 
Somatostatin(-)  
Corticotroph  ACTH  15 – 20%  CRH(+) 
Vasopressin 
augments  
Gonadotroph  LH,FSH  10-15%  GnRH (+) 
Prolactin (-) 
Somatotrophs  GH  40-50%  GHRH (+) 
Somatostatin (-) 
Lactotrophs  Prolactin  10 – 25%  PRF (+) 
TRH (+) 
Dopamine (-) 
 
Table 1.1 – Cell types and functions within the anterior pituitary together with 
neuro-hormonal regulation. Adapted from Endocrinology  - An Integrated 
approach(1) 
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Blood Supply to the pituitary gland and hypothalamus 
The pituitary gland is one of the most vascularised tissues in the in the body, making 
it vulnerable to ischaemia. Its blood supply is complex, with the hypothalamus being 
supplied from the circle of Willis, and the two lobes of the pituitary gland being 
supplied from the superior and inferior hypopyseal arteries. The superior 
hypophyseal artery forms a capillary bed around the nuclei within the median 
eminence of the hypothalamus. These capillaries then drain to the long portal veins 
which then form a second capillary bed around the cells of the anterior pituitary, 
allowing the hypothalamic hormones to exert their paracrine actions on the anterior 
pituitary. Ischaemia can therefore affect the pituitary directly in addition to the 
hypothalamus resulting in disturbances to the endocrine functions of the pituitary 
gland. Ischaemic damage is similar in its effects to other causes of pituitary damage, 
such as pituitary tumours or radiotherapy, in that somatotrophs are normally most 
commonly affected, followed by gonadotrophs, with the relatively smaller numbers 
of thyrotrophs being the most resilient. In the absence of an anatomical lesion, 
posterior pituitary function is normally well preserved(1).  
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               Section II: Growth Hormone 
a) Structure and Synthesis 
The human GH (hGH-N) gene is located on chromosome 17q, and is one of 5 similar 
genes. Only genes GH1 and GH2 (producing GH V) produce growth hormone (GH) 
with any systemic relevance.(2) 
 
Human growth hormone (GH) consists of a 191 amino acid, 22,129 kDa single chain 
protein with 2 di-sulfide bridges (figure 1.1). Whilst this is the prototype pituitary 
hormone another isoform does exist in the healthy state, constituting around 5% of 
pituitary GH, with a third isoform known to be produced under disease conditions 
(Genetic GHD T2) but not thought to be important in the healthy state (3) . Placental 
growth hormone (GH V), is similar in structure and is produced by the placenta in 
increasing amounts during pregnancy, being the principal type of GH in the maternal 
circulation by term. It has similar biological effects to pituitary GH, although has less 
lactogenic activity(4). Further isoforms of GH are also produced by the placenta 
from the remaining 3 genes (called Chorionic Somatomammotrophins), however 
these have little or no biological activity at the GH receptor and are readily 
distinguished by most assays. 
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Figure 1.1- Structure of human growth hormone 
(taken from Baumann et al(3)) 
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b) Physiological control of GH secretion 
i) Neuropeptide Hormones Growth Hormone is regulated by a number of 
endogenous and exogenous factors which may act directly or indirectly on the 
pituitary and hypothalamus. 
 
Growth Hormone Releasing Hormone – This is the primary neuropeptide 
responsible for regulating the pulsatility of growth hormone release(5). It is a 44 
Amino acid protein which is produced predominantly from the arcuate nucleus of  
the hypothalamus(6) It is derived from a 108 amino acid pre pro hormone, and has 
been found in the hypothalamus in 2 forms GHRH (1-40) and GHRH (1-44)(7, 8). 
Both forms are believed to have equal biological activity. GHRH acts by stimulating 
both gene transcription in pituitary somatotrophs, and release of stored GHRH from 
intracellular stores(9, 10). An intact GHRH system is required for the action of all 
other GH releasing stimuli.(5) 
 
Somatostatin (also known as somatotrophin release inhibitory factor) - This 
neuropeptide hormone is produced in the paraventricular nuclei of the hypothalamus 
and is derived from a 116 amino acid pro hormone. It has 2 principal forms SS28 and 
SS14(11) and is responsible for inhibition of GH release(12, 13). It antagonises the 
actions of GHRH and ghrelin(14-16), and also acts directly on the pituitary to inhibit 
GH release, but not its production(17) which leads to a moderate rebound GH release 
on termination of SS infusion(18), particularly given its short half life of 3 minutes. 
It is the main negative regulator of GH secretion, however its main action seems to 
be to reduce the magnitude of GH pulses and interpulse basal GH levels rather than 
the frequency of GH pulses which are determined by GHRH and are unaffected by 
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SS infusion(19) In addition to GH inhibitory effects it also inhibits release of TRH 
stimulated TSH, glucagon, gastrin and  insulin(20), as well as other gut hormones. It 
has a lesser inhibitory effect on ACTH and Prolactin(5).  
 
Ghrelin. The most recently discovered neuroendocrine hormone, ghrelin is a 28 
amino acid peptide which is formed from the 117 amino acid preproghrelin. It is 
produced in the endocrine cells of the stomach(21) however has also been isolated 
from the arcuate nucleus of the hypothalamus and the cells of the anterior 
pituitary(22), specifically somatotrophs, thyrotrophs and lactotrophs(23) where it is 
thought to exert a paracrine action. The actions of ghrelin are complex; it is known to 
stimulate GH release from somatotrophs in vitro(24) and in vivo however in this 
situation it requires an intact GHRH system(14) – it does not however act through 
this system as the amount of GH released by ghrelin is greater than that by GHRH 
alone(25). Ghrelin acts via the GH secretagogue receptor (GHS-R) which is strongly 
expressed in the hypothalamus and pituitary(22), as well as other peripheral tissues. 
In addition to its GH releasing actions, ghrelin is involved in appetite, gastric 
motility(26), gastric acid secretion, energy balance(27), insulin secretion, ACTH and 
prolactin release(25). It also has cardiovascular(28) and anti-proliferative effects(2). 
 
Leptin – Leptin is produced by white adipose tissue, and is primarily involved in 
regulation of body fat via hypothalamic appetite sensors(29, 30). Whilst leptin and its 
receptors have been found in normal pituitary tissue and pituitary adenomas(31, 32), 
in vivo studies have failed to demonstrate an up-regulation of GH production in 
response to leptin(33). 
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Other neuro-peptides regulating GH release include GABA, Galanin, Neuropeptide 
Y(34) and endogenous opiates(35). Other physiological states will also affect GH 
release. GH levels are reduced in obesity and states of hyperglycaemia, Obesity has 
been clearly associated with impaired GH secretion: for each unit increase in BMI, 
there is a 6% reduction in the daily GH secretion rate(36). GH levels are however 
increased following exercise, physiological or psychological stress, hypoglycaemia 
and starvation(35). Sex steroids (oestrogen and testosterone) both amplify the 
magnitude of GHRH pulses and reduce the orderliness of pulse frequency leading to 
increased GH secretion(37-39), particularly during puberty.  
 
Insulin Like Growth Factor 1: IGF-1 is produced in the liver and local tissues in 
response to GH stimulation; however it is hepatic IGF-1 which exerts the greatest 
feedback on the pituitary gland(6). IGF-1 levels in the blood declines rapidly if 
unbound, however because the majority of IGF-1 is bound by the IGF-1 binding 
proteins, measurable changes in IGF-1 may take 3 – 5 days to become evident after 
an intervention (e.g. prolonged fasting)(5). Whilst the precise site of IGF-1’s 
feedback actions is unknown, it is suspected that it may work by feed back on both 
the hypothalamus and pituitary(40), although in humans the finding of a lower level 
of negative feedback by IGF-1 infusions in patients with hypothalamic 
hypopituitarism suggests that an intact hypothalamus is required for a full effect(41). 
 
ii) Pharmacological Stimuli. Corticosteroids are known to have a biphasic effect on 
GH secretion, with an acute increase in GH measured over minutes to hours, 
followed by long term GH suppression(42, 43). GH secretagogues such as hexeralin 
and GHRP-6 have a potent effect on GH release by binding to the GHS-R1a receptor 
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on the somatotrophs of the pituitary(35) in a similar way to ghrelin. This forms the 
basis of several pharmacological stimulation tests(44-46). Alpha-adrenergic 
pathways stimulate GH release via increasing GHRH and reducing somatostatin, as 
do muscarinic pathways. This forms the basis for the use of clonidine (an alpha 2 
receptor agonist), L Dopa (metabolised to adrenaline or noradrenaline) and 
pyridostigmine (an anticholinesterase) to stimulate GH secretion(47). Beta 
adrenergic pathways however inhibit GH secretion. 
 
iii) Pulsatility of GH release. GHRH acts as the primary pulse generator, with 
somatostatin as the main inhibitor of GH release. GH release is governed by a 
complex interplay of these hormones, with SS inhibiting GHRH release, GHRH 
stimulating SS(48) and SS also inhibiting its own release(49). Whilst SS inhibits 
basal and peak levels of GH, it does not reduce pulse frequency. In addition to these 
‘short’ feedback loops, GH also acutely inhibits hypothalamic GHRH secretion(50, 
51) and stimulates SS(48, 52, 53). More long-term feedback is likely to be provided 
by IGF-1.  
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Figure 1.2 -  The physiological regulation of GH release. Adapted from  Khoo B, 
Grossman A Normal and Abnormal Physiology Hypothalamus and Pituitary 
gland(54) 
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iv) Other influences on GH secretion 
Age: GH is secreted in reduced quantities in old age (the somatopause). This is a 
GHRH mediated response, since the pituitary response to GHRH remains intact 
despite aging(55, 56), and the pool of pituitary GH is relatively preserved into older 
age(57).  
Gender: There is evidence of gender specificity in the pattern of GH release. Men 
demonstrate a predominantly nocturnal pattern of GH secretion with daytime 
quiescence, whereas women maintain both higher pulse frequency and basal GH 
levels during the day.(5)  
 
Sleep: GH release is associated with the onset of slow wave sleep in humans(58), 
however the mechanism leading to the nocturnal pattern of GH secretion is uncertain. 
It has been demonstrated that cortisol release is not implicated in the nocturnal 
pattern of GH pulse generation(59), and neither is SS(60, 61), however GHRH is 
likely to play a role, given the finding that nocturnal GH release is reduced by 77%  
following infusion of a GHRH antagonist(62). Small peaks were however noted 
despite this which suggests that there maybe a further, as yet unknown factor 
regulating nocturnal GH release in humans(5).  
 
Gonadal Steroids: It is known that the increase in gonadal steroids at the onset of 
puberty is accompanied by increased GH and IGF-1 levels(63, 64), however whether 
these events are coincidental or causal is unclear. Oestrogens are seen to increase GH 
secretion, an effect that is mirrored only by aromatizable androgens such as 
testosterone. It is however also known that oestrogens reduce hepatic IGF-1 
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synthesis which may simply remove the negative feedback resulting in increased GH 
levels.(5) 
 
Nutrition: Total body fat and visceral fat are negatively correlated with growth 
hormone secretion(65), and hence important factors to consider when assessing 
patients with possible GHD. Obesity leads to markedly reduced levels of GH. This 
may be by 3 mechanisms. Firstly free fatty acids are powerful inhibitors of GH 
secretion, most probably via SS activation, since the GH response to GHRH is 
attenuated in healthy volunteers maintained on lipid infusions(66) and FFA’s are 
raised in obesity(67) . Secondly, free IGF-1 levels may be elevated in obesity as a 
result in reduced IGFBP1 – this may lead to increased negative feedback on the 
pituitary(68). Thirdly decreased frequency of GH pulses is seen in obesity(69).  
 
The role of Ghrelin in modulating the GH suppression in obesity is unclear.  Ghrelin 
levels have been shown to be reduced in obesity(70-72), Reduced nocturnal secretion 
of ghrelin has also been noted in obese subjects(73). Lindeman et al however, despite 
confirming an exponential negative correlation between ghrelin and BMI, found a 
positive correlation between ghrelin and visceral fat in obese subjects, with a 
negative correlation between visceral fat and 24 hour GH secretion, and no change in 
ghrelin levels in patients who lost weight, despite an increase in GH secretion, 
suggesting that ghrelin is not involved in GH regulation in obesity(74). 
 
   Hyperglycaemia is known to suppress GH secretion acutely(75, 76), and this is 
associated with attenuated responses to GHRH and GH secretagogues suggesting 
increased SS tone(77, 78), however this is then followed by a rebound increase in 
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GH levels as the SS inhibition ceases and stored pituitary GH is released. 
Hypoglycaemia however causes a rapid increase in GH levels via GHRH 
activation(79) as part of the physiological counter regulatory response.  
 
In conclusion GH release is predominantly under the control of the hypothalamus 
primarily influenced by the interplay of GHRH and Somatostatin. GH can be 
stimulated by a number of pharmacological agents, several of which are used in 
pharmacological testing. A number of physiological factors including age, gender, 
sleep status, gonadal steroids, nutrition and glycaemic state also influence GH 
production and release.  
 
GH release is markedly reduced in states of hyperglycaemia and obesity and a 
number of possible mechanisms have been postulated. Whilst Ghrelin is a powerful 
GH secretagogue, it does not appear that ghrelin is responsible for changes in GH 
secretion in states of obesity. 
 
c)Functions of GH 
The primary function of GH is, as its name would suggest, the promotion of 
longitudinal growth in childhood. It does however have wide ranging action on 
muscle, bone and adipose tissue as well as a number of other organs of the body.  
GH may act both directly on organs and tissues, and via the insulin like growth 
factors; Whilst GH is required for differentiation of precursor cells, IGF-1 is 
responsible for clonal expansion of the differentiated cells- the dual effector 
theory.(80)  
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GH has a diabetogenic effect by antagonising the effects of insulin. This has been 
seen in studies in GH replete volunteers given GH where hyperinsulinaemia has been 
noted during acute and chronic GH administration, leading to hyperglycaemia when 
given over longer periods(81). A lipolytic effect has also been demonstrated(82). GH 
increases lean body mass, primarily by an increase in skeletal muscle mass. GH has 
been shown to stimulate skeletal muscle protein synthesis(83). A summary of the 
effects of GH in health is shown in fig 1.3 and table 1.2. 
 
The effects of GH are most potently seen by the effects of GHD. This will be 
discussed more fully in the following section.  
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Figure 1.3 Systemic effects of GH in health. Adapted from endocrinology an 
integrated approach(1) 
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Promotion of somatic growth  
IGF-I generation  
Nitrogen retention 
Lipolysis 
Beta cell hyperplasia 
Sodium retention 
Lactogenesis 
Growth plate elongation  
IGF-BP3 and ALS generation 
Amino acid transport into muscle 
Insulin antagonism 
Early insulin-like effect 
Phosphorus retention 
Stimulation of immune function 
 
Table 1.2 - Principal biological activities of GH. Adapted from Baumann et al(3) 
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Section III:  Growth Hormone Deficiency (GHD) 
a)Causes 
i) Childhood onset GHD: GH deficiency may arise in childhood or be adult onset in 
nature. Childhood causes may be subdivided into those which are congenital or 
acquired. Congenital causes include genetic mutations causing multiple pituitary 
hormone deficiencies such as PROP1, HESX1, PIT-1 and LHX3/4, or isolated 
deficiencies such as PITX2 mutations(84). Structural lesions such as empty sella, or 
midline defects such as septo-optic dysplasia many also be implicated. 
 
As in the adult population, acquired GHD may be secondary to pituitary tumours, the 
most common being craniopharyngioma, or the treatment of such, namely pituitary 
surgery and hypothalmo-pituitary irradiation; post irradiation the chance of 
developing GHD is over 50% if the biological effective dose is greater than 
40Gy(85).  Infiltrative diseases such as Langerhans cell histiocytosis, sarcoidosis or 
tuberculosis are rare causes. Whilst traumatic brain injury has been described as a 
cause of childhood onset GHD(86) the precise incidence is unclear. By far the most 
common cause of childhood onset GHD is idiopathic. In this situation the majority of 
children will have normal GH secretion when retested on completion of growth(87, 
88), whereas in those children with a defined genetic or structural cause, GHD is 
likely to persist into adulthood(89).  
 
ii) Adult Onset GHD: In contrast to childhood, adult onset GHD is normally 
secondary to a structural defect. Adult onset isolated GHD is very rare, and in this 
situation consideration must be given to the accuracy of the diagnostic test, 
particularly where obesity is present, and in the presence of a normal IGF-1(84). The 
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commonest structural lesion in adulthood is a pituitary adenoma. Whist micro-
adenomas are almost never associated with GHD, macro-adenomas are associated 
with pituitary hormone deficiencies in 30 – 60% of patients(84). This may be due to 
compression of long portal vessels or due to raised intrasellar pressure(90). 
Parapituitary space occupying lesions such as craniopharyngioma, arachnoid cysts, 
Rathkes cleft cysts, meningiomas, gliomas and astrocytomas may also affect 
pituitary function. As in children, pituitary surgery frequently causes 
hypopituitarism, although surgery may be followed by recovery of previously 
deficient pituitary hormones(91-93), however GHD is least likely to recover(91). 
Hypothalamo-pituitary irradiation causes hypopituitarism in over 50% of patients(94, 
95).   
 
Subarachnoid haemorrhage (SAH) and traumatic brain injury (TBI) have previously 
been thought to be rare causes of GHD, however interest in recent years has led to a 
number of studies challenging this view. A meta analysis in 2007 demonstrated an 
incidence in of hypopituitarism of 27% for TBI and 47% for SAH(96). This will be 
discussed further in later sections. The causes of GHD are summarised in Table 1.3. 
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Table 1.3 – Causes of GHD (Adapted from Molitch et al(84)) 
 
 
 
 
  
  
Congenital 
Genetic: 
Transcription factor defects 
GHRH receptor gene defects 
GHS receptor gene defects 
GH receptor gene defects 
Post receptor gene defects 
Structural: 
Agenesis of corpus callosum 
Septo optic dysplasia 
Empty sella syndrome 
Holoprosencephaly 
Encephalocele 
Hydrocephalus 
Arachnoid cyst 
Associated with midline defects 
Acquired 
Trauma (perinatal or postnatal) 
CNS infection 
Tumours of hypothalamus or 
pituitary 
Infiltrative/granulomatous disease 
Cranial Irradiation 
Surgery 
SAH 
TBI 
Idiopathic 
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b)Diagnosis 
 The accurate diagnosis of GHD can be difficult. Whereas in children GHD is 
accompanied by growth failure, in adults no such firm auxiological end point exists. 
Diagnostic testing includes many confounding factors such as age and BMI, both of 
which may cause a physiological reduction in GH levels which cannot be 
differentiated biochemically from pathologically low GH levels. In patients with a 
structural lesion and multiple pituitary hormone deficiencies the diagnosis is 
somewhat easier, as in patients with  greater than 3 pituitary hormone defects, the 
chance of GHD accompanying these is over 97%(97).  
 
The much more common situation of patients with single or dual deficiencies does 
however need much more careful consideration. As GH is secreted in a pulsatile 
nature, basal hormone measurements are of little use and diagnosis is normally made 
by stimulation testing. Multiple stimulation tests are in use in clinical practice 
including the insulin tolerance test (ITT), the glucagon stimulation test (GST) and the 
GHRH/Arginine test (GAT). Other tests using GHRH and one of a number of GH 
secretagogues are also in use; however their use is less widespread. It is important 
that each test is used with an appropriate cut off value specific to the assay and the 
test used.  
 
The ITT, GST, GAT, and GHRH/GHRP tests are all validated for the diagnosis of 
adult GHD. Only one test is required for a diagnosis of GHD, however in patients 
with possible hypothalamic disease, the combined tests may be inappropriately 
normal as these tests stimulate both the hypothalamus and the pituitary. Therefore in 
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patients with a history of cranial irradiation, an ITT should be performed if a 
combined test is normal(98).  
Insulin Tolerance test: The ITT is considered to be the gold standard diagnostic test 
for GHD. This tests both GH and cortisol reserve by inducing hypoglycaemia (blood 
glucose <2.2mmol/l) and evaluating the response of GH and cortisol. This test works 
by physiological mechanisms and tests the complete GHRH-GH axis. It has however 
been shown to have poor intra subject reproducibility(99, 100), has a considerable 
number of unpleasant side effects, and is associated with a high potential for 
mortality and morbidity. Furthermore it can only be conducted in the inpatient setting 
under medical supervision, and is contraindicated in seizure disorders and 
cardiovascular disease  
 
Glucagon Stimulation Test: The GST is widely used due to its ease, low cost and 
generally well tolerated protocol. It has been shown to be a safer and effective test of 
GH reserve(101-105). Side effects are few, but include nausea, tiredness, flushing 
and vomiting in around 20% of patients. It has few contraindications 
(hypothyroidism and insulinoma). It is however the most time consuming of all tests, 
and can produce differing results depending on whether given subcutaneously or 
intramuscularly, The IV route of administration has been demonstrated to have a 
poor efficacy for GH stimulation. There have also been concerns about the ability of 
glucagon to stimulate cortisol release which will be discussed further in chapter 4. 
 
Combined Growth Hormone Releasing hormone Arginine Test: The GAT has 
been widely used in Europe and the United States. This test uses the hypothalamic 
stimulus of arginine, which is thought to act by inhibition of somatostatin, paired 
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with the direct effect of GHRH in releasing stored pituitary GH. Both agents are 
weak stimuli in isolation in adults; however their combination is synergistic and has 
been shown to have good reproducibility and a higher level of tolerability than both 
the ITT and GST. Like all combined tests, falsely normal results can be seen in 
patients with disease suspected to be of hypothalamic origin e.g. post irradiation, 
because GHRH directly stimulates the pituitary.  
 
Effect of age on GH stimulation tests 
Age has been shown to be a significant influence on GH release, and studies of 
spontaneous GH secretion have shown that this declines with increasing years, by 
around 14% per decade(106).  
 
Biller et al however found no significant effect of age in any of 6 stimulation tests 
(ITT, arg, arg/ghrh, l dopa, arg/l dopa)(44), although when the GST was conducted 
in healthy older men age 50-69 years 20% were found to have a peak GH 
<3micrograms/l, which was not validated by ITT(107). Other factors such as obesity 
were not however taken into consideration in this study.  Toogood et al investigated 
patients over the age of 60 years with and without hypothalamo-pituitary disease by 
arginine stimulation tests, 24 hour GH profiles and IGF-1 levels and found that there 
was a significant difference in all 3 indices between healthy older volunteers and 
patients with hypothalamo-pituitary disease suggesting that these patients may still 
benefit from GHR(106).  
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Effect of Gender on peak GH levels 
Biller et al found a significant effect of gender in control subjects undergoing the 
GAT  (p=0.03), and the arginine test alone  (p=0.01) however the groups in this 
study were not equal (4 women, 20 men). There was no significant difference in the 
ITT, l dopa or L dopa/arg tests. Likewise there were no significant differences in the 
patients with MPHD. In females, phase of the menstrual cycle may affect response to 
GH stimulation testing, with higher levels found in the pre-ovulatory phase in 
women with normal menses. 
 
Effect of BMI on GH stimulation tests  
GH secretion declines in overweight subjects, with 24 hour GH secretion reduced by 
75% in obese men compared with age matched controls(69). Abdominal fat mass is a 
better predictor of 24 hour GH release when compared to total body fat(65). GH 
secretion is suppressed to a varying degree even in mildly overweight subjects 
undergoing testing. This is a confounding factor, since most patients with GHD are 
likely to be obese(108). All tests examining GH secretion are affected by BMI, Colao 
et al also postulated a link between waist circumference and GH secretion(109). This 
reduction in GH secretion in obesity is mirrored by increasing insulin resistance and 
other adverse features of the metabolic syndrome as demonstrated by Di Somma et 
al(110). This has led to suggestions from Cordido et al who studied healthy 
volunteers with obesity with and without a suboptimal GH response to GHRH 
arginine, that reduction in GH secretion is the pituitary manifestation of the 
metabolic syndrome(111).  
The GST  has been shown to be unaffected by BMI in hypopituitary patients with 
GHD following structural lesions(103), however a  correlation with BMI in healthy 
  
 32 
controls has been demonstrated even though the mean population BMI of the 
controls in this study was only 25.8 kg/m
2 
.  A review of the KIMS database by 
Toogood demonstrated that the GST was affected by BMI, particularly between 20-
30kg/m
2
.(112). Yuen et al compared a weight based versus fixed dose GST protocol 
and demonstrated a link with age and BMI, finding that the weight based regime led 
to higher peak GH and cortisol levels. They concluded that because of the link with 
BMI weight based dosing was likely to be more accurate, however this could not be 
compared in this retrospective study(113). The link between BMI and peak GH has 
also been replicated in the ITT(114-116) and GHRH/Arg(117). This reduction in GH 
levels has also been seen in patients with normal IGF-1 levels(118) which are less 
affected by obesity(119).  
The GAT has subsequently been studied in obesity, and validated cut offs by BMI 
established(98) although it has been suggested that waist circumference may be a 
more accurate measure than BMI in obese patients(120).  
 
In conclusion a number of physiological tests are available for the diagnosis of GHD. 
Whilst the ITT is considered the gold standard, it has potential complications, has 
poor intra subject reproducibility and, like other tests is affected by BMI, age and 
gender. The GST is safe and effective however likewise the test can be affected by 
BMI, age and gender. The GAT has been validated with different BMI cut offs, 
however as it stimulates the pituitary directly it may fail to correctly diagnose 
patients with GHD following hypothalamic damage. Although only one test is 
required for the diagnosis of GHD according to consensus guidelines, it may be that 
multiple tests taking into account confounding factors in diagnosis may lead to the 
most accurate classification of GHD.  
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c) Assays 
One obstacle to successful standardisation of GHD diagnosis has been the lack of 
standardisation within the GH assay. There has never been a standard assay, and cut 
offs depend upon the assay used. In 1997 polyclonal radio-immunoassays were 
replaced with 2 site monoclonal assays which normally report values <50% that of 
the polyclonal assays(119).  
 
Furthermore prior to 2007 there was no universal calibration standard, however from 
this time the universal calibration standard IS 98/574 in which 1mg corresponds to 
3IU somatotropin has been recommended by the Growth Hormone Research 
Society(121). Until this point GH was also reported in two different units, namely 
mU/L and g/L. g/L are now universally used for reporting of GH concentrations 
and all values in this thesis will follow this convention.  
 
d) Markers of GH action. 
 The primary marker of GH action is IGF-1. IGF-1 is a single chain polypeptide 
hormone which is structurally homologous to pro-insulin(122). IGF-1 is produced 
both by the liver and in numerous peripheral sites, and circulates bound to the IGF 
binding proteins, of which IGFBP3 is the most functionally significant. IGF-1 is 
almost completely bound in the circulation which acts to prevent potential insulin 
like activity becoming manifest given the concentration in the circulation is around 
1000 times that of insulin(123). The binding proteins also dramatically expand the 
half-life of IGF-1 in the circulation, and regulate the paracrine effects of IGF’s. The 
main site of IGFBP3 is the liver and, like IGF-1 is under control of GH. In 
childhood, IGF-1 is a reliable marker of GH action, however in adulthood IGF-1 
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levels are dependant on a milieu of other influences, such as age, gender, oestrogen 
and prolactin levels, liver disease and fasting state(124).  
 
As such compared to childhood onset GHD, IGF-1 levels have historically been felt 
to be of much less use in the diagnosis of GHD. Hoffman et al(125) found that even 
after correction for age, 70% of GHD patients had an IGF-1 level in the normal 
range, compared to Deboer et al who demonstrated 93% of young adults with 
childhood onset GHD had an IGF-1 level below the normal range(126). An analysis 
of the KIMS database by Lisset et al found that whilst 83% of patients with child 
hood onset GHD had an IGF-1 level less that 2 SD, in adult onset GHD this was only 
52%(127). Age of onset of the GHD was the most significant factor predicting 
accuracy of the IGF-1 level in diagnosis, however gender, BMI and associated other 
hormonal deficiencies also contributed significantly to the variability. The age 
related reduction in IGF-1 levels means that IGF-1 is particularly unhelpful in this 
group, with only 21% of elderly patients with GHD having an IGF-1 level below the 
normal range(128).  
 
Whilst IGF-1 levels are not found to be sensitive, they are specific. In the absence of 
poor nutrition or liver disease, Biller et al found that whilst 44% of patients with 
MPHD had normal IGF-1, 100% of these patients with IGF-1<2SD had GHD(44). 
Given the difficulties in interpretation of GH stimulation testing the role of IGF-1 
which is similarly influenced by factors such as age and BMI is currently unclear. 
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e) effects of GHD 
i) Glucose Insulin Metabolism. GHD has been shown to be associated with a state 
of insulin resistance(129, 130), and hypopituitary adults have an increased 
prevalence of the metabolic syndrome(131, 132). This is paradoxical as in early 
physiological studies, infusions of GH were also shown to antagonise insulin(133), 
and in conditions of GH excess such as acromegaly, the diabetogenic effects of GH 
are clear to see.  
 
Whist the insulin resistance of GH excess may be due to the inhibitory effect of the 
GH induced lipolysis on glucose uptake (the Randle hypothesis)(82), the insulin 
resistance of GHD may be due to inhibition of the glucose storage pathway and 
reduced activity of glycogen synthase in peripheral tissues(130).  
 
High dose GH treatment is known to reversibly increase insulin resistance in children 
taking supra-physiological doses of GHR. In adults, short term GHR has been shown 
to increase insulin resistance (134-136). It has been shown by Segerlantz et al that 
this is due to the lipolytic effect of GH as hypothesised, since inhibition of lipolysis 
during acute GH administration does not result in insulin resistance (137). 
Regardless of causation however, it is thought that the long term improvements in 
body composition and visceral fat may ultimately result in  improvement in insulin 
resistance, particularly when given at low dose with the aim to maintain an IGF-1 
level within the normal range(138, 139).  
 
ii) Lipid Profiles. GHD is known to be associated with an adverse lipid profile with 
worsening of total and LDL cholesterol, and in some cases reduced HDL with 
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elevated triglycerides(129, 140, 141). Abdu et al demonstrated that this adverse lipid 
profile was directly associated with the increased cardiovascular risk seen in these 
patients(142). GHR has been shown to reduce LDL, however Mcallum et al did not 
demonstrate any change in triglyceride levels. Deepak et al demonstrated a reduction 
in LDL with an increase in HDL cholesterol after 6 months GHR, which was 
associated with a reduction in hs-CRP implying a reduction in overall cardiovascular 
risk(140).  
 
Colao et al demonstrated an improvement in lipid profiles and cardiac performance 
in 15 patients with GHD given GHR, however in 15 untreated patients with GHD a 
further deterioration in both indices was seen when compared with controls(143). A 
recent analysis of the German KIMS database did not however show any benefit of 
GH therapy on long term (4-10 years) lipid profiles(144). This was postulated to be 
due to the lower GH doses, and the long term effects of aging which lead to 
increasingly adverse lipid profiles in the normal population. Studies implying benefit 
as above have tended to be over the shorter term. The reason for concentration on 
lipid profiles is the implied benefits on cardiovascular mortality and morbidity.  
 
Whilst the effects of GHR would be expected to reduce cardiovascular mortality and 
morbidity, evidence is currently lacking of long term cardiovascular benefit(145). 
 
iii) Body Composition.. GH is an anabolic hormone, however also has both lipolytic 
effects and anti-natriuretic effects(146). Patients with GHD therefore suffer with an 
overall gain in fat mass and reduction in lean body mass. A variety of studies have 
looked at the effect of GHR on body composition and despite a number of different 
  
 37 
methodologies and the possible confounding effect of the GH induced restoration of 
circulating volume, all have demonstrated the same conclusions. Table 1.4 shows 
these studies, methodologies and their conclusions. 
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Author Year n 
(onset) 
Duration 
(months) 
LBM FM TBW ECW 
Salomon 1989 24(MO) 6     
Jorgensen 1989 21(CO) 4     
Orme 1992 8(AO) 2     
Binnerts 1992 8(AO) 6     
Whitehead 1992 14(MO) 6/6     
Amato 1993 7(CO) 6     
Bengtsson 1993 10(AO) 6/6     
Chong 1994 7(AO) 3     
Herlitz 1994 16(MO) 6     
Jorgensen 1994 10(CO) 36     
Hansen 1995 29(AO) 12     
Beshyah 1995 38(MO) 6     
De Boer 1995 46(CO) 12     
Snel 1995 30(MO) 6     
Lonn 1996 9(AO) 6     
   24     
Moller 1996 7(AO) 1     
Johannsson 1996 34(AO) 24     
Johannsson 1996 68(AO) 6     
   12/18     
Baum 1996 32(AO) 18     
Hoffman 1996 7(AO) 7 days     
Christ 1997 13(MO) 3     
Attanasio 1997 74(CO) 6     
  99(AO) 12/18 / / /  
MO, mixed onset; AO, adult onset; CO, childhood onset; LBM lean body mass; FM, 
fat mass; TBW, total body water; ECW, extracellular water. 
 
Table 1.4 Studies examining the effect of GH replacement on body composition 
(Carrol et al 1998)(146)  
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 Lean Body mass: GH has been shown to be involved with regulation of lean body 
mass. Healthy volunteers given GH demonstrated increased whole body protein 
synthesis and mitochondrial oxidative capacity(147). Compared with healthy 
controls patients with GHD have been shown to have reduction in lean body mass of 
7-8%. Salomon et al demonstrated that in 24 patients given GH for 6 months, lean 
body mass increased by a mean of 5.5kg whereas in a control group treated with 
placebo, no significant difference was seen(148). This has been replicated in 
subsequent studies. This has been shown to be due to increases in skeletal muscle, 
with increases in thigh muscle cross sectional area having been shown(149, 150). 
 
Fat mass: As previously discussed, GH has been demonstrated to have lipolytic 
actions. Compared with predicted values of fat mass matched for gender and BMI, 
Salomon et al demonstrated that patients with GHD had a mean of 7% greater fat 
mass(148). Recently data from the KIMS database has demonstrated that whilst 
patients with hypopituitarism have an increased fat mass at a younger age, they do 
not demonstrate the age related increase in fat mass seen in normal controls(108). 
The distribution of fat mass in untreated GHD is mainly central and in particular in 
the visceral fat compartment(151). Snel and others have demonstrated that these 
changes are reversed by GHR with a reduction of 4-6kg in GHD adults treated with 
GHR(146, 152).  
 
iv) Extracellular fluid. Studies have demonstrated that total body water is reduced 
in GHD, mainly due to reduction in extracellular fluid(153-155), although reduced 
plasma volume and total blood volume contribute to this(155, 156). Treatment with 
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GH results in increases in extracellular fluid after 3-5 days of treatment(157) with 
increases in blood volume after 3 weeks(156). 
 
v) Bone mineral density. In a study of 36 adults with GHD, 19% were found to 
have osteopaenia(158). Furthermore in a study of 89 GHD adults and 360 controls, 
GHD patients had a 2.5 fold higher fracture rate(159). Patients with GHD have been 
shown in many studies to have reduced bone mineral density(146). GHR does not 
result in short term improvements in bone mineral density, however longer term 
studies demonstrate improvements in BMD at 2 years(160) and at 6 years (161). 
Data on whether GHR reduces fracture risk in the long term are currently not 
available(162). 
 
vi) Muscle strength and exercise performance: Patients with GHD have reduced 
strength and exercise capacity with easy fatigability and markedly reduced energy 
levels(163). These patients have been shown to have reduced muscle mass and 
isokinetic muscle strength compared to normal controls, although intrinsic muscle 
strength remains the same. These features have been shown to improve with GHR 5 
years after replacement commenced(164) and to normalise after 10 years of 
GHR(165).  
 
vii) Quality of Life: QoL response to GH therapy has been reported on in detail over 
a number of years. Psychological well being has been demonstrated to be reduced in 
hypopituitary adults fully replaced with the exception of GH when compared with 
controls(166). Stabler found increased prevalence of anxiety and social phobia in 
adults who suffered with GHD as children who subsequently discontinued GH, 
  
 41 
despite achievement of normal adult height(167). In a study of 86 GHD patients and 
86 age matched controls, Rosen et al reported reduced energy, difficulties in sexual 
relationships increased emotional labiality and social isolation(168). Wallymahmed 
et al compared patients with diabetes, GHD with controls and demonstrated 
increased levels of depression, mental fatigue and reduced self esteem and life 
fulfilment in patients with GHD compared with the other 2 groups, suggesting an 
effect of GHD rather than simply chronic disease(169). Likewise Mukerjee et al 
demonstrated similar impairments in QoL in patients with GHD secondary to cancer 
or pituitary adenomas, with a similar response to treatment, implying an independent 
GH effect on quality of life(170). 
 
 Increased levels of atypical depression have been reported in GHD patients, again 
improving with treatment(171). Deijen found that QoL was worse in patients with 
multiple pituitary hormone deficiencies compared to isolated GHD(172), however a 
retrospective review of the Pfizer KIMS database did not corroborate this 
finding(173). 
 
Double blind placebo controlled trials examining QoL changes after GHR have 
shown mixed and sometimes confusing results; Macauley et al demonstrated 
increased mood and energy in GHD patients after 6 months of replacement when 
assessed by the Nottingham health profile, Psychological general well being schedule 
and the general health questionnaire(174). Likewise Bengtsson et al showed 
improvements in the comprehensive psychological rating scale in 26 patients given 
GH, although no improvements were seen in a second questionnaire, the symptom 
checklist 90(157). Whitehead et al did not demonstrate any changes in QoL in 14 
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patients after 6 months of GHR, however IGF-1 failed to rise in the treatment group 
which may have reflected poor compliance(150). Beshyah et al conducted a 
randomised controlled trial in 40 adults with GHD(175); In the blinded portion of the 
study (first 6 months) improvements were seen in the general health questionnaire 
(GHQ) in the placebo group but not in the treated group, however the placebo group 
had significantly worse GHQ scores prior to treatment which may simply reflect a 
return to baseline in this group. After 6 months the study continued as an open label 
study, and improvements in QoL were seen at 12 months but not 18 months 
following commencement of treatment.  
 
Burman et al measured psychological well being and sense of well being in 36 adults 
and 36 controls(176). They confirmed reduced QoL in GHD patients prior to 
treatment; Following treatment in this blinded cross over study, improvements were 
seen on placebo, however further improvements were seen once GHR was given. 
Arwert et al produced a meta-analysis of patient reported outcomes in 2005 and 
concluded that there was no evidence that GHR improves patient reported outcomes 
in GHD patients(177). A further meta-analysis however by Deijen et al looked at 
improvements broken down into effects on QoL, well being and health status. Whilst 
QoL showed only a small effect size (d=0.18) well being demonstrated a medium 
effect size (d=0.47). Deijen concluded that many studies claiming to demonstrate an 
improvement in QoL were in fact demonstrating an improvement in well being(178).  
 
One confounding factor in all studies is the range of measures of change seen in 
different studies. Attempts have since been made to produce a single validated QoL 
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questionnaire with the publication of the QOL AGHDA score by Mckenna et al 
(179), and the Questions on Life Satisfaction Hypopituitarism Module(QLS-1H) by 
Blum et al(180). The QoL AGHDA score has been validated in a number of different 
populations(181-185), and the score has also been divided into dimensions, namely 
memory, tiredness, tenseness, socialisation and self confidence(186).  
 
Normative data using a number of different populations has also been collated and 
published(187-189). A recent review of the KIMS data base looking at patients 
treated for between 4 and 10 years did demonstrate improvements in QOL AGHDA 
score(144), which were equal in patients with isolated GHD or multiple hormone 
defects in patients with structural pituitary lesions(190). 
 
In conclusion insulin resistance is seen both in GHD and in GH excess, however the 
long-term benefits of GHR are thought to outweigh the effects of insulin resistance 
seen with GHR. Whilst lipid profiles have been shown to improve in short term 
studies there is not currently long term evidence of benefit or changes in morbidity 
and mortality. There is however overwhelming evidence of benefit on body 
composition with increases in lean body mass and reduction in fat mass, which 
would be expected to have beneficial effects to health. There is however insufficient 
long term evidence to be able to demonstrate reductions in cardiovascular mortality 
or morbidity due to GHR. 
 
 GHR also results in increases in extracellular fluid. Such body composition 
abnormalities in patients with GHD mean that any body composition analysis 
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depending on algorithms from normative data must be validated in this group. QoL 
does improve in patients with GHD given GHR, however in some patients the effect 
may be short lived. Improvements depend on the tools used and domains measured. 
There is not currently evidence of long term changes in QoL in patients with GHD 
and other long-term comorbidities as is the case in conditions such as TBI and SAH.
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Section IV: Other pituitary hormone deficiencies 
Cortisol deficiency: 
Whilst primary adrenal failure is commonly isolated, secondary corticotrophin 
insufficiency is usually associated with hypopituitarism, with the main causes being 
as described in the above discussions. Isolated corticotrophin deficiency is rare, 
unless associated with suppression of the hypothalamo-pituitary –adrenal axis by 
exogenous corticosteroids, however may occur in chronic alcoholism and 
lymphocytic hypophysitis(191).  Unlike primary hypoadrenalism corticotrophin 
deficiency is not associated with deficiencies of mineralocorticoids. 
 
The symptoms of hypocortisolaemia can be vague and difficult to separate from 
other pituitary defects. Whist acute deficiencies may result in weakness, dizziness, 
nausea and vomiting, hypotension and hypoglycaemia, chronic cortisol deficiency 
produces tiredness, pallor, anorexia and weight loss(192). Replacement is easily 
given with oral hydrocortisone, however the aim of treatment – to mirror the normal 
diurnal variation in cortisol with highest concentrations on waking can be difficult to 
achieve, and modified release preparations are not yet available. 
 
Cortisol is normally highly bound to albumin and other plasma proteins. Diagnosis of 
cortisol insufficiency based on total cortisol measurements should therefore be made 
with caution in otherwise sick patients in whom hypoalbuminaemia may also be a 
concern. (193).Measurement of free cortisol is more helpful, and is becoming more 
widely available by measurement of salivary cortisol. 
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The gold standard for diagnosis of cortisol insufficiency has always been the insulin 
tolerance test(194). Originally a cut off value of 580 nmol/L was proposed based on 
a comparison of the ITT against 20 patients undergoing major surgery(195). Hurel et 
al examined normal responses to ITT and synacthen in 57 volunteers (30 SST, 27 
ITT)(196). They demonstrated a mean (SD) response to synacthen of 628(392-864) 
nmol/L and to ITT of 693(519 – 866) nmol/L with good correlation between cortisol 
responses to ITT and SST.  
 
They went on to test these values in patients with pituitary disease, however and 
found that in patients who failed the ITT, 60% would have passed the SST at the 
lower end of the normal cut off found in healthy volunteers (390nmol/l). They found 
however that this figure reduced to 10% if a cut off of 600nmol/l were to be used in 
the SST, and therefore proposed this higher threshold for assessment of patients with 
hypothalamo-pituitary disease by SST, with a normal cut off for the ITT of 
520nmol/l.  
 
 A lower cut off of 500nmol/ has since been recommended with the 
acknowledgement that normal individuals may peak lower than this(193), however 
the finding of a lower sensitivity for diagnosis of secondary AI by synacthen testing 
in a meta-analysis by Dorin et al led the authors to suggest that either the ITT or the 
metyrapone test should be used in patients with a high probability of secondary 
AI(197). Pavord et al looked at cortisol responses to ITT and concluded that a basal 
cortisol response >400nmol/l was predictive of satisfactory cortisol reserve thus 
making dynamic testing unnecessary(198). Karacca et al(199) demonstrated 100% of 
30 volunteers passed SDSST at a cut off of 550nmol/l however they defined an 
  
 47 
acceptable response as attaining this level up to 2 hours post stimulus. Had the 30 
min level been taken as is the case in other studies, 20% of healthy volunteers would 
have failed this test. The SST has far less risk than the ITT, however as this tests the 
adrenal glands directly, this mechanism relies on the presumed atrophy of adrenal 
glands as a result of lack of stimulation by ACTH. Therefore the SST can not be used 
in patients less than 1 month after the acute insult(193).  
 
The synacthen test has historically been performed using a dose of 250 g, however 
this supra-physiological dose led to concerns about the sensitivity of this test in 
predicting adrenal insufficiency, and so the low dose test was introduced with the 
aim of improving the sensitivity of this method(200). Since this time however both 
standard and low dose tests have been demonstrated to have similar operating 
characteristics(194, 197). Despite these findings the Standard dose test remains the 
test of choice for secondary adrenal insufficiency in the united kingdom(201).  
 
The GST has also been used to assess cortisol reserve in patients with hypothalamo-
pituitary disease(104), however the precise cut off remains unclear. Littley et al 
compared cortisol responses to ITT and GST in 6 healthy men, finding a mean peak 
of 481nmol/L (range 289 – 717) in the GST compared to 602nmol/L (range 493-792) 
in the ITT(202). Whilst there was no significant difference between the means of the 
two tests, the range in the GST was considerably wider, with 4 subjects of the 6 
failing to attain a level of >500nmol/L. The lack of a demonstrable difference in this 
study is likely to be due to insufficient statistical power. Of note the peak cortisol in 
two of the six subjects was greater than 3 hours post glucagon, demonstrating the 
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requirement for longer testing protocols when testing cortisol reserve. The GST has 
previously been shown to produce great variability in normal subjects(203-205).  
 
Tanriverdi et al looked at cortisol responses to glucagon in 22 healthy volunteers, 
reporting a median value of 450nmol/L with the lowest normal value being 
295nmol/L – this was recommended as the normal cut off value for subsequent 
studies, however a low dose SST was used to confirm deficiencies(206). The largest 
study of cortisol responses to glucagon in health was undertaken in 55 healthy 
volunteers by Karaca et al who compared the GST with standard and low dose 
synacthen tests(199). They reported a mean cortisol response to glucagon of 
592nmol/l with the lowest response of 251nmol/L. When compared to synacthen 
tests, the LDSST returned similar results with a mean peak cortisol of 697nmol/l and 
lowest value of 345nmol/l. If the conventional cut off of 550nmol/l was applied to 
the GST, it demonstrated only 43.6% specificity, with 56% of healthy volunteers 
demonstrating a suboptimal response. Of these suboptimal responses 25% also failed 
the LDSST whereas all volunteers passed the SDSST however as previously 
mentioned, an acceptable response to SDSST in this study was any response up to 2 
hours post stimulus.  
 
In conclusion subtle corticotrophin deficiency, whilst less common than GHD,  can 
be difficult to spot, with vague symptoms which overlap with other conditions. The 
ITT and metyrapone tests are acceptable methods of testing cortisol reserve, however 
their potential morbidity and side effect profile make them impractical. Both 
standard and low dose synacthen tests show good correlation with the ITT however 
up to 20% of normal volunteers will fail these tests at a cut off of 500nmol/l; 
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furthermore they do not test the complete HPA axis. The GST has been shown to act 
via an ACTH dependant mechanism(202) however produces wide variability in 
results leading to a much lower threshold for cortisol response of between 250 and 
300nmol/l. It is likely that in the absence of an optimal response to a single test, 
multiple tests are more efficacious in reducing the false positivity in this field.  
 
Hypothyroidism: 
In common with corticotrophin deficiency, thyrotrophin deficiency is normally found 
in association with other pituitary hormone defects. Once again symptoms can be 
non specific, however generally mirror those found in primary hypothyroidism, 
namely fatigue, weakness, failure to lose weight appropriately and cold 
intolerance(192).  
 
Levels of thyroxine are generally higher than in primary hypothyroidism as a result 
of some residual TSH secretion. Thyrotropin deficiency can be diagnosed by the 
finding of a free T4 level below the normal range, in the face of an inappropriately 
normal or low TSH level(207). The TRH test has historically been used to 
differentiate secondary (pituitary) hypothyroidism from tertiary (hypothalamic) 
hypothyroidism however Pavord et al audited 232 TRH tests and found that the TRH 
stimulation frequently gave results at odds with the baseline samples, and therefore 
recommended that routine use was not advisable(198). 
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Hypogonadism: 
Male hypogonadism: 
 Pituitary disease in men is associated with hypogonadotrophic hypogonadism. 
Hypogonadism has been defined as a low serum testosterone in the presence of 
symptoms and signs of testosterone deficiency including reduction in testicular size, 
reduced facial hair, decreased libido, depression, lethargy and defects of 
cognition(208, 209). This becomes more complicated in older and more obese 
individuals, as testosterone declines with age (see figure 1.4), and with increasing 
BMI, with 19% of otherwise healthy men satisfying the criteria for 
hypogonadism(210). 
 
Testosterone in adult men is required for maintaining libido, secondary sexual 
characteristics and spermatogenesis, however is also involved in accrual and 
maintenance of muscle and bone mass and erythropoeisis. Testosterone exhibits a 
normal diurnal rhythm and circulates in 3 forms  - free testosterone, bound to 
albumin and bound to sex hormone binding globulin – only the first 2 forms are 
biologically active(209), thus it is the free testosterone level which is a better marker 
of testosterone status than total testosterone.  
 
One major confounder in men with hypogonadism is the effect of obesity. It has been 
show that the age related decline in testosterone is worsened in obesity, and affects 
both total and free testosterone levels(211). This reduction in androgen levels may be 
a marker for disorders of insulin-glucose metabolism, and may in fact contribute 
towards their pathogenesis (212). Weight loss will normalise testosterone levels in 
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around 70% of hypogonadal obese men(213), however the benefits of testosterone 
replacement in obesity are yet to be determined(212). 
 
Testosterone replacement results in improvements in body composition with 
reduction in fat mass and visceral fat(214, 215) however a meta-analysis by Haddad 
et al failed to demonstrate any benefit of testosterone replacement on cardiovascular 
morbidity(216). Replacement does however result in improvements in libido, QoL, 
bone mineral density, muscle mass, mood, erythropoesis and cognition(209).  
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      Figure 1.4: Reducing levels of total and bioavailable testosterone with increasing age(208). 
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Female Hypogonadism: 
Female hypogonadism is found in patients with menstrual disturbance or 
amenorrhoea in whom a low oestrodiol level is found in the presence of normal or 
low gonadotrophins. In postmenopausal women where LH and FSH should be 
elevated, normal or low levels indicate hypogonadism(192, 207). Since the oestrodiol 
and gonadotrophins levels vary, it is important to use reference ranges appropriate to 
the menstrual stage.  
 
Symptoms of hypogonadism are similar to in the male with the addition of breast 
atrophy, dyspareunia and infertility(207). Replacement therapy results in 
improvements to symptoms and re-establishment of menses, however infertility 
remains as only end hormones and not gonadotrophins are replaced. 
 
In conclusion, diagnosis of male and female hypogonadism requires careful attention 
to symptoms and interpretation of biochemistry. False diagnosis, particularly in men 
can occur from failure to take account of age related norms, and the effects of obesity 
on binding proteins. Where deficiency is confirmed to be present, sex steroid 
replacement in males and females is effective in reversing symptoms.  
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Section V: Subarachnoid Haemorrhage 
a) Aetiology:  
SAH is caused by rupture of intracranial aneurysms in 85% of cases, the remainder 
being attributable in 5% of cases to other malformations or bleeding disorders(217). 
In 10% of cases, no cause is found(218-220). Most aneurysms are found on the circle 
of Willis with 15% of aneurysms occurring in the vertebro-basilar circulation. 
Aneurysms commonly arise at bifurcations with the commonest site being the 
junction of the internal carotid and the posterior communicating artery (41%) 
followed by the junction of the anterior communicating artery and anterior cerebral 
artery (34%) and middle cerebral artery (20%)(221). 20% of patients have multiple 
aneurysms(222). Aneurysms may be associated with polycystic kidney disease and 
connective tissue disease(217). Risk factors for aneurysm rupture include 
haemodynamic stress, atherosclerosis and hypertension(223, 224)  
 
b) Epidemiology:  
SAH affects in the region of  10/100,000 individuals in the UK per year(225), with 
peak incidence between the ages of 50 and 60 years(226, 227). Haemorrhage is more 
common in women than men in a ratio of 3:2, however this ratio is reduced in 
patients less than 40years(217). A seasonal variability has been noted in SAH 
incidence with a biannual peak in spring and autumn(228). 
 
 In aneurysmal SAH risk is increased if there is a history of SAH in first-degree 
relatives, and is tripled if 3 or more relatives are affected by SAH (227, 229). Other 
risk factors include hypertension, smoking(230, 231) and heavy alcohol 
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consumption(232, 233). Intracranial aneurysms are detected in 2-5% of 
autopsies(234) and a prospective study of over 8000 asymptomatic individuals by 
MRI scanning demonstrated an aneurysm incidence of 6.8% rising to 10.5% in 
participants with a family history of SAH(235). 
 
c)Grading: 
 SAH may be graded clinically by the Hunt and Hess Scale or the World Federation 
of neurosurgeons scale(236, 237). Grading of intracranial  blood is calculated by the 
fisher scale(238, 239).  
 
d) Management: 
 Aims of management are to manage symptoms, identify and treat the underlying 
cause, and prevent complications. Analgesia, control of hypertension, adequate 
hydration and seizure control are all mainstays of acute management(217). 
Nimodipine, a calcium channel blocker is given prophylactically to reduce the 
incidence of vasospasm. Following confirmation of the clinical diagnosis by CT scan 
or lumbar puncture, further imaging by CT angiography and/or Angiography is 
performed to identify aneurysms which are now managed most commonly by 
endovascular coiling, although craniotomy with aneurysm clipping may still be used. 
Whilst 1 year outcome has been shown to be better with coiling(240, 241), there 
remains concern about the increased likelihood of coiled patients requiring 
retreatment due to re-bleed or recurrence   with a 6.9 times likelihood of this in one 
long term follow up study(242).  
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e) Complications:  
i) Re-bleeding: This is commonest in the first 24 hours with a 4-6% risk(243, 244)  
declining thereafter. 50% of patients who re-bleed will die. 
ii) Hydrocephalus: Early hydrocephalus occurs in 20-30% of patients, being more 
frequent in patients with a higher grade SAH. External ventricular drainage is 
effective and VP shunting may be required. One quarter of patients who survive the 
acute phase may develop delayed hydrocephalus(217).  
 
iii) Hyponatraemia: Hyponatraemia occurs in around one third of SAH 
patients(217). This may be due to a combination of cerebral salt wasting and the 
syndrome of inappropriate antidiuretic hormone secretion (SIADH). Management of 
SIADH normally consists of restriction of free water with isotonic fluid replacement. 
 
iv) Vasospasm: Vasospasm is the main risk factor for delayed ischaemic 
neurological deficits, and occurs in 28.5% of cases(245). It is caused by pathological 
changes leading to wall thickening, luminal narrowing and impairment of vessel 
relaxation in addition to vasoconstriction(246) reduced blood flow may lead to 
ischaemia and infarction in the affected territory. The amount of blood in the 
subarachnoid space is a good predictor of vasospasm(238, 247, 248). Management 
aims to prevent onset with prophylactic nimodipine, and treat aggressively when it 
occurs. Hypervolaemia, hypertension and haemodilution (the triple H therapy) has 
been used to prevent ischaemic damage (249-251), and measures to directly reduce 
the amount of subarachnoid blood such as intra cisternal thrombolysis have been 
trialled with some success(252). Using current management techniques 25% of 
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patients with vasospasm will die, whereas 54% of patients will have a good outcome, 
the intervening patients having varying levels of neurological compromise.  
 
 
f) Outcome:  
Up to one quarter of patients will die before receiving medical attention(226) and a 
further 25% of patients developing vasospasm will subsequently die. In survivors, 4-
12% have physical impairment such to impair their ability to perform activities of 
daily living(253-256). A much larger number of patients 44-93% suffer impairments 
in their instrumental activities of daily living, including skills such as managing 
finances, shopping and housekeeping(257-259).  
 
SAH also results in major psychosocial problems(259, 260). Only one third of 
survivors regain functional independence(261) and 92% of patients assessed for their 
health related quality of life reported moderate to severe problems 12 months post 
event, although scores had improved by 12-14% since 3months post event(262).  
 
Problems persist for many years; a study of 610 SAH survivors examined a mean of 
8.9 years post SAH showed that 26% had stopped work, and a further 24% were 
working reduced hours or were in positions of reduced responsibility. 7% were 
divorced due to SAH related issues. 59% reported a change in personality, with 
increased irritability and emotionality being the most common findings. There was 
an increase in depressive symptoms, and 10% of patients had scores on the hospital 
anxiety and depression score suggesting significant depressive or anxiety symptoms. 
Only 25% of respondents reported complete recovery(261).  
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In conclusion SAH is an important condition with high mortality and morbidity. 
Complications such as re-bleeding and vasospasm are common. Whilst complete 
physical recovery may occur, patients are frequently left with complex psychological 
and psychiatric issues which are difficult to treat. Many of these complex difficulties 
appear similar to the problems faced by patients with untreated GHD as discussed in 
more detail in the following section.  
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Section VI: Hypopituitarism following Subarachnoid 
Haemorrhage 
a) Aetiology:  
Compared with other causes of hypopituitarism where there is an obvious and logical 
aetiology, the cause of hypopituitarism in SAH is more occult. Whist radiological 
studies may not document any abnormality, a post-mortem study of 102 patients 
dying as a result of SAH demonstrated hypothalamic lesions in 68%(263) consisting 
of ischaemic necrosis, macro-haemorrhages and micro-haemorrhages with lesions 
localised to paraventricular and supraoptic nuclei.  
 
In the case of aneurysms closes to the midline, bilateral lesions were seen. Possible 
reasons postulated by Crompton et al included increased pressure in the chiasmatic 
cistern, direct damage of the perforating arteries by subarachnoid blood as they 
passed through the subarachnoid space, vasoconstriction, and subarachnoid blood 
passing up the sheaths of the perforating vessels then rupturing into the cerebral 
parenchyma. Other authors have suggested vasospasm(264) and damage done during 
craniotomy(265) as other possible explanations. In a case series of 10 patients with 
non aneurysmal SAH, necrotising pituitary adenoma was highlighted as a possible 
explanation for hypopituitarism(266). 
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b) Incidence: 
 Over the last decade SAH has increasingly been recognised as a cause of 
hypopituitarism, with an overall incidence in the chronic phase (over 5 months post 
injury) of between 37.5% and 55%(267-269). Schneider et al conducted a systematic 
review in 2007 concluding that the incidence of post SAH hypopituitarism was 47%, 
however studies have used different tests, cut offs and populations making 
comparisons between studies difficult. Recently a registry has been set up by German 
endocrinologists in order to evaluate the epidemiology of hypopituitarism after 
subarachnoid haemorrhage and traumatic brain injury. 
 
The first case report of hypopituitarism post SAH was described in 1972, however 
this did relate to an intrasellar aneurysm(270). Osterman et al described 50 patients 
over 3.5 months post SAH investigated by baseline pituitary function tests and 
analysis of the circadian rhythm of 11-hydroxycorticosteroids and the metyrapone 
test. Whilst abnormalities of the HPA axis were found, it was concluded that frank 
hypopituitarism was rare(271). 
 
Kelly et al recognised the commonality of symptoms between patients with 
hypopituitarism and patients with TBI or SAH, demonstrating an incidence of 
hypopituitarism of 40% in 24 patients (2 SAH) over 3 months post insult when 
compared to 18 closely matched controls. Investigation was done by ITT, GnRH test 
and TRH test. Five patients (four men) were found to be hypogonadal on GnRH test 
however all had normal testosterone levels. The GnRH test has however been shown 
to be unreliable in this context(198).  
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Kreitschmann – Andermahr et al  investigated 40 patients between 1 and 6 years post 
SAH by ITT, Arginine, TRH and GnRH testing (265). They found deficits in 43% of 
patients from the cohort whose mean BMI was 26 kg/m
2
. Defects are shown in Fig 
1.5. Four patients had corticotrophin deficiency on ITT, whilst eight patients had 
GHD. Three of these patients did however pass the Arginine test having failed the 
ITT; two of these patients had an elevated BMI. Only one of the eight patients had an 
IGF-1level <-2 SD. Patients with GHD post SAH had gained significantly more 
weight since their SAH and also had a significantly higher BMI than those patients 
without GHD. The very high incidence of isolated corticotrophin deficiency has not 
been replicated, and may be accounted for by poor test- retest reproducibility, or 
borderline attainment of hypoglycaemia(272). 
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4 5 .0 0 %   n o rm a l
3 2 .5 0 %   A C T H  d e fic ie n c y
2 .5 0 %   T R H  d e fic ie n c y
1 2 .5 0 %   G H  d e fic ie n c y
7 .5 0 %   G H  a n d  A C T H  d e fic ie n c y
 
Figure 1.5 – Adapted from Kreitschmann – Andermahr et al: Incidence of pituitary 
dysfunction in 40 patients with SAH(265) 
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Dimopoulou et al investigated endocrine function 12-24 months post SAH by basal 
hormone testing and low dose synacthen testing(268). They found an overall 
incidence of 14/30 patients with endocrine abnormalities however no dynamic test 
for GH secretion was undertaken; the 37% incidence of GHD reported was based on 
IGF-1 levels alone.  
 
Aimaretti et al conducted the first and only longitudinal study employing dynamic 
function testing at two time points in the first 12 months(267). 32 patients were 
included. This involved testing with the GHRH/Arginine test, and single early 
morning measurements of other pituitary hormones. They demonstrated an incidence 
of hypopituitarism at 3 months post SAH of 46.8% falling to 37.5% at 12 months. 
GHD (21.8% at 12 months) was most frequently observed followed by 
hypogonadism (6.25%) hypocortisolaemia (6.25%) and hypothyrotropinaemia 
(9.3%). Whilst mean BMI was 24.7kg/m
2 
, the cut of off 9µg/L used in this test did 
not reflect the large changes seen in the GAT with increasing BMI, therefore the 
incidence of severe GHD is likely to be over estimated. Furthermore single early 
morning cortisol measurements are less sensitive than dynamic tests in diagnosing 
corticotrophin deficiency. Finally, when diagnosing hypogonadism, no account was 
taken of free testosterone or SHBG concentrations. Significantly this longitudinal 
study did not find any new cases of hypopituitarism at 12 months in patients with 
normal pituitary function at 3 months, in contrast to the findings in patients with 
traumatic brain injury in this study.  
 
Further studies have broadly replicated the findings of these initial studies with 
minor variations in the subtypes of hormonal deficits described(273-275), deficits 
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have also been noted in the acute phase after SAH(275, 276) although differentiation 
from adaptive hormonal responses is difficult, with physiological responses to 
critical illness known to mimic central hypogonadism and hypothyroidism, and some 
drugs used in the intensive care setting known to affect the binding of hormones to 
their binding proteins(272). 
 
 Conflicting with previously published data Klose et al. reported only 1 case of GHD 
in a series of 62 patients following SAH, which was not verified when the test was 
repeated.(272) This study used robust BMI appropriate cut offs, and confirmatory 
testing of abnormal results. Whilst 58% of patients were found to have hormonal 
alterations correlated with lower GCS and presence of hydrocephalus in the acute 
phase, none was confirmed on testing at 12 months. Such rigorous testing may 
underestimate the prevalence of hypopituitarism and peak GH was significantly 
lower in the patient group compared with the controls (confounded by the fact that 
controls were significantly younger and fitter than the patients). 
 
Despite the focus on this complication there is still a paucity of data in this area with 
only 122 SAH patients included in the systematic review performed by Schneider et 
al(96), and considerable differences between studies exist, confounded by issues 
such as differences in tests, different cut offs, different treatment modalities and 
different levels of morbidity in the patient population. Other questions remain about 
whether cardio-metabolic and psychological outcomes are influenced by the state of 
pituitary function.  
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In patients with traumatic brain injury, it has been shown that patients with 
hypopituitarism have an adverse lipid profile and unfavourable body composition 
compared with those with normal pituitary function(277). No such studies have 
however been performed in patients following SAH. Likewise both TBI patients and 
SAH patients have been shown to have reductions in QOL, energy, physical heath, 
emotion, well-being and increased rates of depression(278, 279). There have 
however been no prospective studies to demonstrate whether hormone replacement 
improves these factors as it is known to do in other causes of adult 
hypopituitarism(143, 170, 171, 176, 280-285).  
 
In conclusion there is considerable overlap between symptoms seen post SAH and 
symptoms seen in GHD. Unlike other causes of GHD there is no overt pituitary 
damage although hypothalamic damages has been seen at post-mortem in SAH 
patients. Estimates of post SAH hypopituitarism vary greatly and are highly 
dependent on the test used, population studied, including age and adiposity, cut off 
for GHD employed, and treatment given for the original SAH. Compared with other 
patient groups only very small numbers of patients have been studied in this field. It 
is not yet known whether replacement of hormone deficiencies in this population 
improves symptoms or not.  
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Section VII- Hormonal influences on liver function 
Non-alcoholic fatty liver disease (NAFLD) is an increasingly recognised cause of 
chronic liver disease affecting, in some series, up to 30% of the population(286). 
NAFLD is the commonest cause of abnormal liver function tests(287). NAFLD 
spans a spectrum of histo-pathological abnormalities ranging from simple hepatic 
steatosis, steatosis with necro-inflamation  (NASH) and NASH with varying degrees 
of fibrosis which may progress to cirrhosis and its complications including liver 
failure and hepatocellular carcinoma (HCC)(288).  
 
The hallmark of NAFLD is an echo-bright liver on abdominal ultrasonography, often 
accompanied by elevated liver enzymes, however liver enzymes may be 
normal(289), and most patients are asymptomatic, with liver disease identified 
incidentally. Both hepatic and cardiovascular mortality are increased in these 
patients. Regarded as the hepatic manifestation of the metabolic syndrome(290), 
NAFLD is associated with obesity, dyslipidaemia and abnormal glucose tolerance, 
and as such is a multifaceted disorder encountered in disparate clinical settings 
including primary care, gastroenterology, cardiology and gynaecology. Whilst 
obesity is the commonest metabolic cause, a number of other endocrine disorders 
may be associated with NAFLD including thyroid dysfunction, GHD, adrenal 
insufficiency and polycystic ovary syndrome(291).  
 
The evolution of NAFLD to NASH is thought to involve a two hit hypothesis. In the 
first hit, hepatocytes develop an increased triglyceride content, followed by a second 
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hit involving increased oxidative stress(292). A number of endocrine mechanisms 
including hypothyroidism, PCOS and adrenal failure contribute to the development 
of NASH(291). Thyroid replacement has been shown to improve NAFLD after 6 
weeks treatment(293). With adverse lipid profiles and elevated triglycerides being a 
feature of patients with hypopituitarism, and the reduction in lipolysis seen in GHD, 
an association between hypopituitarism and  in particular GHD and NAFLD has 
been examined as discussed below.  
Growth Hormone Effects in NAFLD: 
Whilst the liver is known to have receptors for GH, and indeed is the site of 
production of IGF-1, the effect of GH in regulating liver health is thought to be 
indirect. As previously discussed, the metabolic phenotype  of patients with GHD is 
one of hyperlipidaemia, hypertriglyceridaemia, obesity and insulin resistance and 
along with these features, NAFLD has been found to be common in this population. 
There is evidence to suggest that there is an independent association of GHD with 
NAFLD. Brobeck et al induced hypothalamic damage in animal models of pituitary 
disease, and found that this inevitably led to liver damage(294).  
 
Lonardo et al looked at 61 patients with GHD and 104 controls, finding that GH 
levels were an independent predictor of fatty liver disease in men(295), and Bredella 
et al demonstrated that GH peak to GHRH/Arginine testing was correlated with 
hepatic triglyceride content in healthy obese patients(296). Furthermore individuals 
with cirrhosis have been shown to have reduced synthesis of IGF-1(291). Adams et 
al looked at 21 patients with GHD and NAFLD(297); they noted development of risk 
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factors for the metabolic syndrome, including development of central obesity and 
insulin resistance, with development of NAFLD a mean of 6.4 years after the 
development of hypothalamo-pituitary dysfunction. Biopsies on ten of the patients 
revealed cirrhosis in 6, NASH in 2 and simple steatosis in a further two patients. He 
concluded that GHD patients were at high risk for development of NAFLD.   
 
In patients with hypopituitarism the increased risk of liver pathology would appear to 
be related to GHD; Ichikawa et al looked at 18 patients with hypopituitarism, with 
and with and without GHD, diagnosing NAFLD by the finding of an abnormal liver 
spleen ratio(298). They found an increased incidence of NAFLD only in patients 
with GHD (7/13 GHD vs. 0/5 no GHD). This was despite the two groups of patients 
demonstrating no significant difference in BMI, cholesterol or triglyceride levels. In 
a single case report Takano et al demonstrated improvement in NAFLD after GHR 
but not after prior replacement with hydrocortisone or thyroxine(299). 
 
There is further evidence for the amelioration of liver disease by GHR. A case report 
in 2003 demonstrated reduction in liver fat as part of a constellation of improvements 
including improved lipid profiles, reduced insulin resistance and beneficial body 
composition in a 15 year old boy receiving GH for Alstrom syndrome(300). A 
further case in 2007 documented dramatic improvements in biopsy proven NASH 
after 6 months GHR as shown by normalisation of liver enzymes and improvements 
on biopsy(301).  
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Evidence for the molecular basis of these improvements comes from animal studies. 
Such studies have demonstrated reduced GH receptors in rats with cirrhosis with 
further reductions as cirrhosis progresses (302). GHR in this scenario has been 
shown to improve liver transaminases, increase levels of mRNA expression for the 
GH receptor, regress fibrosis and reduce portal hypertension.  The mechanism for 
this is thought to involve activation of STAT 5A and 5B, transcription factors which 
induce transcription of genes critical for liver metabolism(303).  
 
Whilst these clinical case reports suggest an increased prevalence of NAFLD in 
hypopituitarism and in particular patients with GHD, and the animal studies support 
a molecular mechanism, only one  case control study matching for  BMI (which is 
known to be independently associated with NAFLD(304)) has been performed.  
Nyenwe et al looked at 141 patients with hypopituitarism, retrospectively diagnosing 
the presence of NAFLD based on a variety of criteria including liver biopsy and 
abdominal imaging or biochemistry. They matched these patients with a similarly 
obese population of control subjects without hypopituitarism(305). They found an 
increased incidence of abnormal transaminases in this population (24% vs. 11%) 
however this study was limited by its retrospective nature and imprecise definition of 
NAFLD. No detailed observational studies looking at the effect of GHR on hepatic 
triglyceride content have been conducted.  
 
Intramyocellular lipids  
IMCL act as a source of rapid energy for exercising muscle, therefore IMCL are 
depleted by acute exercise. Likewise however athletes undergoing endurance 
training, have elevated levels of IMCL. There is however a paradox in that it has also 
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been noted that overweight sedentary adults have elevated levels of IMCL and that in 
this situation this abnormal build up of lipid can be associated with insulin 
resistance(306).  
 
Bredella et al who looked at the relationship between GH levels, obesity IHCL and 
IMCL in premenopausal women, found increased levels of IMCL in obesity, together 
with an inverse correlation between IMCL and peak GH levels following GHRH/Arg 
stimulation(296). 
 
Tripp et al went further looking at IMCL in detail in patients with GHD compared 
with matched controls(307), followed by re-examining the patients after 4 months of 
GHR. They looked at IMCL in states of both lipid accumulation and depletion. It 
was noted that patients with GHD exhibited greater variation between depletion and 
repletion, with volunteers retested after 4 months GHR returning towards the control 
group. Given that insulin sensitivity did not change between groups or following 
GHR it was concluded that changes in insulin sensitivity were not responsible for the 
difference. 
 
Krag et al however using a higher dose of GHR in healthy volunteers did note an 
increase in IMCL in association with increasing insulin resistance(308), however 
they did not study depletion repletion cycles. It therefore remains unclear the effects 
or mechanism of effect of GH on IMCL in skeletal muscle.  
 
In conclusion there is a demonstrable link between GH and accumulation of IHCL 
and IMCL. GHD patients are at increased risk of development of NAFLD post 
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diagnosis and this would appear to be an independent GH effect. Animal studies 
provide a possible molecular mechanism. There is however an increase in both 
obesity and insulin resistance in patients with GHD and both of these factors are risk 
factors for increases in both IHCL and IMCL. There are currently insufficient studies 
looking at IHCL and IMCL in a quantifiable way using closely matched controls to 
be able to isolate the individual risk factors and to measure the effect of GHR on 
IMCL and IHCL.  
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Chapter 2 
 
Patients and Methods 
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1. Patient Recruitment for studies 
GHD and NAFLD study. All patients with biochemically severe GHD (Peak GH 
<3nmol/l) and QOL AGHDA score >11/25 (“symptomatic patients”) who were 
about to commence treatment were approached for inclusion in this study provided 
they did not have any of the exclusion criteria asset out in chapter 3.  
 
Patients with severe GHD who did not have a QOL AGHDA score >11/25 
(“asymptomatic patients”) and who therefore did not warrant treatment were also 
approached for inclusion in the cross sectional arm of this study. Other asymptomatic 
patients were recruited during routine follow up visits to the endocrine clinic. A 
number of known asymptomatic patients were also invited to take part in the study 
by letter after authorisation from the local ethics committee. 
 
Healthy controls were recruited from university and hospital staff; in addition a 
number of our patients’ relatives also volunteered to act as healthy controls in the 
study.  
TANITA validation study. Patients and volunteers undergoing the studies above 
underwent estimations of body composition by TANITA analysis. Data from all 
groups were used to validate the TANITA methodology and to highlight differences 
between groups. 
 
Glucagon Validation study. Healthy volunteers were recruited from hospital and 
university staff by local advertisement on the relevant intranets. Relatives of patients 
undergoing the GST were also invited to take part.  
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SAH study. All patients referred prospectively for assessment to the neuro-
dysfunction clinic were included in the prospective longitudinal study of pituitary 
function following SAH provided that they had undergone dynamic function testing 
at more than one point. The neuro-dysfunction clinic was set up by myself to screen 
patients following TBI and SAH and ran from may 2009 until December 2010. 
Referrals were accepted from any source including other tertiary specialties and 
general practitioners, however the majority of patients were referred on discharge 
from the Walton centre by the neurovascular nurse specialist. In addition a number of 
patients who had suffered an SAH some years earlier were referred from the 
neurosurgical clinic or general practitioners. The progress of these ‘retrospective’ 
patients, including response to treatment was also tracked.  
 
TBI study. Data were obtained from the Pfizer KIMS database. The database was 
interrogated for all patients with adult onset GHD due to traumatic brain injury or 
NFPA. Patients who had previously received growth hormone replacement were 
excluded, as were those NFPA patients who had received cranial irradiation.  
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2. Ethical Approval 
Ethical approval was not required for the prospective SAH study, as this was an NHS 
clinical service, and the data collection constituted clinical audit. The GH and non-
alcoholic fatty liver disease study was approved by Liverpool East Regional Ethics 
committee, as was the glucagon study. 
 
3. Hormonal and Lipid measurements 
 
Total cholesterol, high density lipoprotein (HDL), low density lipoprotein (LDL), 
triglycerides (TG), glucose, alanine aminotransferase (ALT), aspartate 
aminotransferase (AST) and gamma-glutamyltranspeptidase (GGT), were measured 
using standardised assays in the hospital laboratory at Aintree University Hospital. 
Serum GH and IGF-1 levels were analysed in the hospital laboratory using 
chemiluminescent immunometric assays using IMMULITE 2000 (Siemens Medical 
Solutions Diagnostics) according to the manufacturer's instructions. Details of all 
assays are shown in table 2.1. 
 
4. Diagnosis of GHD 
All patients deemed to be at risk of GHD underwent dynamic function testing for 
measurement of GH reserve. This was initially performed by GST. Glucagon testing 
was carried out in the   outpatient clinic or on the day case ward. Following an 
overnight fast an indwelling venous cannula was inserted, and blood was drawn for 
growth hormone, cortisol and glucose measurement. Glucagon (Novonordisk) 1mg 
(1.5mg for patients weighing  >90kg) was administered subcutaneously following 
which blood for cortisol, GH and glucose was drawn at 90,120,150,180 and 210 
minutes. By convention in our unit fixed dose glucagon stimulation testing was used. 
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Weight based dosing has been evaluated, being associated with higher side effects 
and a later GH peak, however may be of benefit in older and more obese 
patients.(113)
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Analyte Analyser Assay Analytical 
Sensitivity 
Total CV % Reference Range 
GH Siemens Immulite 2000 from 
Siemens Healthcare Diagnostics 
Solid phase 2-site chemiluminescent 
immunometric assay 
0.01 /L 4.2 – 6.6 Dependent on 
stimulation test 
IGF-1 Siemens Immulite 2000, as above Solid phase, enzyme labelled 
chemiluminescent immunometric assay 
2.6 nmol/l 3.7 – 8.1 11-31 nmol/L 
Cortisol Siemens Centaur, as above Competitive immunoassay using direct 
chemiluminescent technology 
5.5 nmol/l 4.22 – 6.58 07.00-09.00 
119- 618 nmol/L 
TSH Siemens Centaur, as above 2 site sandwich using direct 
chemiluminescent technology 
0.01 mIU/L 3.17 – 5.87 0.4- 4.5 
mIU/L 
FT4 Siemens Centaur, as above Competitive immunoassay using direct 
chemiluminescent technology 
3.9 pmol/l 1.89 – 3.4 8- 21.0 pmol/L 
Prolactin Siemens Centaur, as above 2 site sandwich using direct 
chemiluminescent technology 
6.4 mIU/L 2.9 – 6.6 <500 mIU/l female 
<350mIU/L 
male 
Testosterone Siemens Centaur, as above Competitive immunoassay using direct 
chemiluminescent technology 
0.35 nmol/l 2.7 -7.6 8.5 – 29 nmol/L 
Oestrodiol 
 
Siemens Centaur, as above Competitive immunoassay using direct 
chemiluminescent technology 
25.7 pmol/l 7 – 12.3 Females ND-587 
pmol/L 
Males ND-150pmol/L 
LH Siemens Centaur, as above 2 site sandwich using direct 
chemiluminescent technology 
0.07IU/L 2.7 – 3.8 0.8- 7.6 iu/L 
FSH Siemens Centaur, as above 2 site sandwich using direct 
chemiluminescent technology 
0.3IU/L 2.2 – 3.9 Male 0.7- 11.1 IU/L, 
Female mid cycle 5.8- 
21.0 IU/L 
Cholesterol Beckman Coulter AU 2700 from 
Beckman Coulter UK Ltd 
Enzymatic method producing red 
quinoneimine dye measured at 
540/600nm 
0.07 mmol/l 1.06 – 1.45 <5mmol/L 
HDL-
Cholesterol 
Beckman Coulter AU 2700, as above Enzymatic method producing blue dye 
measured at 600/700nm 
0.002 mmol/l 1.32 – 1.92 >1 mmol/L 
LDL Calculated not assayed Calculation: 
[-(trig)/2.2 – (HDL) + (chol)] = LDL 
  N/A 
Table 2.1 – Endocrine Assays and methods used in this thesis
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Following the test patients were given refreshments and advice on frequent meals for 
the rest of the day. Patients found to have isolated GHD underwent a second test of 
GH reserve by combined growth hormone releasing hormone (GHRH) and arginine 
testing. Following an overnight fast an intravenous cannula was inserted and blood 
was drawn for GH measurement. GHRH (1 microgram/kg to a maximum of 200 
micrograms) was given intravenously following which the patient received an 
infusion of Arginine 10% solution (0.5g/kg to a maximum of 30g). Samples for GH 
were drawn 30, 60, 90 and 120 minutes after the start of the test. Following the test 
the patient was allowed to eat and drink. GHD was defined as a peak GH level <3 
micrograms/l for the GST; the response to arginine was stratified by BMI (cut off for 
severe GHD: GH<11µg/l for BMI <25kg/m
2
, <8µg/l for BMI 25 – 30kg/m2 and 
<4µg/l for BMI >30kg/m
2
). 
 
5. Diagnosis of other hormone deficiencies 
All patients underwent dynamic function testing for cortisol reserve by GST as 
previously described followed by standard dose (250 g) short synacthen testing 
(SDSST) if inadequate reserve was demonstrated on GST. Synacthen testing 
involved insertion of an intravenous cannula. A blood sample was then drawn for 
estimation of baseline cortisol. Following this tetracosactrin, a synthetic ACTH 
preparation was instilled into the cannula over 5 minutes. A blood sample was then 
drawn 30 minutes following the injection for peak cortisol. A peak cortisol less that 
500nmol/l to GST and SDSST would confirm suboptimal cortisol reserve.  
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Gonadotrophin levels were measured together with the relevant sex hormone (either 
testosterone or oestrodiol) to screen for gonadotrophin deficiency. In males samples 
were measured between 9am and 10am. An early morning testosterone level below 
the normal range of 8.5nmol/l in the presence of normal or low gonadotrophin levels 
would indicate gonadotrophin deficiency. Due to the effects of obesity on free 
testosterone, overweight patients underwent measurement of sex hormone binding 
globulin and free testosterone to confirm gonadotrophin deficiency. In females, 
premenopausal women were considered gonadotrophin deficient if they had a low 
oestrodiol level in the face of normal or low gonadotrophins. Postmenopausal 
women would be considered gonadotrophin deficient if gonadotrophins were within 
the premenopausal range. 
 
 Secondary hypothyroidism was defined as a free thyroxine level below the normal 
range, in the face of a normal or low thyroid stimulating hormone. 
 
6. MRI Scan Protocols 
MRI scanning was undertaken at the Magnetic Resonance and Image Analysis 
Research Centre (MARIARC) at the University of Liverpool. Patients attended on a 
mutually convenient day. Participants were fasted and asked to refrain for exercise 
for the preceding 24 hours, however were allowed to drink water freely on the 
morning of the test. 
Following completion of a screening form to ensure there were no contraindications 
to scanning, patients underwent whole body MRI scanning followed by non-invasive 
quantification of intrahepatic and intramyocellular lipid content by proton magnetic 
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resonance spectroscopy (
1
H-MRS) in a 1.5T Siemens Symphony scanner (Siemens 
Medical Solutions, Erlangen Germany). 
 
Whole body MRI was conducted as follows: Whole body axial T1 weighted fast spin 
echo scans were taken coronally with a 10mm slice thickness followed by a 10mm 
gap using the body coil. The patient was scanned in the prone position. Image fat 
analysis was conducted by an external company (Vardis) with fat volume in litres 
reported.   
 
Participants underwent MRI scanning in a 1.5T Siemens Symphony scanner 
(Siemens Medical Solutions, Erlangen, Germany). Coefficients of variation for all 
the following methodologies have been previously published (309-311), 
methodologies are summarised below: 
 
Volumetric analysis of subcutaneous and visceral fat: Abdominal subcutaneous 
adipose tissue (SAT) and abdominal visceral adipose tissue (VAT) was calculated 
from whole body axial T1-weighted fast spin echo scans (axial scans, 10 mm slice 
thickness followed by a 10 mm gap using the integral body coil). The abdominal 
region was defined as the image slices from the slice containing the femoral heads, to 
the slice containing the top of the liver/base of the lungs. All scans were analysed 
centrally. Scans were anonymised prior to analysis thus ensuring the observer was 
blinded to all clinical details. 
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Proton magnetic resonance spectroscopy (
1
H-MRS): In liver, NAFLD was defined 
as IHCL > 5.6%(312). Three voxels of interest were identified in the liver standard 
sites avoiding ducts and vasculature (figure 2.1). In skeletal muscle a single voxel 
was identified in each of the tibialis anterior (TA) and soleus (Sol) muscles, avoiding 
bone, fascia and the neurovascular bundle. Single voxel spectroscopy was conducted 
at each of these five sites. Voxel size was 20x20x20 mm, TE 135 ms, TR 1500 ms, 
with 64 acquisitions. Where the musculature was too small to allow placement of a 
20mm voxel, a 15x15x20 mm voxel was placed and the number of acquisitions was 
increased to 200 to maintain signal-to-noise ratio. In both liver and muscle, voxel 
placement in post-treatment studies was guided by reference to the pre-treatment 
images. 
1
H MR spectra were quantified using the AMARES algorithm in the 
software package jMRUI-3.0(313, 314). As previously described, IHCL is expressed 
as % of CH2 lipid signal amplitude relative to water signal amplitude
31
 after 
correcting for T1 and T2(311), and IMCL is expressed as CH2 lipid amplitude relative 
to total creatine amplitude after correcting for T1 and T2 (315).  
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Figure 2.1: Upper: Representative 1H MR spectra from the livers of subjects with 
(A) high liver fat content 18.1% and (B) low liver fat content 2.1%. The MR Image 
shown (C) shows typical placement of the PRESS voxel in different regions of the 
liver. Lower: Representative 1H MR spectra from the (A) tibialis anterior and (B) 
soleus muscles of calf. The image shows position from which each spectrum was 
acquired. 
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7.  Diagnosis of NAFLD 
Non alcoholic fatty liver disease was defined as an average intrahepatic fat content 
by 1H MRS of >5.6% as defined by Szczepaniak et al (312). 
 
8. Growth Hormone Replacement 
Individuals who were biochemically GH deficient, and who had impaired quality of 
life defined as a QOL AGHDA score ≥ 11 points (‘symptomatic’ patients) were 
commenced on GH replacement in accordance with UK National Institute of Health 
and Clinical Excellence (NICE) guidance. The initial GH dose was 0.2 mg/day 
titrated at monthly intervals to achieve an IGF-1 level within the normal range. 
Patients were supervised by an experienced endocrine nurse and symptoms and signs 
carefully monitored. Patients with biochemical GHD but with a QOL AGHDA score 
<11 did not commence growth hormone.  
 
9.  Body Composition Analysis and Auxology 
Weight, percentage body fat and visceral fat rating was measured fasted  to the 
nearest 0.1 kg wearing light clothing on TANITA scales (Tanita BC420, Dolby 
Medical, Stirling, UK) and height measured to the nearest 0.5 cm using a 
stadiometer. Patients were advised to avoid vigorous exercise in the 24 hours prior to 
testing and to drink normally on the morning of the investigation to avoid errors in 
analysis caused by an abnormal state of hydration.  
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10. Quality of Life assessment 
Quality of life was measured using the validated questionnaire Quality of Life Adult 
Growth Hormone Deficiency Assessment (QoL AGHDA). Participants were asked 
to fill this in making reference to their perceived quality of life over the previous 
month.  
 
11. Protocol for Prospective screening for hypopituitarism following 
SAH 
Patients referred for screening prospectively were seen 3 times over the course of 12 
months following their SAH. The initial visit was 3 months after their SAH. At this 
point they underwent a full clinical history and examination. They then underwent a 
glucagon stimulation test of pituitary function provided that there was no 
contraindication in addition to fasting lipid profile, liver function and renal function 
(sodium, potassium, urea, creatinine, GFR). Patients were seen a second time 3 
months later went changes were noted and basal hormone levels, fasting lipids, renal 
and liver function repeated. If patients demonstrated a suboptimal cortisol response 
to glucagon stimulation then they had a short synacthen test at this visit, unless their 
initial peak cortisol level was less than 300nmol/l in which case they would have had 
a synacthen test as soon as possible after the glucagon stimulation test results were 
received.  
 
Patients were seen one further time 12 months after their subarachnoid haemorrhage 
at which point they had a repeat glucagon stimulation test to detect evolving 
hormone deficiencies, or to confirm persistence of deficiencies already found on 
earlier screening. At all 3 visits patients also filled in the quality of life questionnaire 
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QOL AGHDA. A summary of the screening protocol is included in the table 2.2 
below. 
 
12. Protocol for Retrospective screening for hypopituitarism following 
SAH 
Patients referred over 12 months after their SAH or TBI underwent the same 
evaluation as in visit 1 above. Repeated testing was not undertaken in this group as it 
was assumed that all deficiencies would be static in this chronic phase of the 
recovery.
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Visit number Investigations 
1. 3 months post insult GST, fasting lipids, renal, liver, QOL 
2. 12 months post insult GST, fasting lipids, renal, liver, QOL 
 
Table 2.2 - Prospective screening programme for patients following SAH 
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13. Grading of SAH 
Note was made of the severity of the subarachnoid haemorrhage in all patients 
attending the neuro-dysfunction clinic. This was done both clinically using details 
from presentation at the neurosurgical centre (the world federation of neurosurgeons 
[WFNS] grade), and radiologically by measuring the blood load on the initial CT 
scan (the Fisher grade). Data from case notes was used to calculate the WFNS grade 
whilst Fisher Grade was calculated by a two observers, Dr Mani Purthuran and Dr 
Biswas, consultant neuro-radiologists at WCNN.  Both grading systems are shown in 
the table 2.3. 
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Grade WFNS Fisher 
GCS Motor Deficit 
I 15 - No blood detected 
II 14-13 - Diffuse blood <1mm thick 
III 14-13 + Localised clot or thick layer >1mm thick 
IV 12-7 +/- Diffuse or no blood with intracerebral or 
intraventricular blood 
V 6-3 +/- - 
 
Table 2.3 – Description of fisher grades and WFNS grading system used in grading 
severity of SAH(316, 317)
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Chapter 3 
 
Estimation of Liver Fat in patients with Growth 
hormone Deficiency and the effect of growth 
hormone replacement 
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Abstract 
Non-alcoholic fatty liver disease (NAFLD) is reported to be more common in 
patients with GHD than the general population. We aimed to determine i) liver fat in 
patients with GHD compared to age and BMI-matched controls, and, ii) effect of 6 
months growth hormone replacement (GHR) on liver fat. We also aimed to examine 
the relationship between changes in liver fat and changes in other fat depots of the 
body, namely abdominal visceral and abdominal subcutaneous fat. In doing so we 
also sought to validate bio impedance analysis as a method for quantifying different 
fat depots by comparing this to the gold standard of MRI scanning. 
 
We concluded that NAFLD is equally common in patients with GHD and matched 
controls. GHR is associated with a hierarchical reduction in fat deposition (fat loss: 
visceral >subcutaneous>liver). Bio impedance was less well correlated to MRI 
measures of body composition in patients with GHD in comparison to controls, and 
hence this is not an accurate surrogate measure in this patient group. Further studies 
involving GHD patients with NAFLD are required to conclude the role of GHR in 
treating NAFLD.  
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Introduction 
Untreated GHD is associated with multiple features of the metabolic syndrome 
including insulin resistance, obesity, dyslipidaemia and hypertension(297, 298, 318). 
Body composition analysis in GHD has shown increased central adiposity and 
visceral fat, and reductions in lean muscle mass, which have been linked to the 
metabolic syndrome(148, 319). Furthermore reductions in extracellular fluid volume 
have been seen in patients with GHD(155, 320), which is important when 
considering bio impedance as a method for calculating body composition. Treatment 
with recombinant growth hormone (rGH) has been shown to improve many of these 
features(321-324). 
 
Non-alcoholic fatty liver disease (NAFLD), as the hepatic manifestation of the 
metabolic syndrome, has similarities with adult GHD, being associated with insulin 
resistance and increased cardiovascular mortality(290). Patients with GHD tend to 
gain weight more rapidly and are on average more obese than controls(108, 325), so 
it could be argued that the increased prevalence of the metabolic syndrome in GHD 
is simply related to obesity. Against this, GHD is an independent predictor of 
NAFLD in patients with hypopituitarism(295). Furthermore, patients with 
hypopituitarism including GHD have increased prevalence of NAFLD compared 
with body mass index (BMI) matched patients with hypopituitarism and normal GH 
secretion(298). These data suggest that GHD may be an independent risk factor for 
the development of NAFLD. Previous studies in this area have been limited by 
reliance on less sensitive methodologies to detect NAFLD such as abdominal 
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ultrasonography. Studies have also suffered from poor matching of clinical 
characteristics, such as age and BMI, between the cases and controls.  
Whilst rGH has been shown to produce clinically significant improvements in body 
composition, lipid profiles and insulin sensitivity, reports of improvement in NAFLD 
have been limited to isolated case reports(299-301). Likewise, treatment with rGH 
has been shown to improve insulin sensitivity in obese patients without GHD(326-
328) and in patients with type 2 diabetes(329), but the effect on liver and muscle fat 
has not been documented. With proton magnetic resonance spectroscopy (
1
H-MRS) 
it is possible to non-invasively quantify triglyceride within liver(311) and skeletal 
muscle(315) (intrahepatocellular lipid, IHCL and intramyocellular lipid, IMCL). 
These measurements are metabolically and physiologically relevant as IHCL is a 
better predictor of metabolic risk than visceral fat in obese patients(330), and IMCL 
is also inversely associated with insulin sensitivity in sedentary patients(306). These 
measurements can easily be combined with whole body magnetic resonance imaging 
(MRI) for volumetric analysis of total and regional subcutaneous and visceral fat.   
 
Whist MRI scanning provides accurate body composition data, its use is time 
consuming and expensive, limiting its use both in large scale research studies and in 
clinical practice.  Furthermore many categories of patients are unable or unwilling to 
undergo MRI scanning due to a number of medical contraindications or due to 
inability to tolerate the scan itself. Finally the dimensions of the scanner can prove 
difficult when considering that by definition the population we intend to study is 
obese. Body composition analysis by bio impedance provides a comparatively 
inexpensive and portable method(331) with few contraindications hence provides a 
possible solution and has been developed and validated in particular sectors of the 
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population. Its use has been validated for estimation of skeletal  fat(332), total body 
fat and abdominal adipose tissue(333-335) although inaccuracies have been seen in 
patients with greater abdominal adiposity(336), possibly due to the larger quantity of 
subcutaneous adipose tissue(335). 
 
Bio impedance has not however been validated in patients with GHD in whom 
altered body composition has been well described, and in whom hydration of tissues 
differs to healthy participants. This has been demonstrated by changes in bio 
impedance when GH therapy is commenced(154). In preparation for further studies 
we aimed to ascertain whether the calculations inherent in the estimation of 
abdominal visceral fat were appropriate and accurate in a group of patients with 
GHD. 
 
The aims of this study were therefore as follows: 
1. Based on the previous reports of increased prevalence of NAFLD in patients 
with GHD, compared with controls matched for age, gender and BMI, we 
hypothesised that that the primary outcome measure of liver fat would be 
higher in GHD patients compared to controls. We anticipated that the altered 
phenotype might explain the clustering of cardio-metabolic risk factors 
observed in this patient group.  
2. Consistent with this hypothesis, we further hypothesised that treatment with 
rGH for 6 months would be associated with reductions in IHCL and IMCL.  
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3. We wished to ascertain whether bio impedance analysis was suitably accurate 
in this population of obese patients with and without GHD to enable its use in 
future studies in whom MRI scanning would not be practically possible.  
 
Methods 
The Liverpool research ethics committee approved the study. Written informed 
consent was obtained from all subjects before the study. 
Study design 
This was a cross-sectional study comparing long standing (>1 year) untreated GHD 
patients who were fully GH naive with controls who were mean matched according 
to age and BMI; thus we used 2 independent but comparable groups. Within this 
study a nested cohort of 12 patients commencing rGH were studied longitudinally 
before and six months after commencement of rGH. The nested cohort was 
necessary, because only patients with a symptom score >11/25 using the validated 
questionnaire (Assessment of Growth Hormone Deficiency in Adults)(179) received 
treatment in accordance with UK National Institute for health and clinical excellence 
guidance.  
Clinical and laboratory measurements 
Twenty eight GHD patients attending the tertiary endocrine service at University 
Hospital Aintree, Liverpool were recruited between April 2009 and February 2011. 
The time from the pituitary insult to study recruitment was a median of 5 years 
(range 1 to 33 years). Baseline characteristics are shown in Table 3.1. Of the 2 
patients with Cushing’s disease, both were in long term remission (>5 years).  
Inclusion criteria included GH response less than 3 µg/l after glucagon 
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stimulation(104). Twenty-four controls were recruited by local advertisement. 
Exclusion criteria included alcohol intake > 21 units/week for men and >14 units per 
week for women(329), drugs associated with steatosis, a history of viral hepatitis, 
auto-immune or metabolic liver disease (haemachromatosis, alpha-1 antitrypsin 
deficiency or Wilson’s disease). In addition controls were ineligible if they had a 
history of traumatic brain injury, subarachnoid haemorrhage or an intracranial 
intervention which may have hypopituitarism as a consequence. Controls were 
screened for GHD by clinical history and examination. 
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Patient 
No. 
Diagnosis No of hormone deficiencies in 
addition to GHD 
1 Macroprolactinoma 2 
2 Idiopathic Hypopituitarism 2 
3 Meningioma, craniotomy, DXT 3 
4 Mid brain tumour, DXT 0 
5 Macroprolactinoma, DXT 3 
6 SAH 0 
7 Macroadenoma, TSS 0 
8 Frontal Oligoastrocytoma, craniotomy, DXT 1 
9 SAH 0 
10 Cushing’s TSS 0 
11 Macroadenoma, 0 
12 SAH 0 
13 TBI 1 
14 Macroadenoma 0 
15 Pineal germinoma, DXT 1 
16 Macroprolactinoma, DXT 3 
17 Macroadenoma, TSS DXT 3 
18 Macroprolactinoma 1 
19 Macroadenoma, TSS 0 
20 Empty sella 0 
21 Pituitary apoplexy, TSS 1 
22 SAH 0 
23 Cushing’s, TSS, DXT 2 
24 Suprasellar arachnoid cyst 2 
25 Pituitary apoplexy 2 
26 Intrasellar meningioma, craniotomy 2 
27 TSHoma, TSS, radioiodine 0 
28 Macroprolactinoma 3 
 
Table 3.1 Original diagnoses, management and number of associated pituitary 
hormone deficits in 28 patients with growth hormone deficiency. SAH – 
subarachnoid haemorrhage, TBI traumatic brain injury, DXT radiotherapy, TSS 
transphenoidal surgery. 
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Of the eight women in the growth hormone deficient group all except two were pre-
menopausal, of which two women were taking hormone replacement therapy. In the 
control group three women were post menopausal. Seven patients and two controls 
were taking statins for hypercholesterolaemia, whilst seven patients in each group 
were on anti-hypertensive medications, none of which would be expected to affect 
liver fat. One patient in the growth hormone deficient group was taking metformin 
for type 2 diabetes and remained on the same dose. Two patients in the GHD group 
were taking anti-convulsants. Six patients with GHD were also taking hydrocortisone 
replacement. Following an overnight fast, patients had blood drawn for IGF-1, total 
cholesterol, high density lipoprotein (HDL), low density lipoprotein (LDL), 
triglycerides (TG), glucose, alanine aminotransferase (ALT), aspartate 
aminotransferase (AST) and gamma-glutamyltranspeptidase (GGT).  
 
Weight, percentage body fat and visceral fat rating was measured to the nearest 0.1 
kg wearing light clothing on TANITA scales (Tanita BC420, Dolby Medical, 
Stirling, UK) and height measured to the nearest 0.5 cm.  
 
MRI methods 
MRI methods were as previously described in chapter 2. 
Statistical analysis 
As this was an exploratory study, no power calculation was undertaken. By the same 
rationale, no correction for multiple comparisons has been undertaken and as such 
results should be considered as hypothesis generating rather than conclusive. 
Normally distributed variables are presented as mean and standard deviation and 
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non-normally distributed variables as median and inter-quartile range.  Categorical 
variables are presented as counts. Where the relevant assumptions were met, the 
independent samples t-test was used to compare the healthy control and GHD groups 
on continuous demographic variables. Where natural log transformation was 
unsuccessful in achieving normality, the Mann-Whitney test was used. For 
categorical variables the chi-squared test was used to compare the healthy control 
and GHD groups. ANCOVA was used to compare IHCL between the healthy control 
and GHD groups in order correct for potentially confounding differences between 
groups, despite mean matching. 
 
For those patients measured before and after GHR, paired t-tests were used to 
determine the size of the difference between time points, where the relevant 
assumptions were met. Otherwise the Wilcoxon matched-pairs test was used. For all 
parametric statistical tests undertaken an estimate of the difference between groups 
with corresponding confidence interval is provided. Where variables have been log 
transformed this ‘difference’ represents the ratio of geometric means. Correlation 
analyses were performed using Spearman’s non-parametric rank correlation 
coefficient. Calculations were performed using Stata Statistical software (Stata 
Statistical Software: Release 12. College Station, TX: StataCorp LP.) and GraphPad 
Prism (version 5.0 for Windows; GraphPad Software, San Diego, CA). P<0.05 (two-
tailed) was considered statistically significant. 
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Results: 
When comparing GHD patients and controls, differences in age, BMI, gender and 
waist circumference were sufficiently small to be able to consider them comparable 
(see Table 3.2). As expected, IGF-1 was significantly lower in GHD; however no 
differences were noted in ALT, AST, GGT, or plasma lipid measurements. Alcohol 
intake was greater in the control group (median eleven units, controls vs. three units, 
patients, p=0.01), however there was no association between alcohol intake and liver 
fat in this group (R=0.24, p=0.27). There were no differences between symptomatic 
GHD patients (SGHD) and asymptomatic patients (AGHD) in any measurements, 
including IGF-1 (SGHD 12 (0-29) nmol/l vs. AGHD 11 (7-36) nmol/l; p=0.77) and 
peak GH(SGHD 1.53 (0-3.0) µg/l vs. AGHD 1.09 (0-2.33); p=0.82). All patients 
with GHD were therefore analysed as a single group. There was no correlation 
between severity of GHD (as measured by number of associated pituitary hormone 
defects) and the level of IHCL, IMCL or subcutaneous adipose tissue. There was a 
positive association between the number of associated pituitary hormone defects and 
quantity of visceral adipose tissue (r=0.4, p=0.03). 
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Measurement Controls 
(n=24) 
GHD (n=28) Difference (95% CI) p value 
Age (years) 52.6 (12.0) 52.6 (14.0) -0.1 (-7.5 to 7.4) 0.99 
BMI (kg/m
2
) 27.9 (25.1, 32.1) 27.8 (24.7, 34.7) - 0.93 
Male: female 16:8 20:8 - 0.71 
Waist circumference (cm)
†
 101 (94, 112) 101 (93, 115) 0.99 (0.92 to 1.06) 0.70 
Hip circumference (cm)
†
 105 (100, 114) 101 (97, 117) 1.0 (0.95 to 1.08) 0.61 
AGHDA 
Peak GH (µg/l) 
IGF-1 (nmol/l) 
Random GH (µg/l) 
   - 
   - 
18.0 (14.0, 23.0) 
0.11 (0.06, 0.26) 
14 (5.5, 19.5) 
1.1 (0.2, 2.3) 
11.5 (9.0, 16.5) 
0.15 (0.06, 0.40) 
- 
- 
- 
- 
  - 
  - 
0.0007 
0.68 
Fasting glucose (mmol/l)) 5.0 (0.6) 4.8 (0.7) 0.2 (-0.2 to 0.5) 0.41 
ALT (u/l) 26.0 (24.0, 35.0) 24.5 (20.0, 31.5) - 0.35 
AST (u/l)
†
 27.5 (21.5, 31.5) 25.0 (21.0, 35.0) 1.06 (0.85 to 1.31) 0.61 
GGT (u/l)
†
 32 (24, 45) 25 (18, 56) 1.05 (0.74 to 1.52) 0.75 
Cholesterol (mmol/l) 5.6 (4.6, 6.0) 5.0 (4.7, 5.6) - 0.38 
HDL (mmol/l) 1.3 (1.2, 1.6) 1.2 (1.1, 1.4) - 0.05 
LDL (mmol/l) 
Triglycerides (mmol/l) 
3.4 (2.9, 4.0) 
1.2 (0.9, 1.5) 
3.0 (2.7, 3.5) 
1.4 (1.1, 1.9) 
- 
- 
0.19 
0.11 
IHCL (% CH2/water)
†
 
IMCL-Sol (CH2/creatine)
†
 
IMCL–TA (CH2/creatine)
†
 
Abdominal SAT (l) 
Abdominal VAT (l)
†
 
5.0 (1.5, 12.7) 
11.5 (6.6, 15.8) 
6.9 (5.3, 15.0) 
5.8 (4.3, 7.4) 
3.6 (3.0, 5.8) 
2.8 (1.3, 8.6) 
12.3 (6.4, 18.4) 
6.9 (2.0, 32.7) 
5.7 (4.6, 11.8) 
5.8 (4.3, 7.4) 
1.17 (0.49 to 2.78) 
0.97 (0.70 to 1.36) 
0.78 (0.50 to 1.22) 
- 
0.75 (0.57 to 0.99) 
0.72 
0.87 
0.27 
0.78 
0.04 
 
Table 3.2 - Baseline characteristics of control subjects and GHD patients. Results 
presented as median and range. 
†
Variables analysed after logarithmic 
transformation. 
 
  
 101 
Abdominal visceral and abdominal subcutaneous adipose tissue: VAT was 
significantly greater in GHD than in controls despite there being no significant 
difference in SAT. There was a correlation between VAT and IHCL and IMCL-TA 
but not IMCL-Sol in controls (table 3.3), whilst in GHD only IMCL-TA was 
correlated with VAT.  
 
Intrahepatocellular lipid: IHCL was correlated with BMI in both the patient and 
control groups (Figure 3.2), ANCOVA was used to compare liver fat between the 
two groups whilst correcting for BMI in order to robustly correct for small 
differences between the groups. In this analysis the ratio of geometric means was 
0.81 (95% CI: 0.38, 1.72), p=0.72 indicating that it was not possible to demonstrate a 
difference between the two groups even after correction for BMI. There was no 
significant difference in the proportion of patients with IHCL > 5.6% in each group 
(GHD 32%, controls 50%, difference 19% (95% CI: -45%, 7%) p=0.16), and no 
significant difference in IHCL after adjustment for the covariates of age, gender and 
BMI. (p=0.35). There was no correlation between IHCL and age or gender in either 
group. IHCL was negatively correlated with IGF-1 in the control group (r=-0.50, 
p=0.02) but not the patient group. 
 
Intramyocellular lipid: There was no significant difference between the groups in 
IMCL in either TA or soleus muscles (p= 0.3 (TA); p=0.9(Sol)). IMCL increased 
with age with the exception of IMCL-TA in GHD. IMCL-TA was positively 
correlated with VAT in both groups, but not with BMI. There was no association 
between IMCL and IHCL in either group. 
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Hepatic enzymes: IHCL was associated with ALT and GGT in both controls and 
patients (Table 3.3). In addition ALT was positively correlated with VAT in patients 
but not controls, and GGT was inversely associated with IGF-1 in both groups 
(controls r=-0.65 p=0.001; GHD r=-0.65, p=0.001) 
 
 
 
 
 
 
 
 
 
 
  
 103 
CONTROLS IHCL IMCL - TA IMCL - Sol 
 n r p n r p n r p 
Clinical 
Age (years) 
Gender 
BMI (kg/m2) 
Waist circumference (cm) 
Biochemical 
ALT (u/l) 
AST (u/l) 
GGT (u/l) 
Fasting glucose (mmol/l) 
Total Cholesterol (mmol/l 
Fasting triglyceride (mmol/l) 
HDL (mmol/l) 
LDL (mmol/l) 
IGF-1 (nmol/l) 
Body composition 
 Abdominal SAT (l) 
 Abdominal VAT (l) 
 
24 
24 
24 
24 
 
22 
24 
22 
24 
23 
23 
23 
23 
23 
 
22 
22 
 
0.119 
0.139 
0.608 
0.464 
 
0.455 
-0.31 
0.533 
0.237 
0.3 
0.304 
0.287 
0.122 
-0.504 
 
0.216 
0.677 
 
0.607 
0.5 
0.003* 
0.03* 
 
0.05* 
0.884 
0.015* 
0.302 
0.199 
0.2 
0.2 
0.6 
0.02* 
 
0.4 
0.001* 
 
23 
23 
23 
23 
 
21 
23 
21 
23 
22 
22 
22 
21 
22 
 
22 
22 
 
0.531 
-0.05 
0.356 
0.445 
 
0.026 
-0.099 
-0.183 
0.101 
-0.118 
-0.039 
0.088 
-0.110 
-0.259 
 
0.06 
0.580 
 
0.009* 
0.829 
0.1 
0.03* 
 
0.911 
0.652 
0.428 
0.647 
0.6 
0.862 
0.7 
0.627 
0.244 
 
0.793 
0.005* 
 
23 
23 
23 
23 
 
21 
23 
21 
24 
22 
23 
23 
23 
22 
 
22 
22 
 
0.590 
-0.032 
0.176 
0.241 
 
0.006 
-0.03 
0.294 
0.002 
-0.144 
-0.025 
0.003 
-0.172 
-0.260 
 
-0.04 
0.300 
 
0.003* 
0.886 
0.422 
0.268 
 
0.980 
0.884 
0.196 
0.991 
0.522 
0.912 
0.990 
0.444 
0.243 
 
0.859 
0.175 
 
Table 3.3 - Association of clinical, biochemical and MRI parameters with IHCL, IMCL Soleus and IMCL Tibialis anterior in 24 
controls.  *p value <0.05
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GHD IHCL IMCL - TA IMCL - Sol 
 n r p n r p n r p 
 
Clinical 
Age (years) 
Gender 
BMI (kg/m2) 
Waist circumference (cm) 
Biochemical 
ALT (u/l) 
AST (u/l) 
GGT (u/l) 
Fasting glucose (mmol/l) 
Total Cholesterol (mmol/l 
Fasting triglyceride (mmol/l) 
HDL (mmol/l) 
LDL (mmol/l) 
IGF-1 (nmol/l) 
Body composition 
 Abdominal SAT (l) 
 Abdominal VAT (l) 
 
 
28 
28 
28 
27 
 
28 
22 
23 
27 
28 
25 
28 
23 
28 
 
28 
28 
 
 
-0.12 
0.03 
0.48 
0.46 
 
0.52 
0.21 
0.45 
0.5 
-0.22 
0.06 
0.05 
-0.08 
-0.26 
 
0.370 
0.184 
 
 
0.52   
0.88 
0.01* 
0.02* 
 
0.004* 
0.34 
0.03* 
0.008* 
0.24 
0.78 
0.78 
0.97 
0.18 
 
0.05* 
0.34 
 
 
27 
27 
27 
26 
 
27 
21 
22 
26 
27 
24 
27 
22 
27 
 
25 
25 
 
 
0.119 
0.062 
0.216 
0.305 
 
0.000 
-0.104 
-0.018 
0.453 
0.399 
-0.150 
-0.274 
0.140 
-0.319 
 
0.301 
0.395 
 
 
0.555 
0.757 
0.279 
0.130 
 
0.999 
0.655 
0.936 
0.02* 
0.169 
0.485 
0.167 
0.536 
0.104 
 
0.127 
0.041* 
 
 
27 
27 
27 
26 
 
27 
21 
22 
26 
27 
24 
27 
22 
27 
 
27 
27 
 
 
0.680 
-0.187 
-0.332 
-0.163 
 
0.1 
0.073 
-0.019 
0.108 
0.119 
-0.068 
-0.096 
-0.013 
-0.171 
 
-0.402 
0.026 
 
 
<0.001* 
0.349 
0.09 
0.425 
 
0.625 
0.753 
0.932 
0.599 
0.555 
0.751 
0.633 
0.954 
0.393 
 
0.04* 
0.899 
 
Table 3.4- Association of clinical, biochemical and MRI parameters with IHCL, IMCL Soleus and IMCL Tibialis anterior in 28 patients 
with GHD. * p value <0.05
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Lipid profiles and fasting glucose: There was no significant difference between total 
cholesterol, HDL or LDL between the groups. No components of the lipid profile 
had any significant association with IHCL in either group; however fasting TG was 
negatively correlated with IGF-1 in GHD. There was no difference in fasting glucose 
between patients and controls, although there was a positive correlation with age in 
both groups (controls r=0.46, p=0.02; GHD r= 0.46, p=0.02). Whilst there was no 
association between IHCL and fasting glucose in controls, there was a positive 
correlation in GHD (see table 3.3). 
 
IGF-1: In controls IGF-1 was associated with all markers of adiposity (waist 
circumference, BMI, VAT and SAT, the correlation being most striking for VAT     
(r =-0.615, p=0.035). IGF-1 was inversely correlated with IHCL in controls, even 
after correction for age and VAT (r= -0.504, p=0.028). In GHD there was no 
association between IHCL and IGF-1 levels, or with markers of adiposity (BMI, 
waist circumference, VAT or SAT). 
 
Effect of rGH: Results are summarised in Table 3.4 and Figure 3.2. Twelve patients 
completed six months of rGH treatment, of whom four had NAFLD (liver fat 
>5.6%). Both VAT and SAT reduced in response to treatment, with the VAT: SAT 
ratio also reducing significantly (p=0.02), indicating a proportionately greater 
reduction in visceral fat. There was no overall change in IHCL    (Pre GH 2.7% (0.2 
– 44.8%) Post GH3.2% (0.1 – 20.6%)) (p=0.1). However, subdividing the patient 
group into those with high (n=4) and low (n=8) baseline liver fat (defined as > or 
<5.6% liver fat), reductions in liver fat were seen in the high liver fat group treated 
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with rGH (Figure 3.1b) however this was not statistically significant (p=0.07). The 
magnitude of change in IHCL was positively correlated with the baseline IHCL (r= 
0.906, p=<0.001), thus patients with the highest higher initial liver fat demonstrated 
the greatest improvement (Figure 3.2c).  
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Parameter Pre GH Post GH Difference(95% CI) p value 
Weight 
BMI (kg/m
2
) 
75.4 (69.5, 96.4) 
28.9 (24.6, 33.0) 
77.7 (69.4, 98.4) 
30.0 (25.6, 33.2) 
0.4 (-1.9 to 1.1) 
0.2 (-0.4 to 0.8) 
0.58 
0.54 
IGF-1(nmol/l) 12 (9, 12) 25 (21, 29) 13 (9 to 17) <0.00005 
ALT (u/l) 21 (17, 34) 28 (14, 32) 1 (-13 to 15) 0.88 
AST (u/l) 24 (22, 37) 23 (20, 26) 2 (-12 to 16) 0.75 
GGT (u/l) 29 (20, 56) 33 (20, 45) - 0.06 
Cholesterol (mmol/l) 5.3 (4.7, 5.7) 5.0 (4.7, 5.6) -0.2 (-0.6 to 0.2) 0.26 
LDL (mmol/l) 3.3 (2.6, 4.4) 3.1 (2.7, 3.8) -0.2 (-0.9 to 0.6) 0.65 
HDL (mmol/l) 1.15 (1.0, 1.4) 1.3 (0.9, 1.4) -  0.65 
TG (mmol/l) 1.6 (1.4, 1.9) 1.6 (1.3, 2.5) - 0.80 
Glucose (mmol/l) 4.8 (4.4, 5.3) 5.0 (4.5, 5.4) 0.24 (-0.06 to 0.53) 0.10 
IHCL (% CH2/water) 2.8 (0.6, 14.7) 3.2 (0.8, 9.2) - 0.10 
IMCL TA 
(CH2/creatinine) 
7.0 (6.2, 9.5) 7.4 (6.9, 11.5) 1.0 (-2.4 to 4.6) 0.51 
IMCL Sol 
(CH2/creatinine) 
10.2 (6.0, 16.6) 12.3 (8.9, 16.1) 0.9 (-3.2 to 5.1)  0.63 
Abdominal VAT  (l) 5.6 (4.2, 6.7) 4.4 (3.2, 5.1) -1.5 (-2.3, -0.62) 0.0027 
Abdominal SAT (l) 
VAT:SAT ratio 
6.2 (4.3, 11.9) 
0.8 (0.6, 1.3) 
6.8 (3.8, 11.2) 
0.71 (0.4, 1.0) 
-0.6 (-0.9 to -0.2) 
- 
0.0026 
0.02 
 
Table 3.5 - Anthropometric, biochemical and MRI derived parameters pre and 6 
months post GH replacement in 12 patients (5 female) with GHD. 
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Figure 3.2 A. Relationship between liver fat (logarithmically transformed) and body 
mass index in GHD patients and healthy controls demonstrating no difference in 
liver fat between patients and controls; B. Box and whisker plot demonstrating 
reduction in liver fat following 6 months rGH in 4 patients with elevated liver fat at 
baseline. C. Scatterplot demonstrating the correlation between baseline liver fat and 
absolute change in liver fat (r=0.906;p=<0.001). 
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Correlation between Bio impedance and MRI derived measurements.  
Clinical characteristics 
Altogether 23 patients and 24 controls were entered into this comparison. Smaller 
numbers were due to unavailability of the bio impedance equipment at the time of 
some participant’s attendance. Date for these subgroups are therefore presented 
separately. Groups were well matched for gender, age and BMI. There were 17 
males in the patient group and 18 males in the control group. Median (range) age of 
patients was 53.08 (23,77) years and controls 54.5 (25,77) years. Median BMI was 
27.5 (22.2,46.3) kg/m
2
 and 27.9 (22.9,44.5) kg/m
2
 for controls. Results of both 
Tanita analysis and MRI analysis are shown in table 3.6. Graphical illustrations of 
clinical correlations are shown in Figure 3.3. 
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Measurement Patients  (n=23) Controls (n=24) p value 
Total Body Fat Tanita 
(%) 
27.3(18.2,51.7) 28.1(16.7,52.6) 0.9 
Visceral fat Tanita (units) 12(4,33) 12(3,35) 0.7 
Abdominal Subcutaneous 
Fat MRI (litres) 
6(3,23) 6(3,17) 0.8 
Abdominal Visceral Fat 
MRI (litres) 
5.2(2.6,10.7) 3.5(1.6,14.2) 0.07 
 
Table 3.6 - Body composition measurements on 23 patients and 24 controls 
demonstrating no significant difference between the 2 cohorts.  
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Correlations between MRI and TANITA data 
Controls: MRI measured abdominal visceral fat correlated strongly with Tanita 
visceral fat rating (Figure 3.1B R=0.83 p=<0.0001). In regression analysis age, BMI 
and gender were not significant. R
2
 for regression model 0.83.  
 
GHD pre treatment: MRI measured abdominal visceral fat correlated significantly 
with Tanita visceral fat rating (Figure 3.3A R=0.67 p=0.001). In Regression analysis 
BMI was the most significant predictor of visceral fat. Age, gender and visceral fat 
rating were not significant after correction for BMI. R
2
 for regression model 0.73. 
 
GHD post treatment: MRI measured abdominal visceral fat correlated with Tanita 
visceral fat rating (R=0.64, p=0.034). In regression analysis Tanita visceral fat was 
the most significant predictor. Age, BMI and gender were non significant. R
2
 for 
regression model 0.582. 
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Figure 3.3  - Clinical correlation of Visceral fat rating ascertained by Tanita scales 
vs. MRI estimation of abdominal visceral fat in patients with GHD (Figure A 
R=0.67) and normal controls (Figure B R=0.83). 
 
 
 
 
 
A 
B 
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Discussion 
This study reveals several interesting and novel observations. Firstly, despite higher 
VAT in GHD patients compared with age, gender and BMI matched controls; there 
was no difference in the liver or skeletal muscle fat content between the two groups, 
neither was there any difference in the proportion of people with hepatic steatosis in 
either group. This finding does not support previous observations of an increased 
prevalence of NAFLD in patients with GHD. Secondly, these data provide an 
important insight into regulation of fat deposition by GH with a differential effect of 
GH on the various fat depots. Clearly the most significant effect was the reduction by 
GH treatment on visceral (versus subcutaneous) fat. Whilst GHD patients with 
hepatic steatosis experienced a reduction in liver fat content following treatment with 
rGH, this did not attain statistical significance (p=0.07), most likely due to the small 
number of patients with elevated liver fat in this group. This differential effect has 
led to a poorer correlation of bio impedance with MRI measurements in patients with 
GHD.  
 
We deliberately included a range of BMI and ages to make our study group 
representative of patients with GHD encountered in clinical practice. The BMI of our 
patients at 27.8kg/m
2
 was similar to the range of BMI (28.5 – 29.9kg/m2) seen in the 
GHD patients in a recent analysis of the KIMS database (Pfizer International 
Metabolic Database)(108). Furthermore our study group reflects a range of pituitary 
pathologies, which is a good representation of the average clinic population. We 
therefore believe we have obtained a representative sample of the GHD population. 
Despite the reductions seen in IGF-1 with obesity, our GHD patients had 
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significantly lower IGF-1 levels than our control group, reflecting the pituitary rather 
than hepatic origin of the IGF-1 deficiency in this group.  
 
By using 
1
H-MRS rather than modalities such as CT (measuring liver to spleen 
attenuation ratio) or ultrasonography which are able to assess steatosis semi-
quantitatively(337), we were able to quantify steatosis very precisely. Many previous 
studies used liver transaminases, as a surrogate marker of NAFLD; these may be 
normal in up to 80% of cases(338). In contrast, we can be certain of identifying all 
cases of NAFLD within both of our study groups. The elevated VAT in this 
population is consistent with the previously reported phenotype of patients with 
GHD, having a higher ratio of visceral to subcutaneous fat compared with controls 
matched for BMI. Furthermore, in those patients given GHR, improvements in body 
composition were seen with significant reductions in both subcutaneous and visceral 
fat in keeping with recent data from Eggar et al(339) and the recent meta analysis by 
Hazem et al(340) . 
 
 Our primary outcome measure was IHCL. Our finding that hepatic steatosis is 
equally common in our cohort of patients with GHD and controls is in contrast to a 
number of previous studies, all of which have significant limitations. Ichikawa et al 
found an increased incidence of NAFLD (7/13 vs. 0/5) in 18 lean patients with 
hypopituitarism, but with and without GHD(298). The two groups had similar BMI, 
but neither group of patients was overweight. Furthermore diagnosis was made by 
liver to spleen attenuation ratio using CT, a much less sensitive technique than 
1
H-
MRS. Adams et al also examined the link between NAFLD and GHD(297), however 
the retrospective methodology and lack of a control group means that no comment 
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could be made on the relative prevalence of NAFLD. Longitudinal analysis of these 
patients documented rapid weight gain with deterioration of lipid profiles after 
diagnosis, with NAFLD subsequently being diagnosed a median of 3 years after the 
hypothalamo-pituitary insult. These authors speculated that the cause and severity of 
NAFLD in GHD might be related to the rapid weight gain after diagnosis, which has 
been shown to be a feature in these patients(108, 297) rather than the GHD itself. 
Nyenwe et al examined patients with hypopituitarism retrospectively for features of 
the metabolic syndrome and compared with controls matched for age, obesity, 
gender and race(305). They found greater elevations of serum transaminases in 
patients with hypopituitarism and untreated GHD, although the overall number of 
abnormalities was not significantly different in the two groups (elevated AST 37% 
GHD vs. 34% controls). Finally, Hong et al examined 40 men with hypopituitarism 
with abdominal ultrasonography and compared with 34 age matched controls, 
finding a higher prevalence of NAFLD in hypopituitary patients (32.5% controls vs. 
70.6% patients.)(341).The hypopituitary patients however had a significantly higher 
BMI than controls. 
 
We demonstrated an inverse association between IGF-1 and IHCL in our control 
group but not in GHD. A similar association was found by Arturi et al(342), 
Stavastano et al(337), and by Bredella et al in premenopausal women using 
methodologies similar to our own, although in that study the association was non-
significant after correction for age and visceral adiposity(296), while in our group the 
association remained after correcting for these variables. They also demonstrated that 
peak GH in the combined growth hormone releasing hormone/arginine stimulation 
test was inversely associated with IHCL in premenopausal obese women without 
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GHD(296). In regression analysis GH was found to be a significant predictor of 
IHCL after correction for age and visceral adiposity; however the cross sectional 
nature of this study means that causality cannot be inferred. Volzke et al found an 
inverse association between IGF-1 and severity of hepatic steatosis using a 4 point 
scale in a large cohort of 3863 subjects(343). They likewise were unable to elucidate 
the cause and effect relationship of IGF-1 and liver disease. Ichikawa et al 
demonstrated an association between low IGF-1 levels and fibrosis in patients with 
NAFLD(344), and an association between low GH levels and steatosis in the same 
cohort. Lonardo et al demonstrated that low levels of GH were an independent 
predictor of NAFLD in male patients(295). Despite a significantly lower IGF-1 in 
our GHD patients, neither incidence of NAFLD nor median IHCL were significantly 
different. However it is possible that blunted GH release existed in our control 
population as a result of their obesity.  
 
We did not find an overall reduction in IHCL following treatment with rGH. In 
statistical terms this may be due to the lack of a significant change in IHCL in the 
majority of patients who had normal IHCL, but this masks reductions in steatosis in 
those individuals with elevated IHCL. Given the responsiveness of liver fat to 
hormone replacement demonstrated by our group in a patient after only 6 weeks of 
treatment(293), it would be anticipated that 6 months would be an appropriate length 
of time for some changes to be seen. It would thus appear that there is a differential 
regulation of the different fat depots (visceral, subcutaneous and liver fat depots) by 
the GH/IGF-1 axis with more critical involvement in the regulation of VAT and SAT 
mass compared with liver fat, which may primarily be regulated by other 
physiological mechanisms. The reduction in VAT:SAT ratio also suggests a 
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preferential reduction in VAT rather than SAT, independent of BMI suggesting that 
GH makes patients more metabolically healthy. The important correlation between 
baseline liver fat and the reduction in liver fat is worthy of further study to ascertain 
whether GH may be beneficial in patients with elevated IHCL although to answer 
this question, larger and appropriately powered randomized-controlled studies 
involving NAFLD patients, both with and without GHD, will be required.  
 
We demonstrated that Tanita analysis of visceral fat correlated significantly in all 
groups. It is clear however that this correlation is lower in patients with GHD , and 
that BMI was more closely correlated with the visceral fat in this group. Looking at 
the group of patients who had undergone 6 months of growth hormone replacement 
the correlation was improved, however it is clear that they had not achieved body 
composition similar to healthy controls.  
 
The finding of poorer correlation of bio impedance data with MRI generated 
measurements is unsurprising given the effects of GHD on body composition with 
increased fat mass, lower lean body mass (345) and reductions in extracellular fluid 
volume all being documented(155, 320). The differential effect of GHR on different 
fat depots will also confound accurate bio impedance analysis. It has been shown that 
in untreated GHD whole body resistance is abnormally high, rapidly reducing on low 
doses of growth hormone replacement(154). Bio impedance relies on information 
from transmission through all of these tissues and alterations in extracellular and 
intracellular fluid volumes are known to affect readings, as has been seen previously 
in subjects suffering dehydration after vigorous exercise(346). Tanita devices not 
only measure bio impedance but also interpret this information using algorithms 
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based on BMI, gender and age. Normative data for such algorithms are likely to be 
based on normally hydrated participants. 
 
 Thomas et al investigated the link between intra abdominal adipose tissue on MRI 
and visceral fat as estimated by the newer Tanita technology, the Viscan. In addition 
to multi-frequency bio impedance this incorporates estimation of abdominal 
circumference together with bio impedance analysis particularly of the abdominal 
area. They demonstrated a strong correlation between MRI derived values and 
TANITA generated estimates. They did however notice poorer correlations in obese 
individuals, particularly those with increased abdominal subcutaneous fat. They 
concluded that whilst this equipment was a useful screening tool for population 
analysis of total abdominal fat, prediction of abdominal visceral fat might be limited.  
 
This study has some weaknesses. The relatively small numbers of patients, 
particularly in the intervention arm of this pilot study, mean that conclusions cannot 
be drawn about the effects of rGH on liver fat in NAFLD patients, and that 
population estimates of prevalence cannot be performed. We did find a marginally 
higher alcohol intake in our control population, however the absence of any 
association between liver fat and alcohol intake means that this finding is unlikely to 
be of clinical significance. All participants drank within the safe recommended 
limits(329). There was, as would be expected in a general clinic population, a 
varying length of time between diagnosis of GHD and inclusion in the study. The 
minimum period was 12 months, however this short period of time between 
diagnosis and testing in many patients may result in lower levels of IHCL compared 
with others who have had untreated GHD for a longer period, or those controls who 
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have been obese for many years. 
 We did not perform liver biopsies in our patients meaning that it was not possible to 
differentiate between simple steatosis and the more severe steato-hepatitis. We were 
also therefore unable to demonstrate potential benefits in terms of incidence of or 
improvement in Non Alcoholic Steato-hepatitis which has been reported 
previously(300), or in hepatic fibrosis, which can paradoxically result in lower IHCL 
despite severe liver disease.  Future studies will need to address this issue, possibly 
with the inclusion of transient elastography, clinical fibrosis scores or both(347). 
Finally we accept that whilst this study is aimed to be a proof of concept exploratory 
study techniques such as MRS are unlikely to be helpful in many healthcare settings , 
where this is not routinely available. 
In conclusion, we have demonstrated that there is no significant difference in the 
proportion of people with NAFLD in our patients with GHD compared with controls, 
despite the increased visceral fat volume in patients with GHD. Six months of rGH 
appears to demonstrate encouraging results in reducing liver fat in NAFLD patients 
with significant steatosis however this reduction is less pronounced when compared 
with the marked reduction observed in visceral and subcutaneous fat. We have 
demonstrated good correlation of bio impedance data predicting abdominal visceral 
fat with MRI derived data in normal controls. Whilst we have confirmed changes in 
abdominal visceral fat on MRI scanning in patients with GHD, we have also 
demonstrated that this is not translated into changes in visceral fat on Tanita analysis. 
This is likely to be due to changes in bio impedance in patients with GHDcaused by 
reduced extracellular fluid volume and reduced lean muscle mass, which are not 
compensated for by the standard Tanita algorithm. As such Tanita bio impedance 
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analysis cannot be used for body composition analysis of abdominal visceral fat in 
patients with GHD. 
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Chapter 4 
 
 
Glucagon Stimulation Testing in Health and 
Disease, Validation of methodology and 
correlations with Body Mass Index 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 122 
Introduction 
GHD and hypopituitarism are consequences of many pituitary conditions and have 
been postulated to be common following Subarachnoid Haemorrhage(96). It is 
important to recognise these complications due to clear benefits of replacement on 
health and quality of life. Diagnosis in adults however is challenging, particularly 
with regard to GHD. Compared with childhood GHD, where growth velocity is the 
ultimate evidence of adequate GH secretion, the lack of an auxiological end point 
means that GHD in adult is based entirely on biochemical findings. IGF-1 
measurement, which has been shown to be a reliable marker of GH secretion in 
childhood is felt to be unreliable in adult patients, and so diagnosis is made 
exclusively on the basis of stimulation testing.  
 
Diagnostic uncertainty arises most frequently in the obese patient or the older patient, 
as GH levels are known to vary with both of these factors. Despite this however 
current UK and international guidance gives a single cut off value(97). 
 
In this study we aim to validate our methodology and assay and to ensure that the 
internationally recognised cut off of 3 µg/L is appropriate going forward by 
comparing patients with known GHD with healthy volunteers. We also aim to 
explore the relationship between peak GH and BMI to ascertain whether this can be a 
confounding factor in the diagnosis of GHD in obese patients. 
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Methodology 
Healthy volunteers were recruited, with varying BMI including volunteers with 
BMI>30kg/m
2
.
 
Volunteers were screened for underlying medical conditions which 
may either result in GHD, or interfere with the test. As such patients with a history of 
subarachnoid haemorrhage, traumatic brain injury, pituitary disease, long term or on-
going steroid use, use of opiate medications, tricyclic antidepressant use or history of 
irradiation would not be eligible. Due to uncertainties about the reliability of the 
glucagon stimulation test in subjects with diabetes, this was also an exclusion 
criterion. 
 
Following an overnight fast, patient underwent a standard glucagon stimulation test, 
with 1mg glucagon (1.5mg for patients weighing >90kg) given subcutaneously. 
Following insertion of an indwelling venous cannula, baseline blood tests for cortisol 
and GH were taken. Blood was drawn at 90,120,150,180 and 210 minutes for GH 
and cortisol. Results from this cohort were compared with historical patients from the 
endocrine clinic who have been diagnosed with multiple pituitary hormone defects. 
Since these patients have a >97% chance of being growth hormone deficient(98), it 
will be assumed that this group represents true GHD. A ROC curve was constructed 
for the two groups to determine the cut off giving maximum sensitivity and 
specificity.  
 
Results 
Healthy Volunteers 
15 healthy volunteers were recruited. One participant was excluded however after 
being found to be taking Fibrates which can interfere with GH secretion. The median 
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(range) age of the controls was 47.5 (34,62) years with a BMI of 27.4(20.8,39) 
kg/m
2
.  
 
Of the 14 eligible volunteers, Median IGF-1 was 17.5(10,35) nmol/l. Peak GH was 
6.46(0.56,14.9) µg/L and peak cortisol was 540(271,998) nmol/l. Of the 14 healthy 
controls recruited, four participants would have been classed as growth hormone 
deficient (peak GH<3µg/L). Three of these participants had a BMI greater than 
30kg/m
2
. There was a non-significant correlation between BMI and peak 
GH(Spearman correlation coefficient R=-0.44, p=0.1,figure 4.1). There was no 
correlation between IGF-1 level and peak growth hormone.  
 
Median cortisol level was 540(271, 998) nmol/L. There was no correlation between 
peak cortisol and BMI (R
2 
=-0.14, p=0.62 figure 4.1).  Six controls would be classed 
as having an inadequate cortisol response (<500 nmol/l) on the basis of the GST, 
with the lowest cortisol peak being 271 nmol/l. All these controls subsequently had a 
normal synacthen test.  
 
Patients with Multiple Pituitary Hormone Deficiencies 
33 patients with multiple pituitary hormone deficiencies who had undergone GST 
were identified.  Median age was 45 (14, 78) years. Median BMI was 31.7 (19, 44.7) 
kg/m
2
. Median peak GH was 0.76 (0, 3.1) µg/L. IGF-1 data was not available in this 
cohort. 
 
Healthy Volunteers vs. Confirmed GHD 
Using both datasets a ROC curve was constructed to ascertain the optimal GHvalue 
to correctly diagnose GHD . Using healthy volunteers as confirmed GHsufficient, 
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and patients with multiple pituitary deficiencies as confirmed growth hormone 
deficient. The best fit was achieved with a GH value of 3.0 g/L indicating GH 
sufficiency (figure 4.2). At this value the GST demonstrates an overall sensitivity of 
97% and specificity of 71%. There were insufficient numbers of patients and 
volunteers in each group to stratify the ROC by BMI.  
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Figure 4.1 - Peak GH ( g/L) and peak cortisol (nmol/L) plotted against BMI 
(logarithmically transformed). Demonstrating trend to reduction in peak GH with 
increasing BMI but no association between peak cortisol and BMI. 
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Figure 4.2 -  Receiver Operating Characteristics curve. Demonstrating sensitivity 
and specificity for peak GH level in patients with GHD and healthy controls 
undergoing the GST. Area under the curve 0.93, p<0.0001.  
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Discussion 
The aim of this study was firstly to ascertain whether a cut off of 3 g/L was reliable 
using our local methodology and assays, and secondly to explore the link between 
obesity and GH peak to stimulation to further understand the confounding effect of 
BMI on stimulation testing. We have firstly validated a cut off of 3 g/L, and 
secondly we have confirmed that there is an association between BMI and peak 
growth hormone, which is clinically significant when using this test as a mark of GH 
reserve.  
 
The cut off of 3 g/L has been internationally agreed in consensus statements, 
however Ho et al have stated that local validation is required to ensure that false 
patients are not erroneously diagnosed with GHD(98). This was the primary reason 
for validating our methodology. The GST has been validated previously be other 
centres; Conciaco et al looking at 25 healthy volunteers vs. 33 patients with pituitary 
disease had validated cut off of 3 /L by ROC curve analysis (sensitivity 98%, 
specificity 88%)(102). Berg et al compared the GST to the ITT in 49 patients post 
pituitary surgery(101). Using a GH cut off of 3 g/L, they noted that the GST was 
equally good at distinguishing GHD. ROC analysis however revealed an optimal cut-
off of 2.5 /L with 95% sensitivity and 79% speciﬁcity for GHD using the ITT as the 
gold standard comparator – they did not however investigate healthy volunteers.  
 
Furthermore Kokshoorn et al(348) noted that the frequency of GHD varies between 
studies of SAH and TBI in particular, depending on which test is used. They also 
documented a higher incidence of GHD in studies on TBI patients using the GST and 
GHRP – 6 test. They questioned whether the cut off of 3µg/L for diagnosis of GHD 
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is correct in the GST. Toogood et al however in a review of the KIMS database have 
reconfirmed similarity between the ITT and GST in diagnosis of GHD at a cut off of 
3 g/L(349). In our study we demonstrated that the cut off of 3 g/L does provide the 
best discrimination between GHD and sufficiency, however whilst sensitive at 97%, 
it is only moderate specific 71%. This specificity is lower than Conciaco et al(102), 
however we deliberately selected volunteers with elevated BMI given that our local 
population has a high prevalence of obesity.  
 
BMI is well know to have an effect on a number of stimulation tests, and has been 
shown previously(103, 113, 117, 120, 349-353). There has however been some 
disagreement as to whether, and when this is clinically important. Gomez et al 
showed that the peak GH response to glucagon is correlated with BMI in normal 
controls, even when the mean BMI is 25.8kg/m
2
 (103), however did not find an 
association in patients with pituitary disease. Likewise Berg et al found no 
association between BMI and peak GH in patients following pituitary surgery(96). 
Tzanela et al however noted an association in both healthy controls and patients with 
pituitary disease, demonstrating that 14.3% of overweight controls and 32.1% of 
obese controls failed the ITT with a cut off of 3 g/L(354). Micmacher et al also 
found the GST to be less reliable in middle aged men(107).  
 
We demonstrated an association between BMI and peak GH in our control patients, 
although not in our patients with pituitary disease. Indeed using a cut off of 3 g/L, 3 
out of 4 of our healthy volunteers with a BMI over 30kg/m
2
 would have been 
classified as GHD. Like Tzanela et al(354) we found that all these volunteers had a 
normal IGF-1.  
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With the advent of newer indications for GH stimulation testing namely SAH and 
TBI, new challenges are being presented in accurate diagnosis of GHD. These 
populations are distinct from previous groups of patients where a clear pituitary 
lesion is demonstrable on imaging, and patients have a high incidence of multiple 
deficiencies. Likewise unlike patients with primary pituitary disease, patient with 
TBI or SAH have a clear date of onset, and so it is possible to be clear about whether 
obesity was pre-existing or of new onset following the insult.  
 
It is therefore important to consider what the best test is to be used for diagnosis of 
GHD in this patient group. The 2007 consensus statement on diagnosis of GHD in 
adults(98) stated that ITT, glucagon, GHRH Arginine, and GHRH/GHRP were all 
validated tests for the diagnosis of adult GHD, including TBI and SAH. They also 
stated that only one test was required for a diagnosis of GHD(98, 355). Given that 
there is evidence of post-mortem findings of hypothalamic damage in patients with 
SAH, it could be argued that caution should be applied in using newer combined 
tests, as by stimulating the pituitary directly these can be falsely normal in patients 
with hypothalamic damage(349). This would suggest that therefore in this patient 
group, either ITT or glucagon should be used. ITT however is contraindicated in 
patients with seizures, and cardiovascular disease. Seizures are common in this 
patient group and as the chance of occult cardiovascular disease increases with age, 
routine testing in this patient group, which tend to be aged 40 years and above, is 
problematic. This therefore leaves the GST as the test of choice(105).  
 
Whilst in the GAT, normative values defined by BMI have been established 
(GH<11µg/l for BMI <25, <8µg/l for BMI 25 – 30 and <4µg/l for BMI >30)(356), 
this is not the case for the GST or the ITT. Given that the mean BMI in our clinic of 
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SAH patients is 28.2(Range 20.1 – 42.8) kg/m2 this has to be a consideration. It has 
been shown that using weight based dosing regimens for the GST results in higher 
peak GH levels(113) compared to the fixed dosing regimen used in our study, 
however this requires a longer test as peak responses come later, and the incidence of 
side effects is higher. Given that age related IGF-1 SDS is becoming available this 
could be used, and has been shown to be reliable(107).  
 
Ideally larger studies are required to further elucidate the GH response to glucagon in 
different ages and with varying BMI. Given that an AUC of 0.7 or greater signifies 
that the test is better than simple chance, and assuming a significance level of 0.05 
and SEM 0.08, and assuming equal numbers of patients and healthy participants,   a 
minimum of 22  healthy participants and 22 patients with multiple deficiencies 
would be required in each BMI stratified group. Until this point however it would 
seem reasonable to look to confirmatory testing in the absence of structural pituitary 
disease using a testing method which incorporates BMI specific cut offs.  
 
We found a wide variability in peak cortisol in our healthy volunteers in common 
with other studies. Normal responses ranged from 271-998nmol/l, with 6 volunteers 
(40%) failing the GST with a cut off of 500nmol/L. These findings are similar to 
other authors, with Littley et al(202) finding responses 289-717, and Yuen et al (252-
1104)(113). The breath of variation makes it difficult to find a level with both high 
sensitivity and specificity, and therefore patients with suboptimal cortisol responses 
to GST require an alternative test before being declared cortisol deficient. 
 
In conclusion, we have confirmed that a level for GH peak of 3 g/L offers the best 
balance between sensitivity and specificity, however the relatively poor specificity 
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together with clear influence of BMI requires a confirmatory test, particularly in the 
absence of structural pituitary disease. The GST is a poor marker of cortisol reserve. 
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Chapter 5 
 
Hypopituitarism following Subarachnoid 
Haemorrhage 
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Abstract 
Objective: Hypopituitarism following subarachnoid haemorrhage (SAH) has been 
reported to be a frequent occurrence. However, there is considerable heterogeneity 
between studies with differing patient populations and treatment modalities, and 
most importantly employing differing endocrine protocols and (normal) reference 
ranges of growth hormone. We aimed to examine prospectively a cohort of SAH 
survivors for development of hypopituitarism post-SAH using rigorous endocrine 
testing and compare GH response to glucagon stimulation with a cohort of healthy 
controls of a similar body mass index (BMI). 
Design and Methods: 64 patients were investigated for evidence of hypopituitarism 
three months post SAH with 50 patients tested again at 12 months. Glucagon 
stimulation testing (GST), with confirmation of deficiencies by GHRH/Arginine 
testing for GHD and short synacthen testing for ACTH deficiency, were used. Basal 
testing of other hormonal axes was undertaken.  
Results: Mean age of patients was 53±11.7 years; mean body mass index (BMI) was 
27.5±5.7 kg/m
2
. After confirmatory testing the prevalence of hypopituitarism was 
12% (GHD 10%, asymptomatic hypocortisolaemia 2%). There was no association 
between hypopituitarism and post-SAH vasospasm, presence of cerebral infarction, 
Fisher grade or clinical grading at presentation. There was a significant correlation 
between body mass index and peak GH to glucagon stimulation in both patients and 
controls.  
Conclusions Identification of ‘true’ GHD after SAH requires confirmatory testing 
with an alternative stimulation test and application of BMI-specific cut- offs. Using 
such stringent criteria, we found a prevalence of hypopituitarism of 12% in our 
population. 
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Introduction 
The true prevalence of anterior hypopituitarism after aneurysmal subarachnoid 
haemorrhage (SAH) remains debatable. A number of studies, often incorporating 
patients with both SAH and traumatic brain injury (TBI), have concluded that 
hypopituitarism is common in this patient group (264, 267, 268, 275, 357), with a 
systematic review by Schneider et al in 2007 concluding that hypopituitarism is 
present in 47% of patients in the chronic phase after SAH (96). In contrast Klose et 
al, evaluating 61 patients prospectively concluded that SAH was uncommon having 
failed to identify a single case (358). Lammert et al (359) have recently confirmed a 
prevalence of hypopituitarism lower than previously thought, although in this 
selected cohort not all patients underwent dynamic testing. Currently a number of 
endocrine societies have recommended that all patients should undergo evaluation of 
anterior pituitary function after SAH.(98, 360).  
 
There are limitations to the current literature, which may explain the widely ranging 
prevalence figures of hypopituitarism post-SAH, with a variety of dynamic tests 
using differing cut-off values to determine GHD and a lack of confirmatory testing 
with a repeat or an alternative stimulation test to demonstrate GHD. Other 
confounding factors include assessments at varying time points post-injury and a 
failure to account for the effects of obesity on GH response to stimulation 
testing(118), where obese patients are more likely to receive a falsely positive 
diagnosis of GHD.  Finally, treatment modalities have changed in recent years with 
most patients now treated by endovascular coiling compared with craniotomy and 
clipping(361), which may reduce the severity of the pituitary insult.  
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Accurate diagnosis is essential in this cohort as Subarachnoid haemorrhage (SAH) 
can be a devastating condition which can leave survivors with profound neurological 
disability. Even after a full neurological recovery, many survivors continue to suffer 
from impaired quality of life(279). Given the overlap in symptomatology between 
patients with SAH and hypopituitarism, interest has focused on whether these 
symptoms in SAH may be due to pituitary damage. If confirmed, the question then 
remains as to whether replacement of pituitary hormones, specifically GH may have 
a role to play in improvement in QOL as has been seen in patients with other 
pituitary diseases in which GHR has significantly improved QOL. 
 
The aim of this study was to assess the prevalence and progression of anterior 
pituitary hormone deficiencies, and in particular GHD, with prospective evaluation at 
3 and 12 months post-SAH, using confirmatory testing with an alternative dynamic 
test and accounting for the confounding effects of obesity on GH secretion. We 
hypothesised that by adopting such a rigorous approach, the prevalence of post-SAH 
hypopituitarism would be lower than previously reported.  
 
We further report on a cohort of patients with documented severe, symptomatic GHD 
following SAH, and their response to GHR.  
 
Methods 
Patient recruitment  
Between November 2008 and December 2009, we monitored the presentation and 
progress of 147 patients with a diagnosis of SAH admitted to the Walton Centre for 
Neurology and Neurosurgery, a tertiary neurosurgical referral centre in Liverpool, 
United Kingdom. The outcomes of these patients are shown in Figure 5.1. Eleven 
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patients (7.3%) died in the Neurological Intensive Care Unit and nine (6%) died 
following discharge from the hospital and prior to any endocrine follow up. The 
remaining 127 patients were invited to attend for endocrine follow up at University 
Hospital Aintree, of which 85 patients attended. 21 of these had incomplete 
evaluation for a variety of reasons (needle-phobia, declined consent for dynamic 
function testing or declined further follow up due to lack of symptoms). Thus 64 
patients (50%) (prospective group) underwent complete evaluation of which three 
had a non-aneurysmal SAH. Fifty of these patients were evaluated both at three and 
12 months post-SAH.  
 
In order to ensure that there was no selection bias, baseline characteristics of non-
participants were also recorded where available (table 5.1). The local research ethics 
committee approved the study. 
 
In addition 15 patients (11 female) with a history of SAH over 12 months previously 
who were referred because of symptoms of chronic fatigue and poor QOL and were 
followed at baseline and 6 months. This included 6 patients found to have GHD who 
were evaluated post GHR. Clinical characteristics of these ‘retrospective patients’ are 
shown in table 5.2. Median age was 50(range 33,62) years. Median BMI was 
28(range 20,45) kg/m
2.
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Parameter  Participants 
(n=64) 
Non Participants 
(n=63) 
Age  53.7± 11.6 57.5±13.5 
Body Mass Index  27.5± 5.7 - 
Gender (M:F)  25:39 20:43 
Fisher Grade 
 
1 
2 
3 
4 
Unknown 
3(5%) 
12(21%) 
22(38%) 
21(36%) 
6 
2(4%) 
2(4%) 
14(28%) 
32(64%) 
13 
World 
Federation of 
Neurological 
surgeons Score 
 
1 
2 
3 
4 
5 
Unknown 
49(78%) 
10(16%) 
0 
3(5%) 
1(1%) 
1 
27(62%) 
10(23%) 
2(5%) 
3(7.5%) 
1(2.5%) 
20 
Hydrocephalus  8 (12.5%) - 
Delayed 
Ischaemic 
Neurological 
Deficit 
  
14(22%) 
 
- 
Aneurysm Size 
(n=55) 
<=10mm 
11-25mm 
41 
14 
-   
- 
Aneurysm 
Treatment 
(n= 64) 
Endovascular Coil 
Clipping 
None 
          60 
1 
3 (all non- 
aneurysmal) 
 
Aneurysm 
Location 
 
Middle Cerebral Artery  
Basilar Artery  
Posterior Communicating Artery 
Anterior Communicating Artery 
Pericallosal Artery 
Anterior Cerebral Artery 
Other site 
 
9 
8 
19 
15 
2 
3 
5 
 
Table 5.1 - Clinical Characteristics of 64* patients with subarachnoid haemorrhage 
(*Fisher score unavailable in 6 patients due to transfer in from other hospitals). 
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Numbers (and percentages) demonstrate the distribution of WFNS scores and Fisher 
scores.  
 
 
 
 
Figure 5.1 - Patient flow diagram, demonstrating outcomes of 147 patients admitted 
with a diagnosis of SAH. 
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Patient No. Age Sex Condition Time since insult Treatment WFNS grade (SAH) Pituitary Deficiencies 
1 39 F ASAH 13 months EVC 1 GHD 
2 43 F ASAH 14 months EVC 1  
3 55 M ASAH 12 months EVC 1  
4 33 F ASAH 30 months EVC 1 GHD 
5 47 F ASAH 16 months EVC 1 GHD 
6 62 F ASAH 24 months EVC 1 GHD 
7 51 M ASAH 36 months EVC 1  
8 35 F ASAH 15 months EVC 1 GHD 
9 51 M ASAH 12 months EVC 1  
10 51 F ASAH 11 years Clip 1  
11 50 F ASAH 12 months EVC 2  
12 51 F ASAH 7 years EVC 1  
13 61 F ASAH 4 years Clip 3  
14 44 F NASAH 4 years None 1  
15 44 M ASAH 12 months EVC 1 GHD 
 
Table 5.2 – Clinical characteristics of 15 patients with SAH referred due to symptoms. ASAH, Aneurysmal SAH; NASAH Non 
aneurysmal SAH; EVC Endovascular coiling, GHD Growth Hormone Deficiency, WFNS – world federation of neurosurgeons 
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Clinical protocols  
Patients were assessed prospectively on two occasions, at 3 and 12 months post-SAH 
(or as close as possible to these time points as was practical). An investigation 
algorithm is shown in Figure 2. All patients underwent clinical evaluation, testing of 
basal pituitary hormones and dynamic function testing using the GST. All patients 
with biochemical evidence of cortisol insufficiency or severe GHD  underwent 
confirmatory testing by an alternative method (short synacthen testing and GHRH + 
arginine test).   
The 15 retrospective patients were assessed at just one time point, the time of referral 
to the clinic. 
 
Anthropometric and Quality of Life (QOL) questionnaires  
This was performed as described in the methodology chapter. In the retrospective 
cohort, treatment was offered to severely growth hormone deficient patients if their 
QoL-AGHDA score was ≥ 11 points, in accordance with UK guidance from the 
National Institute of Clinical Excellence (NICE). Growth hormone replacement was 
given at a dose of 0.2mg subcutaneously once daily, with monthly review and dose 
adjustment to achieve an IGF-1 level in the normal range. 
 
 
Clinical and radiological markers of severity of SAH  
Clinical severity was independently graded based on the clinical history and 
examination findings at presentation according to the World Federation of 
Neurosurgical Societies (WFNS) scoring system (362). Admission CT brain scans 
were reviewed by one of two radiologists who were blinded to the clinical condition 
of the patient and Fisher Scale recorded (316) (Table 5.1, 5.2). The number of 
aneurysms, size and location of aneurysm(s), treatment with inotropes and 
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medication use were also recorded. In addition, episodes of delayed ischaemic 
neurological deficit (DIND) (vasospasm) and presence of hydrocephalus were 
recorded. Follow up MRI scans at 6 months were reviewed for evidence of 
infarction.  
 
Biochemical tests  
Following a detailed history and physical examination all patients underwent basal 
pituitary hormone testing including IGF-I, TSH, FT4, FT3, LH, FSH, oestrodiol, 
testosterone and prolactin measurements and a GST for assessment of GHand 
cortisol reserve. The investigation protocol is shown in figure 5.2. 
 
Glucagon Stimulation Testing 
This was performed as previously described. All patients with an inadequate 
(<500nmol/l) cortisol response to glucagon underwent standard dose (250µg) short 
synacthen testing to confirm cortisol deficiency at 12 months, however patients with 
a peak cortisol <350nmol/l, or <500nmol/l with symptoms (such as lethargy) at 3 
months underwent immediate SST – all were normal and no patient in the 
prospective group required hydrocortisone replacement between 3 and 12 month 
assessments. 
 
GHRH/Arginine Tests 
Patients with a GH response to glucagon stimulation <3µg/L underwent GAT as 
previously described.  
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Statistical analysis 
Results are expressed as mean (standard deviation) unless otherwise stated. Smaller 
subgroup data are expressed as median(range). Data analysis was performed using 
SPSS 17.0 for Windows (SPSS, Chicago, IL). p<0.05 (two-tailed) was considered 
statistically significant. 
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Figure 5.2 - Investigation algorithm for hypopituitarism in 64 patients with SAH.  
GST glucagon stimulation test; TSH, thyroid stimulating hormone; FSH, follicle stimulating 
hormone; LH, luteinizing hormone; E2, ethinyloestrodiol; FLP, fasting lipid profile; U/E, urea 
and electrolytes; LFT, liver function tests; SST short synacthen test; GHRH, growth hormone 
releasing hormone; SHBG, sex hormone binding globulin; IGF-1, insulin like growth factor 1, 
cortisol, peak cortisol on dynamic function testing. 
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and free testosterone 
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Results – Prospective cohort 
Clinical Characteristics 
64 patients were clinically reviewed at three months, of which 50 completed follow 
up at 12 months. No patient had known neuro-endocrine disease before the 
pathological event. No patient was receiving glucocorticoid replacement during the 
course of his or her follow up. Clinical characteristics of these patients including 
treatment are summarised in table 5.1. 
 
Of the 64 patients completing the initial testing, 25 (39%) were males and 39 (61%) 
females, mean age was 53.7±11.6 years and mean body mass index (BMI) was 
27.5±5.7kg/m
2
. 39 (61%) patients were either current or recent smokers. All patients 
underwent four-vessel angiography: in three patients however no aneurysm or 
arterio-venous malformation was detected.  Of the 61 patients with aneurysms 
identified, 17 (27%) patients had more than one aneurysm. Additional surgery was 
required in nine cases (External Ventricular Drain insertion for hydrocephalus in 
eight (12.5%) patients, haematoma evacuation in one patient). 14 (22%) patients had 
evidence of DIND (radiological evidence only in 2 patients) during the acute 
recovery period. Eight patients suffered with hydrocephalus. Three patients had 
evidence of infarction follow up MRI scanning, frontal lobe in one patient and 
lacunar infarction in two other patients. Median duration of hospital stay was 12 days 
(range 4 to 130 days).  
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 Glucagon Stimulation Testing GHRH/Arginine + 
synacthen testing 
 3 months 
(n=64) 
12 months 
(n=50) 
12 months 
(n=50) 
Hypopituitarism(any hormone) 29 (45%) 25(50%) 6(12%) 
Growth Hormone Deficiency 13(20%) 11(22%) 5(10%) 
Hypocortisolism 18(21%) 20(40%) 1(2%) 
Hypogonadism 5(8%) 0 0 
Hypothyroidism 0 0 0 
Hyperprolactinaemia 0 0 0 
 
Table 5.3  - Prevalence of individual hormone deficiencies in 64 patients tested at 3 months and 50 patients tested at 12 months 
together with prevalence after confirmatory testing. Note 5 patients (8%) and 7 patients (14%) had multiple deficiencies at 3 and 12 
months respectively. 
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Anterior pituitary function  
The results of pituitary function testing are shown in Table 5.3.  Overall at 12 months 
the prevalence of hypopituitarism was 12% consisting of isolated GHD in 10% and 
asymptomatic hypocortisolaemia (not requiring treatment) in a single patient (2%).  
Likewise there was no change in BMI in the cohort as a whole during this time (3 
months 27.4±5.7kg/m
2
, 12 months 27.8±5.3kg/m
2 
p=0.73). 
 
Patients with hypopituitarism post-SAH were significantly younger, (45(27,50) vs. 
54(20,77) p=0.02) however there was no difference in BMI either shortly after 
diagnosis or at the time of re-testing at 12 months (see table 5.4). Significantly 
however, hypopituitary patients had overall demonstrated weight loss, whilst other 
patients had marginal weight gain. No patients with hypopituitarism had 
hydrocephalus or required inotropes. Only one patient in the hypopituitary group had 
evidence of DIND. There was no association between DIND or requirement for 
surgery and subsequent development of hypopituitarism.  The three patients with 
infarction all had normal pituitary function. There was no difference in the 
distribution of Fisher or WFNS grades between the groups.    
 
Growth Hormone axis 
There was no significant difference in the prevalence of GHD at 3 and 12 months 
based on glucagon stimulation testing. Five patients (8%) and seven patients (14%) 
had multiple deficiencies at 3 and 12 months respectively based on the GST.  There 
was a significant reduction in the prevalence when a second confirmatory test using 
BMI specific cut offs was employed, and no multiple deficiencies were confirmed. 
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There was no difference in mean IGF-I between patients with or without 
hypopituitarism (table 5.4). 
  
Thyroid axis 
There was no significant difference in TSH between the groups at either 3 or 12 
months. A single case of apparent secondary hypothyroidism was detected; however 
the patient was taking phenytoin for seizures related to the SAH. Thyroid function 
subsequently normalised. Two incidental cases of primary hypothyroidism were 
discovered, patients were treated and were biochemically and clinically euthyroid 
prior to pituitary function testing. 
 
Adrenal axis 
A single patient failed to mount a cortisol response greater than 500nmol/l at 12 
months. Peak cortisol to synacthen was 473nmol/l, however the patient was 
asymptomatic without other pituitary deficits and therefore did not require treatment.  
Despite the low prevalence of confirmed adrenal insufficiency on stimulation testing, 
basal cortisol was significantly lower in the hypopituitary group at 3 months. 
Although this difference remained at 12 months, this was not statistically significant. 
  
Gonadotrophin axis 
No cases of female hypogonadism were detected. Five male patients were found to 
have low testosterone in the presence of normal gonadotrophins. Two of these 
patients had clinical symptoms compatible with androgen deficiency (impotence, 
loss of libido) and received androgen replacement between 6 and 12 months after 
repeat testing confirmed the results. In both of these patients however this resolved 
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spontaneously by 12 months and replacement was discontinued. The remaining three 
patients were asymptomatic and were found to have a low sex hormone binding 
globulin (SHBG) presumed secondary to obesity and a normal free testosterone on 
12 month confirmatory testing. 
 
 
Prolactin 
There was no significant difference in prolactin levels between patients at 3 and 12 
months or patients with and without hypopituitarism. No cases of 
hyperprolactinaemia were recorded.  
 
 
Quality of life scores  
Quality of life was impaired at both 3 and 12 months as demonstrated by the QOL-
AGHDA score in which a score of >10/25 indicates significant impairment of quality 
of life(179). There was no significant change in mean QOL-AGHDA score over the 
period of follow up (3 months 11.1±7.6, 12 months 10.4±7.1, p=0.25). There was no 
significant difference in QOL-AGHDA scores between patients with or without 
hypopituitarism (table 5.3) although patients with hypopituitarism had a tendency 
towards higher scores. Quality of life scores at 3 and 12 months were not correlated 
with peak GH or basal cortisol at either time point. 
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Parameter Hypopituitarism at 12 months 
(n=6) 
Normal pituitary at 12 months  
(n=44) 
p value 
Age 45(27,50) 54.6(20,77) 0.02 
Gender (M/F) 6/0 14/30 0.002 
BMI 3 months (kg/m
2
) 28.4(24.2,36.3) 26.6(18.3,43.9) 0.52 
BMI 12 months (kg/m
2
) 27.5(23.2,36.7) 27.7(18.7,47.1) 0.96 
Change in BMI (kg/m
2
)  -0.2(-1,0.4) 0.5(-3.4,3.5) 0.04 
Basal Cortisol 3 months 
(nmol/l) 
202(178,449) 458(146,760) 0.008 
Basal Cortisol 12 months 
(nmol/l) 
256(133,603) 348(192,556) 0.17 
IGF-I 3 months (nmol/l) 18 (14,32) 16.5(3,34) 0.80 
IGF-I 12 months (nmol/l) 22(10,29) 17(4,51) 0.90 
Prolactin 3 months (mU/l) 105(71,163) 116(71,163) 0.94 
Prolactin 12 months (mU/l) 106(95,117) 113(48,286) 0.64  
QOL-AGHDA 3 months 17(6,23) 11(0,25) 0.10 
QOL-AGHDA 12 months 16(3,25) 10(0,25) 0.10 
 
Table 5.4 -Comparison between patients diagnosed with hypopituitarism on confirmatory testing at 12 months and those patients with 
normal pituitary function 
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Effect of BMI on glucagon stimulation testing 
SAH cohort (n=64) 
There was a significant correlation between peak GH to GST and BMI; R=-0.629, 
p<0.0001 (Figure 5.3). In stepwise linear regression in which the variables age, 
gender, need for inotropes, presence of hydrocephalus, WFNS score and fisher grade 
were entered, BMI and inotropes were deemed significant (R=0.581, BMI p=<0.001, 
Inotropes p=0.003). At 12 months the only significant variable affecting peak GH in 
linear regression analysis was BMI at 12 months (R=-0.43, p=0.003). There was no 
correlation between peak cortisol and BMI (R=-0.1, P=0.42). 
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Figure 5.3 -Peak GH response vs. BMI (logarithmically transformed) for patients 3 months following SAH. 
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Results – Retrospective cohort 
Clinical Characteristics 
Fifteen patients (11 female) with a history of SAH were included in the study. The 
median time from insult to referral was 33 months with no patient being assessed less 
than 12 months after the SAH.  The clinical grades at presentation according to the 
grading system of the world federation of neurological surgeons (WFNS) were: 
grade 1, n=13; grade 2 n=1, grade 3 n=1. Fourteen patients were found to have an 
aneurysm as the cause of their SAH, two patients required a ventriculo-peritoneal 
shunt for treatment of hydrocephalus, and one patient required evacuation of a 
haematoma causing raised intracranial pressure. Glasgow outcome score(GOS) at the 
time of assessment was GOS III n=1; GOS IV n=9; GOS V n=5. 
For analysis, patients were divided into 2 groups, those with and without 
hypopituitarism. Results are summarised in table 5.5. 
 
Patient anthropometry 
 There was no significant difference in age or gender in patients with or without 
hypopituitarism. BMI was significantly higher in the hypopituitary patients. Visceral 
fat and total body fat were also non-significantly higher in this group. In the patients 
treated with GHR there was no significant change in weight, BMI, total body fat or 
visceral fat during the 6 months of treatment. 
 
Biochemical results:  
Peak GH levels were significantly lower in the patients with hypopituitarism, along 
with a non-significant reduction in IGF-1. All 6 patients in this group had isolated 
GHD. Three of these patients had a suboptimal cortisol response to glucagon 
stimulation, however subsequently had normal synacthen tests. Basal cortisol levels 
were significantly lower in the patients with hypopituitarism despite their elevated 
BMI.  No deficiencies in the other anterior pituitary hormones were found.   
 
Quality of Life: All patients had significantly impaired quality of life with a QOL-
AGHDA score >11. There was no difference in quality of life scores between those 
patients with and without hypopituitarism at baseline.  
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Follow up data in patients receiving GHR: 
All 6 patients with severe GHD received GHR as all had impairment in QOL 
AGHDA scores. 6-month follow up data demonstrated that median QoL-AGHDA 
score reduced significantly from 18.5 to 10.5 (p=0.046, by Wilcoxon signed ranks 
test, figure 5.4). IGF-1 levels increased significantly (13 nmol/l pre vs. 24.5nmol/l 
post p=0.02) , however there were no other significant changes in other biochemical 
or auxiological parameters. 
 
As a control group, 6 of the patients without GHD who received no treatment also 
completed QoL-AGHDA scores 6 months later. The pre and post scores in both 
groups were compared by ANCOVA.  The difference in scores between groups was -
4.26 (95% CI: -10.24, 1.73, p=0.14). The improvement in scores noted above was 
therefore not significantly different to the change in the control group. 
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 Hypopituitarism (n=6) Normal (n=9) P value 
Age (years) 41.5(33,62) 51(36,61) 0.210 
Gender 5F 6F  
BMI (kg/m
2
) 35.5(27.5,44.5) 23.8(20.2,32.5) 0.03 
Body fat (%) 43.5(26.1,52.1) 32.6(20.5,45) 0.11 
Visceral Fat 12.5(7,16) 6.5(5,10) 0.16 
Peak GH ( g/L) 1.61(0.2,2.9) 6.13(3.48,15.6) 0.008 
IGF-1(nmol/l) 13(11,17) 18(14,27) 0.1 
Basal cortisol (nmol/l) 280(181,345) 442(186,574) 0.045 
Peak Cortisol (nmol/L) 459(380,713) 686(496,818) 0.25 
Cholesterol (mmol/L) 5.1(3.8,5.8) 5.2(3.7,6.8) 0.53 
QOL-AGHDA 18.5(14,25) 18.5(9,25) 0.648 
 
Table 5.5 – Differences between patients with growth hormone deficiency and patients with normal pituitary function at baseline.  
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Figure 5.4 – Change in QOL AGHDA score in patients with symptomatic GHD following SAH before and after 6 
months of growth hormone replacement. 
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Discussion 
We have demonstrated that with the application of rigorous diagnostic criteria, using 
multiple dynamic function tests and BMI-specific cut-offs to define GHD, that 
hypopituitarism occurs in only 12% of patients 12 months post-SAH.  Our observed 
prevalence is lower than the range (37.5-55%) reported by the systematic review by 
Schneider et al. (96), however is comparable to the results of the recent study by 
Lammert et al (359) which found a prevalence of GHD of 10%.  
 
There are two significant differences between the current study and previous studies. 
The first difference relates to the use of multiple and confirmatory GH provocation 
tests.  The importance of confirmatory testing in reliably diagnosing GHD and 
cortisol deficiency has already been highlighted in studies examining hypopituitarism 
in TBI (348).  Klose et al (358) assessed 61 patients for GHD using the insulin 
tolerance test (ITT), or if contra-indicated, the GHRH-Arginine test. In cases where 
GHD was demonstrated, a confirmatory test was performed. With this approach, 
surprisingly, the authors did not identify a single case of hypopituitarism. Their 
approach is however consistent with the findings of Lissett et al (363) who 
demonstrate that a single GH provocation test can only reliably diagnose GHD in 
patients with two or three additional pituitary hormone deficits. For these reasons we 
used two different GH provocation tests to confirm the diagnosis of GHD in all 
patients as none of our patients had multiple pituitary deficiencies.  
 
The second significant confounding factor affecting the outcome of endocrine testing 
in many of the earlier studies is a failure to account for the effects of obesity on GH 
secretion. Obesity has been clearly associated with impaired GH secretion: for each 
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unit increase in BMI, there is a 6% reduction in the daily GH secretion rate (36). This 
impairment is also evident in patients at risk for pituitary function deficit and thus is 
reflected in the results of a variety of GH provocation tests with negative correlation 
of GH peak with BMI (117, 118, 351, 356) including the insulin tolerance test (118, 
364).  BMI-specific GH cut off values to diagnose GHD using the GHRH-arginine 
test have been published(356).  As yet however there have been no analyses of BMI-
specific cut-offs to diagnose GHD when other stimulation tests are used. 
 
Our Endocrine Unit uses the GST as the first line GH provocation test (104), which 
has been validated previously(365, 366) and has been shown to be equivalent to the 
Insulin tolerance test (102, 112). The Endocrine Society in its recent Guidelines 
acknowledged the role of the GST for the diagnosis of GHD, particularly in the face 
of the recent shortage of GHRH(105) and in cases where the ITT maybe contra-
indicated (98, 360). Gomez et al who evaluated the GST in healthy controls found 
that none of their 46 volunteers failed to achieve a GH response <3µg/l, however the 
population used was lean. They did however note a significant correlation between 
BMI and peak GH response (103). We have demonstrated a negative correlation 
between peak GH and BMI in both healthy controls and in SAH patients; patients 
and healthy controls with a BMI > 30kg/m
2
 frequently failed to achieve a peak GH 
level >3µg/l. Assuming our study conclusions had been based only on the outcome 
of a single test (the GST), without consideration of BMI or a second confirmatory 
test, the reported prevalence of hypopituitarism would have been very different, at 
50%, broadly in line with the results of the early studies. This would suggest that the 
GST should not be used in isolation for diagnosis of hypopituitarism following SAH. 
Instead, using strict diagnostic criteria the prevalence of GHD was only 10%.  
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The second possible explanation for our much lower prevalence of neuroendocrine 
dysfunction may relate to the population studied. By offering follow up to all SAH 
survivors we had a large proportion of more favourable grade SAH patients, however 
Klose et al had more higher grade patients, and Lammert et al only included patients 
with fisher score 3/4, yet both groups found an prevalence similar or lower than 
ourselves. Our rate of vasospasm was lower than Lammert et al and comparable to 
Klose et al; however we had the greatest proportion of patients treated by 
endovascular coiling which may have been a significant factor. Kreitschmann-
Andermahr et al (265) had speculated that open surgery may be associated with a 
higher incidence of hypopituitarism, and Bellebaum et al(367) had found a higher 
incidence of neuropsychological morbidity in patients who underwent clipping 
versus coiling.   
 
One of the main strengths of our study is that our cohort of patients is a 
representative sample of all SAH patients, with all surviving patients invited and 
encouraged to undergo evaluation at 3 and 12 months post-SAH, including patients 
with significant disability. Participants and non-participants are of similar age with a 
similar severity of SAH (according to WFNS scores at presentation). Whilst caution 
must be exhibited in using cut off values from alternative assays, we have used 
commercial assays with good standardisation data, and have previously validated the 
cut of of 3micrograms/L for the GST in healthy controls. Furthermore the similar 
prevalence of GHD on GST compared with other studies using  the GST alone is 
further reassurance of the appropriateness of this method. 
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We have also demonstrated that patients with confirmed hypopituitarism have 
significantly lower basal cortisol levels at 3 months and a tendency for lower levels 
at 12 months although they have acceptable peak cortisol responses following 
dynamic testing of the hypothalamic-pituitary-adrenal axis. This was again seen in 
our retrospective cohort were patients with GHD had lower basal cortisol than 
patients without GHD. These patients also tended to have lower quality of life scores 
(QOL-AGHDA), however this was not statistically significant. These findings of 
subtle defects of cortisol production, not apparent on stimulation testing, may 
suggest, disturbances in the circadian rhythm may be present as noted by Osterman 
(271) and lends support to the concept that these patients suffer pituitary 
insufficiency, rather than overt hypopituitarism, as is normally found in other causes 
of hypopituitarism.  
 
Whilst these disturbances are not likely to lead to acute adrenal insufficiency, they 
may be responsible for the often-disabling lethargy seen in these patients. Unlike the 
prospective cohort, patients in the retrospective cohort with GHD did have elevated 
BMI with reduced basal cortisol levels whereas healthy obese patients would 
normally have elevated basal cortisol levels(368).   
 
 However given the complex interplay of both age and BMI on normal adrenal 
responses and ACTH sensitivity(369) these changes could simply represent normal 
physiological variance. This aspect certainly merits further investigation, and 
evaluation of the hypothalamo-pituitary-adrenal axis with 24-hour cortisol 
concentrations and diurnal variability may be informative.  
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With such a low prevalence we were unable to identify any clinical factors that may 
predict hypopituitarism. Kelly et al (264) had suggested the presence of clinical 
vasospasm as a possible aetiological factor, however only one of our patients with 
hypopituitarism had suffered this complication. Lammert et al (359) had also found a 
link between early hypogonadism and vasospasm; we did not find this, however the 
number of cases of vasospasm in that cohort was approximately double the number 
in our cohort. Likewise we found no link with the presence of hydrocephalus in our 
study.  
 
There has been debate over the possible causation of hypopituitarism in SAH. 
Possible reasons postulated by Crompton et al included increased pressure in the 
chiasmatic cistern, direct damage of the perforating arteries by subarachnoid blood as 
they passed through the subarachnoid space, vasoconstriction, and subarachnoid 
blood passing up the sheaths of the perforating vessels then rupturing into the 
cerebral parenchyma. Other authors have suggested vasospasm(264) and damage 
done during craniotomy(265) as other possible explanations. Crompton et al (263) 
had also noted hypothalamic damage due to macro and micro haemorrhage in post 
mortem specimens from patients with SAH. This is significant as GHRH/Arginine 
testing does not act through the hypothalamus and therefore it is possible that use of 
this test may underestimate the presence of hypopituitarism if hypothalamic damage 
were the cause.   Three of our patients had radiological evidence of infarction on 
follow up scanning however this was not associated with hypopituitarism. Unusually 
in this study we included three patients without an identifiable aneurysm (non-
aneurysmal SAH), two of whom were found to have hormonal insufficiencies; this 
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has previously been reported (266) however  recent studies have not included this 
patient group. This group may warrant further study.  
 
In our retrospective cohort we demonstrated a higher incidence of pituitary 
dysfunction, as may be expected when studying a selected group. Only one patient 
with GHD had lasting neurological damage, the remainder having made a full 
physical recovery. It has been shown that patients with SAH have a persistent 
impairment of their quality of life unrelated to physical disability (367, 370), and that 
the symptoms demonstrated in SAH survivors bear close resemblance to those of 
patients with GHD. Whilst the data on treated patients in isolation suggest that there 
are improvements in QOL after GHR, when compared with the control group, this is 
not statistically significant. Our numbers are however small and it is likely that 
failure to achieve significance is at least in part because the study is underpowered. It 
is however possible that this improvement was down to placebo effect, or natural 
recovery from the SAH, although this is less likely as in most cases it was a 
considerable period of time since the initial insult.  
 
It is still more difficult to explain the improvements in QOL seen in untreated 
patients, however in this group there may also be the effect of the reassurance of a 
normal test result on psychological well being. The QOL AGHDA score is also 
relatively crude as a measure of QOL and so subtle or domain specific changes will 
not be picked up. It will also not distinguish from other life factors apart from GHD 
which may affect QOL as demonstrated by the similar scores in both halves of the 
cohort at baseline. This was also found in the study by Kreitschmann-Andermahr 
who studied a cohort of patients following TBI and demonstrated a reduction in QOL 
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in patients with neuroendocrine dysfunction using other QOL tools but no significant 
difference in QoL-AGHDA scores in those patients with or without GHD. Kelly et al 
(278) also found reduced domain specific QOL in patients with post TBI 
hypopituitarism using other measures of QOL.  
 
It remains unclear what role cortisol has to play in determining QOL. As previously 
mentioned we have seen lower basal cortisol levels in our retrospective patients with 
GHD. 
Kreitschmann-Andermahr at al did find a correlation between QOL impairment and 
basal cortisol levels in patients following traumatic brain injury and it may be 
possible that subclinical defects in the HPA axis may partially explain the symptoms 
these patients describe. In our study we found no association between basal cortisol 
level and QOL AGHDA score, however given the limitations of cohort size and 
questionnaire type this aspect would certainly merit more attention in future studies.  
 
In conclusion, we have demonstrated a prevalence of hypopituitarism in our 
prospective SAH cohort of 12% after 12 months follow up, consisting of isolated 
GHD in 10% and asymptomatic hypocortisolaemia in 2%. We did not identify any 
predictive factors for the development of hypopituitarism, however we have 
demonstrated evidence of subtle defects in the hypothalamo-pituitary axis that may 
suggest evidence of pituitary dysfunction. We believe therefore that universal 
screening for the presence of hypopituitarism is not justified, however targeted 
screening in patients who display evidence of delayed recovery from SAH in terms 
of energy, mood and quality of life could be performed. If screened, this should be 
performed at least 12 months after the SAH, when potentially reversible pituitary 
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dysfunction has resolved. Given the effect that confounders, such as obesity, have on 
dynamic testing for GH in particular, reference ranges, which take into account 
obesity, should be used, and in the presence of isolated deficits confirmatory testing 
should be undertaken. Given the findings of Karaca et al that new GHD cases may 
evolve up to three years post insult (371), and our own experience of evolving GHD 
(372), patients with on-going symptoms of suggestive of  hypopituitarism may 
benefit from rescreening despite previously normal results. Whilst we have failed to 
demonstrate statistically significant improvements in QOL, there is a promising 
trend, which merits further study in larger cohorts with more detailed QOL testing 
applied. 
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Chapter 6 
 
Growth Hormone Deficiency after Traumatic 
Brain Injury: cardio-metabolic profiles and 
long-term improvements in quality of life with 
GH therapy - analysis of the KIMS database
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Abstract 
Like SAH, hypopituitarism has been reported to be a frequent consequence of 
Traumatic Brain Injury, with patients with PTHP demonstrated as having a reduced 
QoL. Studies in these patients have shown short-term improvement in QoL and 
cognition with GH treatment, however long-term data are not yet available. We 
aimed to look for evidence of changes in QoL scores and body composition data to 
ascertain if changes were similar to patients with more conventional pituitary lesions.  
We analysed GH treated patients enrolled on KIMS (Pfizer International Metabolic 
Database). We compared 479 TBI patients  with 3773 patients with non-functioning 
pituitary adenoma (NFPA). Cardio-metabolic indices at baseline and changes in QoL 
score were compared before and after GH initiation. As might be expected, patients 
with PTHP are younger but also have a higher incidence of GHD, higher peak GH 
concentration and a more favourable cardio-metabolic profile at baseline. Despite 
this, their baseline QoL is much lower, but has improved to a greater extent after 12 
months (5 vs. 3.5 points, PTHP vs. NFPA; p=0.04). Improvements in QoL are 
sustained for at least eight years post treatment, although persistently remain worse 
than both NFPA and the general population over this period. We demonstrate that 
although the proportion of KIMS patients with PTHP on the KIMS database is 
increasing, absolute numbers remain low with an increased lag period (~2.4 years) 
between injury and GHD diagnosis, compared to NFPA patients. 
 Despite more profound impairments in QoL, with a worse baseline QoL score, GH 
replacement results in significant and sustained improvement in QoL in PTHP. The 
more favourable cardio-metabolic profile in PTHP suggests their disease may not 
confer the same increased cardiovascular risk as NFPA patients. 
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Introduction 
In  our previous study we failed to obtain sufficient power to demonstrate  significant 
improvement in QoL in 6 patients with GHR post SAH, however improvements were 
seen. We therefore looked to utilise the Pfizer KIMS database to ascertain changes in 
QoL in a larger number of patients. The database however only holds details of 3 
patients with GHR following SAH. We therefore looked to study a group with 
similar issues. 
 
There is evidence to demonstrate that, following a traumatic brain injury (TBI), 
patients are at significant risk of developing anterior hypopituitarism, or post-
traumatic hypopituitarism (PTHP) although estimated prevalence is highly 
variable(96, 264, 267, 373-383). Following TBI, patients have significantly reduced 
quality of life and cognitive impairments including memory impairment, reductions 
in executive functioning and decreased information processing speed(384, 385).  
Symptoms of fatigue are further exacerbated in the presence of GHD compared to 
patients with normal GH reserve(278). These functional outcomes, together with 
PTHP, have been associated with abnormal neuroimaging findings in TBI 
patients(386). Cognition and mood can be improved with GHR, with benefits shown 
after one year of therapy(387, 388), however little is known about changes in QoL 
following GHR in this population with only one study reporting improvements in 
QoL(389). 
 
Studies to address how common this problem is have revealed widely differing 
estimates of the prevalence rates of PTHP, partly because of variation in the 
definitions of GHD, the use of different provocation tests to diagnose GHD, and 
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different time points for assessing pituitary function post-TBI(381, 390). 
Furthermore, with several dynamic function tests, results are dependant on the body 
mass index (BMI) of the patient(391).  
 
Despite the high prevalence of PTHP reported in some studies, interrogation of the 
KIMS database by Casanueva et al. in 2005 highlighted only 51 KIMS patients with 
adult-onset PTHP compared with 688 KIMS patients with GHD following non 
functioning pituitary adenoma (NFPA)(392). Subsequent to this a further 
interrogation of the German KIMS database in October 2006 found only 69 cases of 
GHD for this indication(393). These data may suggest deficiencies in the 
neuroendocrine evaluation of patients after TBI and potentially a very high 
prevalence of undiagnosed and symptomatic GHD and hypopituitarism patients. It 
should be highlighted that only patients receiving GH replacement are followed in 
the KIMS database, and therefore, alternative explanations are either these patients 
do not receive GH therapy or have not been registered on the KIMS database.  
 
The aim of the current study was to utilise the KIMS database to examine: i) the 
secular trends in numbers of KIMS patients with PTHP, ii) the cardio-metabolic 
profile and associated defects of patients with PTHP, and iii) the effect of GHR on 
QoL measures over an extended period to assess the degree of long-term response. 
We used patients treated for non-functioning pituitary adenoma (NFPA) as a 
reference group.  
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Patients and Methods 
Patient groups (see figure 6.1) 
In August 2012 the KIMS database (Pfizer International Metabolic Database; a 
pharmacoepidemiological survey of adult hypopituitary patients with GHD; total 
number of KIMS patients = 16266)(394) was interrogated for all patients with a 
diagnosis of TBI. In this study three different groups of patients were analysed: 1) all 
patients with TBI for the assessment of secular trends in the registrations of PTHP 
(Group 1, n=479); 2) patients with TBI, diagnosed with adult-onset GHD, never 
treated with GH before entry into KIMS and who had baseline and a minimum of 12 
months of follow up data for the 1-year analysis of changes in cardio-metabolic 
profile and QoL (Group 2, n=161); 3) patients with TBI, diagnosed with adult-onset 
GHD, never treated with GH before entry into KIMS, from Belgium, France, 
Germany, The Netherlands, Spain,  Sweden and the UK,  and with reported QoL-
AGHDA up to 8 years of follow-up  for the cross-sectional analysis of QoL (Group 
3, n=154). In addition patients with more than one pituitary diagnosis were excluded. 
Patients diagnosed with GHD in adulthood due to a TBI sustained in childhood were 
included.  
 
Data from all patients with a diagnosis of adult-onset GHD caused by NFPA and no 
reports on cranial irradiation, who had baseline and a minimum 12 months of follow 
up data, were used as a reference group. There were 1268 eligible NFPA patients for 
1-year longitudinal analysis and a maximum number of 1143 NFPA patients with 
QoL data at entry into KIMS for cross-sectional QoL analysis. 
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Assessments (see figure 6.1) 
Three separate analyses were made:  
In the first analysis, in order to ascertain whether number of KIMS patients with TBI 
were increasing, the database was interrogated for all registrations from inception to 
2009. In order to ascertain relative proportions, this number was expressed as 
percentage of the total number of registrations. Additionally, in patients with an 
injury date/onset of pituitary disease, the age at onset was compared to age at 
diagnosis of GHD to ascertain the lag time from injury to diagnosis in both TBI and 
NFPA (Group 1).  
In the second analysis, patients with TBI and NFPA were compared at baseline and 1 
year follow-up (Group 2). Data analysed included demographic characteristics, 
number of associated pituitary deficiencies, stimulation test used, GH peak, IGF-I 
SDS , height, weight, body mass index (BMI), cholesterol, HDL-cholesterol (HDL), 
LDL-cholesterol (LDL), triglycerides, lean body mass (BIA), fat mass (BIA), 
systolic and diastolic blood pressure, fasting glucose, HBA1c and total QoL-
AGHDA score.  
In the third analysis, QoL-AGHDA scores in patients with TBI and NFPA were 
analysed cross-sectionally in relation to country-specific normative values up to 8 
years of KIMS follow-up (Group 3). 
The QoL-AGHDA, a disease-oriented instrument, consists of 25 items that evoke 
yes/no answers, acknowledging or denying certain problems(179). QoL-AGHDA 
score is scored from 0 (best QoL) to 25 (worst QoL).  The instrument is reliable and 
valid with a high level of internal consistency(184). The normative reference values 
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for the QoL-AGHDA were derived from general population samples from 7 
European countries(186-189). 
 
The analysis was also performed for the following QoL-AGHDA dimensions: 
problems with memory and concentration (6 items), tiredness (7 items), tenseness (3 
items), social isolation (5 items) and problems with self-confidence (4 items) and the 
results presented as proportion of items with impairment within each 
dimension(186).  
 
Serum IGF-I and lipids were centrally analysed: at Kabi Pharmacia, Stockholm, 
Sweden (1994-1997), and thereafter at Sahlgrenska University Hospital, Gothenburg, 
Sweden. The following assay methods were used: until November 2002, 
radioimmunoassay after acid/ethanol precipitation of IGF-binding proteins (Nichols 
Institute Diagnostic, San Juan Capistrano, CA, USA); until September 2006, 
chemiluminiscence immunoassay (Nichols Advantage system); and after September 
2006, Immulite 2500 (DPC Siemens)(395). Intra-assay, inter-assay, and total 
coefficients of variation were less than 9% in the concentration range of 125–1046 
g/L. The assay detection limit was 13.5 g/L. Age and gender-specific reference 
ranges were used to determine an IGF-I SDS for each patient(396). Serum total 
cholesterol, HDL-cholesterol, and triglycerides were measured by standardized 
methods and serum LDL-cholesterol was calculated according to the Friedewald 
formula(397). Waist and hip measurements were conducted according to KIMS 
Guidelines(397), circulated to all participating physicians, and BMI was calculated 
as body weight (kg)/height (m
2
).  
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Figure 6.1 -  Investigation algorithm demonstrating inclusion criteria and analyses 
performed. 
  
•ANALYSIS 1 
•a) Changes in number and proportion  of KIMS patients 
with TBI &NFPA over time. 
•b) Change in time from injury/onset pituitary disease to 
GHD diagnosis over time. 
GROUP 1 
All TBI &NFPA 
n=479 (TBI),  
n=3773 (NFPA) 
•ANALYSIS 2 
•Comparison of baseline and 1 year data 
•Auxology 
•Cardio-metabolic indices 
•QoL changes  
GROUP 2 
TBI & NFPA 
Adult onset, GH naïve 
Baseline and 1 yr data available 
n= 161 (TBI) 
n=1268 (NFPA) 
•ANALYSIS 3 
•Cross sectional analysis of QoL-AGHDA scores 
•Years 1 - 8 
GROUP 3 
TBI & NFPA 
Adult onset, GH naïve 
QoL-AGHDA data till yr 8 
n=154 (TBI) 
n=1143(NFPA) 
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Statistical Analysis 
Descriptive statistics were presented and analysed with means and SD, or 
proportions, depending on the type of variable.  Regression analysis on time between 
injury date (TBI)  or date of diagnosis of NFPA and diagnosis of GHD was adjusted 
for age (numerical), gender, calendar-year (numerical)  and were performed with 
PROC REG, SAS version 9.2. 
 
The statistical analyses for baseline outcome variables and 1-year change outcome 
variables were performed by covariance analyses for unbalanced designs (PROC 
GLM, SAS version 9.2). Group comparisons were adjusted, in general, for age at 
measurement, and gender, except for the analysis of GH peak, which additionally 
were adjusted for type of stimulation test. Adjusted means are presented at age 45 
years and equal gender distribution. For the analyses of dimensions of QoL-
AGHDA, mixed-linear regression was used as the within-patient dimension scores 
are expected to be correlated.  The number of items differed by dimension, so 
standardisation was necessary and this was achieved by computing the percentage of 
items within a dimension that a patient expressed problems with. The covariance 
structure was estimated with an unstructured variance-covariance matrix. 
Adjustments were made for age and gender. Analyses were performed at yearly visits 
(cross-sectionally). 
 
Confidence intervals were Wald based. Statistical significance was set to p<0.05. 
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Results 
Analysis 1: 
KIMS registrations 
The proportion of registrations due to TBI increased over time, with the highest 
proportion being recorded between 2005 and 2009 (Table 6.1).  
Time from injury to GHD diagnosis 
Based on all available reports, injury date was recorded in 141 TBI patients. Mean 
age of injury was 25.9 (SD 13.8) years. 10 patients were below the age of 19 years 
when the injury occurred. There was a trend over the calendar year for a longer lag 
time between injury date (TBI) or diagnosis of pituitary disease (NFPA) and GHD 
diagnosis. In order to understand the significant factors implicated in the delay 
between diagnosis (onset of pituitary disease in KIMS)/injury date and treatment, a 
regression analysis was undertaken with years between injury diagnosis/injury as the 
dependant variable, and diagnosis group, age at GHD diagnosis, gender, calendar-
year of GHD diagnosis as explanatory variables. The time between pituitary disease 
onset and GHD diagnosis was 4.6y in NFPA patients vs. 7.0y for TBI patients (as 
estimated at calendar-year 2000 and males age 45 at diagnosis). Thus TBI patients 
were generally diagnosed on average 2.4 years later (95% CI: 1.36 to 3.55 years; 
p=<0.0001). Females were diagnosed 0.45 years (95% CI: 0.03 to 0.88; p=0.035) 
later than males and time increased on average by 0.14 years by each calendar year 
(95% CI: 0.11 to 0.18; p<0.0001). Time to diagnosis decreased by 0.19 year per 
increased year of age (95% CI: -0.20 to  -0.17; p<0.0001).  
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  <1980 1980-1989 1990-1994 1995-1999  2000-2004   2005-2009 2010 - 2012 
Total no registrations for TBI 
% of all registrations per interval 
15 
2.16 
24 
1.58 
24 
1.25 
68 
1.68 
190 
3.75 
138 
5.91 
19 
3.94 
Total no registrations for NFPA 
% of all registrations per interval 
42 
6.03 
190 
12.50 
467 
24.40 
1209 
29.87 
1157 
22.86 
606 
25.95 
126 
26.1 
 
Table 6.1  - Registrations on KIMS database attributed to traumatic brain injury up until 2012. 
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Analysis 2: 
 
Differences in baseline profiles 
For the analysis of cardio-metabolic profile and QoL on true naïve adult onset 
patients (161 TBI and 1268 NFPA patients) description and comparison of baseline 
characteristics are shown in Table 6.2. TBI patients were significantly younger, 
however there was no significant difference in gender distribution with a male 
preponderance in both groups. TBI patients were significantly shorter than NFPA 
patients by 0.9cm (1.8cm when corrected for age and gender; 95% CI: -3.0 to -0.6 
cm; p=0.004).  
 
Body composition was similar in both groups with the exception of a reduction in 
lean mass in the TBI group.  Cardio-metabolic indices were more favourable in the 
TBI group even after correction for age and gender with lower systolic and diastolic 
blood pressure, and total cholesterol and LDL (Table 6.2).  
 
Despite similar IGF-1 SDS in both groups, peak GH was significantly greater in the 
TBI patients after adjustment for age and gender (p=0.03), but not after additional 
adjustment for type of stimulation test (p=0.12).  There was a non-significant trend to 
a higher peak GH level in TBI patients regardless of test used. Proportions of tests by 
group are shown in figure 6.2.  
 
TBI patients had significantly fewer associated pituitary deficiencies (1.6; 95% CI: 
1.4 to 1.8 for TBI vs. 2.4; 95% CI 2.3 to 2.5 for NFPA) and a higher prevalence of 
isolated GHD (24.9% TBI vs. 6.4% NFPA). The most frequent additional deficiency 
was ACTH deficiency in both groups, followed by TSH, LH/FSH and ADH in TBI 
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patients, and LH/FSH, TSH and ADH in NFPA. QoL-AGHDA score was 
significantly worse in TBI patients compared with NFPA. This was consistent across 
all QoL-AGHDA subdomains of memory, tiredness, tenseness, socialising and self-
confidence (data not shown).  
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Variable 
 
TBI (mean, 95% CI) NFPA (mean, 95% CI) p value 
Age (y) 42.6  40.8, 44.5 53.2  52.5, 53.8 <0.0001 
Gender (%Male) 58  62  NS 
BMI(kg/m
2
) 29.0  28.2, 29.8 28.9  28.6, 29.3 NS 
Height (cm) 169.9  168.8, 171.0 171.7  171.2, 172.2 0.004 
Waist Hip Ratio 0.93  0.91, 0.94 0.92  0.92, 0.93 NS 
Lean Mass(kg) BIA  54.7  52.0, 57.5 58.1  56.9, 59.3 0.02 
Fat mass (kg) BIA 25.7  22.7, 28.7 26.9  25.6, 28.3 NS 
Fasting glucose (mmol/L) 5.0  4.8, 5.3 4.9  4.8, 5.0 NS 
HBA1c (%) 5.3  5.2, 5.5 5.2  5.2, 5.3 NS 
Diastolic BP(mmHg) 79  77, 80 81  80, 81 0.02 
Systolic BP (mmHg) 125  122,128 128  127, 129 0.03 
Cholesterol (mmol/L) 5.37  5.06, 5.68 5.76  5.64, 5.88 0.02 
LDL (mmol/L) 3.25  2.99, 3.51 3.55  3.45, 3.65 0.03 
HDL (mmol/L) 1.27  1.18, 1.36 1.27  1.23, 1.30 NS 
Triglycerides (mmol/L) 1.81  1.41, 2.20 2.19  2.04, 2.34 NS  
Peak GH ( g/L)* 3.22  1.55, 4.89 1.79  1.08, 2.49 NS(0.12)  
IGF-1 SDS  -1.27  -1.63, -0.90 -1.52  -1.66, -1.38 NS 
Additional deficiencies 1.6  1.4, 1.8 2.4  2.3, 2.5 <0.0001 
QoL-AGHDA score 
 
13.9  12.5, 15.4 10.4  9.8, 10.9 <0.0001 
QOL-AGHDA dimensions:      
Memory 0.63  0.56, 0.70 0.46  0.43, 0.49 <0.0001 
Tiredness 0.66  0.59, 0.73 0.50  0.47, 0.53 <0.0001 
Tenseness 0.65  0.57, 0.72 0.50  0.47, 0.53 0.0004 
Socialising 0.38  0.32,0.45 0.30  0.28,0.33 0.02 
Self Confidence 0.42  0.35,0.48 0.27  0.25,0.30 <0.0001 
 
Table 6.2 - Baseline data for 161 TBI patients and 1268 NFPA patients 
demonstrating age and gender adjusted mean and 95% confidence intervals with 
between group differences (* Peak GH adjusted for age, gender, and type of 
stimulation test). QoL-AGHDA dimensions are shown as age and gender adjusted 
mean proportion of items that patients have problems with.
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Figure 6.2 - Growth hormone stimulation tests used for diagnosis of GHD in 161 TBI patients and 1268 NFPA patients
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1 year follow up data 
 
Follow up data for both TBI and NFPA patients are shown in Table 3. Improvements 
were seen in IGF-I SDS and waist hip ratio in both groups, however improvements 
were also seen in body composition in the NFPA group with an increase in lean 
mass, which was not seen in the TBI group. Likewise NFPA patients saw marginal 
increases in fasting glucose and HBA1c with reductions in total cholesterol, LDL and 
triglycerides. There were no significant between group changes in any of these 
variables. Mean GH dose over the 12-month period somewhat higher in the TBI 
group (0.37 mg/day vs. 0.33 mg/day for NFPA patients (mean difference: 
0.04mg/day 95% CI: 0.01 – 0.07; p=0.006; adjusted for age and gender) 
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Variable TBI (mean, 95% CI) NFPA(mean, 95% CI) 
 
Between 
Groups 
BMI (kg/m
2
) -0.19 -0.46, 0.08 -0.04 -0.16, 0.08 NS 
Waist Hip Ratio -0.01 -0.02, 0.0 -0.01 -0.01, 0.0 NS 
IGF-1 SDS 1.59
§
 1.19, 1.98 1.90
§
 1.76, 2.04 NS 
Lean Mass (kg) BIA 0.12 -1.56, 1.80 0.96
§
 0.17, 1.75 NS 
Fat mass(kg) BIA -1.91 -3.88, 0.06 0.87 -1.8, 0.05 NS 
Fasting glucose (mmol/l) 0.17 -0.12, 0.46 0.17
§
 0.06, 0.28 NS 
HBA1c (%) 0.1 -0.04, 0.24 0.1
§
 0.05, 0.15 NS 
Diastolic BP(mmHg) 0.15 -1.71, 2.02 -0.32 -1.12, 0.48 NS 
Systolic BP (mmHg) 1.71 -1.33, 4.75 -1.07 -2.38, 0.23 NS 
Cholesterol (mmol/l) -0.06 -0.34, 0.21 -0.20
§
 -0.31, -0.10 NS 
LDL (mmol/l) -0.12 -0.32, 0.09 -0.16
§
 -0.24, -0.08 NS 
HDL (mmol/l) -0.03 -0.10, 0.05 0.02 -0.01, 0.04 NS 
Triglycerides (mmol/l) 0.08 -0.30, 0.46 -0.15
§
 -0.29, -0.01 NS 
GH Dose (mg/day) 0.37 0.35, 0.40 0.33 0.32, 0.34 0.006 
QoL-AGHDA score 
 
-5.0
§
 -3.7, -6.4 -3.3
§
 -3.0, -4.0 0.04 
QOL-AGHDA dimensions:      
Memory -0.17
§
  -0.23, -0.1 -0.13
§
 -0.15, -0.10 NS 
Tiredness -0.22
§
 -0.3, -0.15 -0.21
§
 -0.23, -0.18 NS 
Tenseness -0.21
§
 -0.3, -0.13 -0.14
§
 -0.17, -0.11 NS 
Socialising -0.14
§
 -0.2, -0.08 -0.09
§
 -0.12, -0.07 NS 
Self Confidence -0.2
§
 -0.27, -0.14 -0.08
§
 -0.11, -0.06 0.0008 
 
Table 6.3 - 12 month data for 161 TBI patients and 1268 NFPA patients 
demonstrating age and gender adjusted change within groups between baseline and 
1 year, together with significant changes between groups at 1 year. (
§
 significant 
difference within group between baseline and 1 year.) 
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Analysis 3 Improvements in Quality of Life 
Year one Data 
At baseline TBI patients had significantly worse QoL-AGHDA scores compared to 
NFPA patients (13.8 vs. 9.7). When reassessed 12 months after treatment 
commenced, QoL-AGHDA score had improved significantly in both groups, with 
the improvement being greater in the TBI patients (5.0 vs. 3.5 points; p=0.04) 
however the overall score remained worse in TBI patients.  
 
QoL-AGHDA dimensions  
Data on dimensions at baseline are shown in Table 2. Responses at baseline showed 
significant impairment in all dimensions in both TBI and NFPA patients. TBI 
patients had greater impairment in all areas compared with NFPA. TBI patients 
showed greatest impairment in tiredness, followed by tenseness, memory, self-
confidence and lastly socialising.  
 
At one year both groups of patients improved significantly in all areas.  Self-
confidence was the only dimension where patients with TBI improved to a 
significantly greater extent than patients with NFPA (table 6.3).  
 
Changes in QoL-AGHDA scores over time 
 QoL-AGHDA scores for eight years post GH start were available in both sets of 
patients.  In the TBI patients the initial improvement in QoL seen after 12 months is 
sustained over the eight-year period, however remains significantly worse than the 
NFPA group (Figure 6.3A). When compared to data from the normal population, 
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TBI patients have a significantly worse QoL score up until year eight when this 
difference becomes non-significant.(Figure 6.3B). 
 
Analysis of QoL-AGHDA dimensions shows that TBI patients saw normalisation of 
socialisation compared with the normal population after 1 year. Self-confidence 
returned to within the range of the normal population by year 6 as did tenseness, 
although small numbers lead to wider confidence intervals by this point. Impairment 
in tenseness and memory never returned to the level of the normal population. 
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Figure 6.3A -  Changes in QoL-AGHDA  score over time demonstrating sustained reduction in score for both TBI and NFPA patients 
but with significantly worse scores for TBI compared with NFPA until 8 years post treatment initiation.
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Figure 6.3B - Changes in QoL-AGHDA  score over time demonstrating significantly reduced QoL in TBI patients compared with the 
normal population up to 8 year follow up. Dotted line indicates level of normal population, n equals number of TBI patients available 
for follow up at each point. 
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Discussion 
In this analysis we have examined the largest cohort of patients following traumatic 
brain injury with one year follow up data on a range of variables. We have 
additionally presented quality of life data for eight years post GHR and compared 
this, not only to other patients with hypopituitarism due to another cause (NFPA), but 
also to the general population. 
 
We had speculated that after the recent interest in PTHP, registrations for this cause 
of GHD would have increased. Whilst the proportion of registrations for this 
indication is increasing, absolute numbers remain low.  The incidence of hospitalised 
TBI patients is 235 per 100,000 population(398). Considering an incidence of GHD 
after TBI between 25-50%, this would suggest that a large number of undiagnosed 
patients with GHD exist, perhaps due to lack of screening programs or poor 
awareness of clinicians.  
 
Our second hypothesis, that with increased awareness, the lag time from injury to 
GHD diagnosis would have reduced, was not confirmed. We demonstrated once 
again a significant lag time between injury date and diagnosis of GHD, with patients 
with TBI diagnosed over 2 years later than NFPA patients. This lag was observed in 
the two previous KIMS studies(392, 393). It may be that a reduction in the lag time 
is observed in future studies.  
 
Our analysis of the cardio-metabolic profile and nature of PTHP in this population 
has reconfirmed that the TBI population is younger, and of similar BMI to NFPA 
patients. Our analysis shows that the nature and risk of PTHP differs from that seen 
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with NFPA. There is a higher incidence of isolated GHD, and a consequent reduction 
in the number of associated pituitary deficiencies, suggestive of less severe 
hypopituitarism than in NFPA, supported by the finding of a trend to higher peak GH 
to stimulation in GHD patients although this can partially be explained by 
differences in stimulation testing, with no significant difference in peak GH observe 
after correction for stimulation test and similar pre-treatment IGF-1-SDS between the 
groups.  
 
The body composition and cardio-metabolic data of PTHP suggest a lower 
cardiovascular risk than in patients with NFPA, with lower cholesterol and LDL 
concentrations, and lower systolic and diastolic blood pressures even after correction 
for age and gender. The only marker of adverse body composition in the TBI group 
is the finding of lower lean muscle mass, which may represent disuse atrophy.  
 
Similar to previous KIMS data, patients post TBI were shorter than counterparts with 
NFPA. Subgroup analysis has shown that this difference can be accounted for by 
patients whose injury date was before 19 years of age (data not shown). This 
suggests that head injury in childhood may in some cases account for reductions in 
growth, although the numbers involved are small. However, Bellone et al 
demonstrated an association between reduced height velocity in children post TBI 
and PTHP in this group(399).  
 
Significantly, this study has provided strong evidence on the beneficial and sustained 
effect of GHR on QoL in this cohort over eight years. It has been shown in many 
studies that TBI patients have reduced QoL, and that TBI patients with PTHP have a 
  
 188 
worse QoL and greater fatigue than compatriots without PTHP(278, 388, 400, 401), 
although this is not universally agreed(402). GHR is known to improve QoL in 
patients with GHD(186), and this is reconfirmed by the improvements in QoL seen 
in the NFPA patients in our group. Short-term studies and case reports have shown 
GHR to improve QoL and cognition in TBI patients with GHD up to 12 months(403, 
404). Kozlowski et al demonstrated improvements in cognition, particularly verbal 
memory and in QoL after 12 months treatment(389), whilst Maric et al demonstrated 
improved cognitive abilities particularly in verbal and non verbal memory, and 
improvements in psychiatric functioning with subsequent worsening in 3 patients 
who discontinued treatment for 12 months(388). Our data show significant 
improvement in QoL-AGHDA score after 12 months, however additionally we have 
demonstrated sustained improvement over a number of years.  
 
Similar to previous data on changes in QoL-AGHDA dimensions in GHD(186), we 
have shown a faster improvement in problems with socialising, and a much slower 
improvement in problems with memory and tiredness. As would be expected QoL 
scores remain significantly lower than both NFPA patients and the normal 
population, most likely reflecting other consequences of injury in these patients. 
Recently it has been shown by Tanriverdi et al that hypopituitarism improves in a 
proportion of patients when pituitary function is rechecked 5 years post injury(377). 
This factor as well as overall physical recovery may be responsible for the continued 
gradual improvement in QoL after the initial 12-month period. 
 
This study does have weaknesses. This data covers only patients with GHD rather 
than the full spectrum of pituitary deficiencies without GHD. This also only includes 
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patients commencing GH, which would indicate that patients, particularly in the UK 
would need to be symptomatic – this could lead over reporting of poor QoL scores 
compared with the overall population of patients with PTHP.  
 
In conclusion our findings suggest that there are likely to be a large number of 
undiagnosed patients with PTHP. We have shown that whilst the ‘phenotype’ of 
PTHP is less severe than PTHP, there are very clinically relevant improvements in 
QoL, which are sustained, in the long term in this population. These important 
findings provide an evidence base for screening and treating affected patients with 
PTHP.  
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Chapter 7 
 
 
 
Discussion and Final Conclusions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 191 
GHD is a clear physiological entity with a definite phenotype. It is clear that GHD is 
associated with adverse body composition and increased cardio-metabolic risk, and 
that GHR in cases of pathological GHD results in clear benefit in terms of QoL and 
improvements in body composition and cardio-metabolic risk factors. This thesis in 
all its components examines the complex interplay between GH secretion and fat 
mass and the implications both for fat deposition but also quality of life and response 
to GHR.  
 
Chapter 3 described the proportion of GHD patients with elevated IHCL compared 
with control volunteers matched for age and BMI. We did not see a difference in the 
proportion of patients with NAFLD based on MRS in the 2 groups, and in hindsight 
based on subsequent studies in this thesis it maybe tempting to speculate on whether 
these ‘GHD’ patients really did have true GHD given that the majority were 
diagnosed by the GST alone as is the clinical practice rather than using confirmatory 
testing. If this were to be the case, it would not have been surprising to see no 
difference. There are however compelling arguments against this view. Firstly 
patients with GHD did have significantly lower IGF-I levels. Secondly body 
composition was very different between the two groups with raised VAT and SAT in 
the GHD group which, due to matching cannot simply be accounted for by BMI per 
se.  
 
In this study we then followed the response to treatment of symptomatic GHD 
patients with GHR. Although this observational study was small, we did as 
previously seen show significant reductions in VAT and SAT suggesting that this 
group behave in similar fashion to other GHD patients studied in the literature. The 
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fact that there was a non-significant reduction in liver fat may therefore suggest that 
the liver is the least sensitive of the 3 fat depots to the effects of growth hormone.  
This study raises questions about the concept of ‘physiological’ vs. ‘pathological’ 
GHD. GH is known to be significantly reduced in obesity with reductions of 75% 
seen in obese patients compared with age-matched controls. Although we did not 
measure peak GH to stimulation in our control population in this study, we do know 
from our subsequent study that a majority of otherwise healthy controls with BMI 
>30kg/m
2
 have a peak GH >3 g/L. Given that patients with GHD are known to have 
insulin resistance, the question raised by this study is whether treatment of 
‘physiological’ GHD results in similar improvements in body composition. i.e. 
regardless of the cause of GHD, does replacement lead to improvement in cardio-
metabolic and body composition outcomes. Since our data has been published, a 
further study by Bredella et al looking at young men with abdominal adiposity 
without GHD has been published. This compared the effect of administration of 
GHD vs. placebo to this group and demonstrated the same improvements in body 
composition and IHCL in GH treated participants as demonstrated in our GHD 
group. Similar to our outcomes, a reduction in VAT/SAT ratio was seen implying a 
greater sensitivity of VAT to the effects of GH.  
 
Future studies in this area will need to investigate the role of GH on the liver and on 
physiological outcomes in more detail. Our small study failed to show significant 
reductions in liver fat most likely due to small patient numbers. Larger multicentre 
studies would be needed in order to achieve this, however the implications of 
reductions in liver fat on the subsequent progression to the complications of NASH 
would be clinically important. Given that Bredella et al noted an inverse relationship 
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between many markers and IGF-I, it may be necessary to include GH dosing 
adjustments as part of this work. As such future studies would need to include a 
marker of NASH rather than simply IHCL, together with other cardio-metabolic 
markers such as hsCRP, adiponectin and apolipoprotein estimation.  
 
Chapter 4 allowed us to look in more detail at the GH response of healthy 
volunteers. We saw a negative correlation between peak GH response to the GST 
and BMI, which mirrored the findings in the earlier chapter, and confirms the 
concept of ‘physiological’ GHD. We were able to confirm our methodology as 
appropriate and validate this against international cut offs.  
 
The problem of diagnostic testing in adult GHD is taking on a new significance with 
the combination of the newer indications for testing which do not necessarily have 
demonstrable structural lesions in the pituitary gland, coupled with changes in the 
general population meaning that more people are becoming obese. The clinician 
needs to be aware of these diagnostic pitfalls and testing strategies to minimize false 
diagnosis need to be developed. The GST does have a valuable place in diagnosis of 
GHD however as demonstrated in chapter 4 it is not fool proof. It is heavily affected 
by BMI as are other tests, and the cortisol response in particular is unreliable. Other 
groups have showed this also. Future strategies could include validation of the GST 
at different levels of BMI as has been done with the GHRH/Arginine test, or the 
introduction of routine second testing for patients without demonstrable pituitary 
lesions on scanning as happens in the paediatric population currently. The role of 
IGF-I in this situation has potential. Although affected by obesity and age, 
standardized SDS scores are becoming available and could prove valuable as a 
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‘sense check’ in interpreting dynamic function testing results. Together with this 
higher resolution 3T MRI scanning has the potential to enable pituitary and 
hypothalamic lesions to be more readily recognized, again aiding in the decision 
around which test to choose and the interpretation of findings. Finally it is clear that 
the GST should not be relied on as a marker of cortisol reserve.  
 
Chapter 5 allowed us to move the theories developed in chapter 4 into a clinical 
context. In this study we looked at a population of patients with SAH and screened 
for hypopituitarism using robust testing with confirmation of deficiencies. The 
advantage of conditions such as SAH and TBI when attempting to evaluate the 
influence of obesity, is that there is a definite point of onset, unlike many other 
causes of pituitary disease in adulthood when patients may have lived with 
conditions and the associated GHD for a number of years. The effects of GHD on 
longitudinal weight gain have been clearly shown(108, 405) , however in SAH we 
were able to evaluate patients and record their BMI before any long-term effect took 
hold.  
 
In the study we demonstrated a clear influence of BMI on the outcome of the GST in 
patients with SAH. This is an effect that was not present in the patients with multiple 
pituitary hormone deficits studied in chapter 4.  We also demonstrated that with 
confirmatory testing the overall incidence of hypopituitarism at 12 months fell to 
12% of which GHD made up 10%. As supportive evidence we did not see significant 
changes in weight in this cohort between 3 and 12 months, which is different to 
studies of patients with confirmed GHD secondary to other pituitary conditions, and 
we did not see differences in QoL AGHDA score between patients with and without 
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hypopituitarism. Whilst overt hypopituitarism is uncommon in this group, such 
robust testing is at risk of overlooking subtle changes in pituitary function. Basal 
cortisol levels were noted to be significantly lower in patients with hypopituitarism at 
3 months and non-significantly lower at 12 months. Impairment in QoL, which has 
been blamed on GHD, previously could indeed be due to alterations in the HPA axis 
in these patients. Future studies could look to estimating cortisol reserve more 
elegantly looking to alterations in diurnal variability of cortisol or changes in total 
daily production of cortisol in the quest to evaluate whether neuroendocrine 
dysfunction rather than deficiency may play a part in the reduced QoL seen in these 
patients.  
 
In this chapter we did evaluate the effects of GHR in a small number of patients with 
GHD diagnosed by standard methods following SAH. Whilst there was a significant 
improvement in the group over the 6-month period, this lost significance when 
comparison with changes in scores in an untreated group was added in.  This study 
demonstrates that with such small numbers of SAH patients treated for GHD it is 
difficult to draw meaningful conclusions around the effect of GHR. We therefore 
turned to the Pfizer KIMS database for a larger number of SAH patients to study. 
Despite such prominence in the medical literature over recent years the Pfizer 
database contained only three patients treated with GHR following SAH. It was 
therefore decided to look at a separate patient group where similar diagnostic 
conundrums are faced, and where there is currently a gap in the literature as to 
outcome, namely patients with traumatic brain injury. 
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Chapter 6  - In this chapter we evaluated the single largest group of patients in the 
project so far. Using the Pfizer KIMS database we evaluated data on a total of 479 
patients with TBI and 3773 patients with NFPA. Our primary outcome was to 
ascertain whether GHR in this population, which is similar to SAH patients in many 
ways,  (definite date of onset, often no demonstrable pituitary lesion, other injuries 
etc. complicating QoL assessment) improved QoL in patients with GHD. In addition 
given the questions raised by this thesis as to the reliability of diagnosis in patient 
groups such as this, we aimed to look for evidence of the ‘severity’ and ‘phenotype’ 
of GHD in this population when compared with patients with NFPA, long considered 
the archetypal pituitary lesion.   
 
We demonstrated evidence of a less severe phenotype, with higher peak GH levels, 
higher incidence of isolated GHD, and less severe cardio-metabolic aberrations after 
correction for age and gender, despite there being no significant difference in BMI. 
We did however demonstrate significant and sustained improvements in QoL 
AGHDA dimensions over eight years post commencement of GH.  It must be 
considered due to this being a GH database, only patients wishing to commence GH, 
or in the UK patients with impairment in QoL were included, this is likely to bias the 
findings towards the more symptomatic patients. Future studies would ideally 
include a randomized RCT of GH vs. placebo in patients with SAH and TBI however 
given the clear benefits of GHR replacement in reducing cardio-metabolic risk and 
QoL in patients with GHD, such studies may be difficult to justify on ethical 
grounds.  
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